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ABSTRACT OF DISSERTATION 
 
 
 
 
QUANTIFICATION OF FACTORS GOVERNING DRUG RELEASE KINETICS 
FROM NANOPARTICLES:  A COMBINED EXPERIMENTAL AND MECHANISTIC 
MODELING APPROACH 
 
Advancements in nanoparticle drug delivery of anticancer agents require 
mathematical models capable of predicting in vivo formulation performance from in vitro 
characterization studies.  Such models must identify and incorporate the physicochemical 
properties of the therapeutic agent and nanoparticle driving in vivo drug release.  This 
work identifies these factors for two nanoparticle formulations of anticancer agents using 
an approach which develops mechanistic mathematical models in conjunction with 
experimental studies.   
A non-sink ultrafiltration method was developed to monitor liposomal release 
kinetics of the anticancer agent topotecan.  Mathematical modeling allowed simultaneous 
determination of drug permeability and interfacial binding to the bilayer from release 
data.  This method also quantified the effects of topotecan dimerization and surface 
potential on total amount of drug released from these liposomal formulations.  The pH-
sensitive release of topotecan from unilamellar vesicles was subsequently evaluated with 
this method.  A mechanistic model identified three permeable species in which the 
zwitterionic lactone form of topotecan was the most permeable.  Ring-closing kinetics of 
topotecan from its carboxylate to lactone form were found to be rate-limiting for 
topotecan drug release in the neutral pH region. 
Models were also developed to non-invasively analyze release kinetics of 
actively-loaded liposomal formulations of topotecan in vivo.  The fluorescence excitation 
spectra of released topotecan were used to observe release kinetics in aqueous solution 
and human plasma.  Simulations of the intravesicular pH in the various release media 
indicated accelerated release in plasma was a consequence of increased intravesicular pH 
due to ammonia levels in the plasma instead of alterations in bilayer integrity.  Further 
studies were performed to understand the roles of dimerization, ion-pairing, and 
precipitation on loading and release kinetics obtained from actively-loaded topotecan. 
Extension of this type of modeling for other types of nanoparticles was illustrated 
with doxorubicin-conjugated polymeric micelles.  Mathematical modeling of 
experimental studies monitoring doxorubicin release identified conjugation stability 
during storage, hydrazone hydrolysis kinetics, and unconjugated doxorubicin partitioning 
affected micellar doxorubicin release.  This work identifies several of the key parameters 
governing drug release from these liposomal and micellar nanoparticles and lays the 
framework for future development of in vivo release models for these formulations.  
 
 
 
KEYWORDS: Drug Release Kinetics, Liposomes, Micelles, 
Topotecan, Doxorubicin 
 
 
 
 
 
 
 
 
 
 
Kyle D. Fugit______________________________ 
Student’s Signature 
 
 
July 31, 2014______________________________ 
Date 
  
  
 
 
 
 
 
 
 
 
 
QUANTIFICATION OF FACTORS GOVERNING DRUG RELEASE KINETICS 
FROM NANOPARTICLES:  A COMBINED EXPERIMENTAL AND MECHANISTIC 
MODELING APPROACH 
 
 
By 
 
Kyle Daniel Fugit 
 
 
 
 
 
 
 
 
 
 
 
 
 
Bradley D. Anderson________________________ 
Director of Dissertation 
 
 
Jim Pauly_________________________________ 
Director of Graduate Studies 
 
 
July 31, 2014______________________________ 
Date 
  
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Dedicated To 
 
My wife, parents, and grandparents 
 
Without their love and support, none of this would be possible 
 
 
 
iii 
 
ACKNOWLEDGMENTS 
 
While this dissertation is the full body of my own work, contributions from many has 
strengthened its message.  No one more so than my dissertation advisor, Dr. Bradley 
Anderson, whose insights, thought processes, and wealth of knowledge have molded me 
into a sound researcher and prepared me for my future career in science.  My exponential 
growth as a scientist during the completion of this dissertation has been in a large part to 
his exceptional mentoring.  I would like to thank my committee members: Drs. Zach Hilt, 
Paul Bummer, and Markos Leggos, whose expertise, comments, and questions have also 
improved the quality of my dissertation.  I would also like to thank my outside examiner, 
Dr. Thomas Dziubla for his comments and time reviewing this dissertation.  I would also 
like to thank Drs. Younsoo Bae and Andrei Ponta for the opportunity to collaborate with 
them on the characterization of their polymeric micelles as well as Drs. Amar Jyoti and 
Menakshi Upreti whose biological insights were invaluable to our collaborative project 
examining liposomal drug release in human plasma.  And of course, I must thank the 
funding which provided with the opportunity to conduct. The resources and funding 
fellowships from the National Science Foundation and National Cancer Institute provided 
were instrumental in the success of this project. 
I have had much encouragement and support during the dissertation process and 
graduate school.  My lab members, Sweta, Dhaval, Michael, Pekka, aided my 
development through their encouraging words and technical knowledge in many of the 
experimental methods I used in the completion of this dissertation.  I must also thank 
several summer students: Jill, Erinn, Amy, Laura, NK, and Kim whom I had the privilege 
of mentoring and whose small projects provided useful information in developing the 
iv 
 
path for this dissertation.  I must also thank Nico for assisting with data collection during 
his rotation in our lab.  I hope that they benefited from my instruction and teaching as I 
much as I benefited from my experience mentoring them. 
On a more personal note, I must thank all of my friends and family for the emotional 
support they provided me during my time in graduate school.  My fellow friends from 
graduate school and those I have met during my time here in Lexington have been a true 
blessing and an immeasurable source of relief during some of the most challenging times 
I have encountered in my life.  But more importantly is the support from my family.  The 
Fugits, Martins, and Wiesners have always believed in me and molded me into the man I 
am today.  No more so than my parents, Dan and Kristi, my sister, Kati, and my 
grandparents: Jim, Shirley, and Hazel who have shown great love and support throughout 
my life.  I am truly blessed to have such a remarkable family. 
Most important of all, I must thank my wife, Ann (the 1st Dr. Fugit).  Words cannot 
begin to explain what the past five years with her has done for me.  To say I am a better 
man for having her in my life is an understatement.  The love and support, but most 
importantly the patience, she has given to me during this process is more than I can 
comprehend.  Luckily, I have the privilege of spending the rest of my life trying to live 
up to the amazing woman that she is.   
  
v 
 
TABLE OF CONTENTS 
ACKNOWLEDGMENTS ............................................................................................. iii 
TABLE OF CONTENTS................................................................................................. v 
LIST OF TABLES ...................................................................................................... xiii 
LIST OF SCHEMES .................................................................................................... xiv 
LIST OF FIGURES ....................................................................................................... xv 
CHAPTER ONE ............................................................................................................. 1 
Statement of Aims ........................................................................................................... 1 
CHAPTER TWO ............................................................................................................. 5 
Introduction ..................................................................................................................... 5 
2.1 Nanotechnology and chemotherapy ........................................................................5 
2.2  Liposomes .............................................................................................................6 
2.2.1  Factors governing liposomal drug release ........................................................8 
2.2.2  Loading Strategies ........................................................................................ 11 
2.3  Polymeric micelles .............................................................................................. 12 
2.4 Topoisomerase inhibitors ..................................................................................... 14 
2.4.1  Topotecan ..................................................................................................... 14 
2.4.2  Doxorubicin .................................................................................................. 15 
2.5 Characterization of nanoparticle drug release ....................................................... 17 
CHAPTER THREE ....................................................................................................... 21 
Dynamic Non-sink Method for the Simultaneous Determination of Drug Permeability 
and Binding Coefficients in Liposomes ......................................................................... 21 
3.1  Introduction ......................................................................................................... 21 
3.2  Experimental ....................................................................................................... 23 
3.2.1  Materials ....................................................................................................... 23 
vi 
 
3.2.2  Preparation and characterization of DSPC/m-PEG DSPE liposomes ............. 24 
3.2.3  Release of TPT from DSPC/m-PEG DSPE liposomes ................................... 24 
3.2.3.1  Sephadex® column removal of unencapsulated drug from passively 
loaded liposome suspensions ............................................................................... 25 
3.2.3.2  Non-sink release studies measured by ultrafiltration ............................... 25 
3.2.3.3  Dynamic dialysis under sink conditions .................................................. 26 
3.2.4  Dialysis tube swelling studies ....................................................................... 26 
3.2.5  TPT dimerization .......................................................................................... 27 
3.2.6  HPLC analyses ............................................................................................. 27 
3.2.7  Model Development and Data Analysis ........................................................ 28 
3.2.7.1  Mathematical model of TPT release from unilamellar liposomes: non-sink 
conditions ........................................................................................................... 29 
3.2.7.2  Dynamic dialysis model of drug release from unilamellar liposomes: sink 
conditions ........................................................................................................... 30 
3.2.7.3  Derivation of unbound drug concentration for modeling of release studies 
at sink and non-sink conditions ........................................................................... 32 
3.2.7.4  Concentration corrections for ultrafiltration recovery and dialysis 
compartment volume........................................................................................... 34 
3.2.7.5  Determination of TPT dimerization constant (K2) .................................. 35 
3.3  Results ................................................................................................................ 36 
3.3.1  Validation of Analytical Methods and Liposome Particle Characterization.... 36 
3.3.2  Recovery from ultrafiltration and volume changes in dynamic dialysis ......... 39 
3.3.3  Comparison of release studies under non-sink and sink conditions ................ 42 
3.3.4  Drug and lipid concentration effects on drug partitioning probed by non-sink 
method ................................................................................................................... 45 
3.4  Discussion ........................................................................................................... 50 
vii 
 
3.4.1  Effect of experimental parameters on extent of drug release under non-sink 
conditions ............................................................................................................... 50 
3.4.2  Applicability to drug release characterization for other drugs and/or 
nanoparticle formulations ....................................................................................... 55 
3.5  Conclusions ......................................................................................................... 56 
CHAPTER FOUR ......................................................................................................... 57 
The Role of pH and Ring-opening Hydrolysis Kinetics on Liposomal Release of 
Topotecan ...................................................................................................................... 57 
4.1 Introduction .......................................................................................................... 57 
4.2 Materials and Methods ......................................................................................... 60 
4.2.1 Materials ........................................................................................................ 60 
4.2.2 Preparation and characterization of DSPC/m-PEG DSPE liposomes for 
lactone-carboxylate interconversion and release studies .......................................... 60 
4.2.3 Fluorescence measurements of aqueous TPT solutions................................... 61 
4.2.4 TPT interconversion studies ........................................................................... 62 
4.2.5 Release of TPT from DSPC/DSPE-PEG-2K liposomes .................................. 62 
4.2.6 HPLC analyses .............................................................................................. 63 
4.2.7 Mechanism-based mathematical model development ..................................... 64 
4.2.7.1 Mathematical model for liposomal TPT release including kinetics of 
lactone ring-opening/closing ............................................................................... 64 
4.2.7.2 Spectrometric determination of the TPT A-ring phenol (pKa1) ................ 72 
4.2.7.3 TPT lactone-carboxylate interconversion kinetics in solution and in the 
presence of liposomes ......................................................................................... 74 
4.2.7.4 Mathematical model for liposomal TPT release assuming equilibrium for 
lactone ring-opening/closing ............................................................................... 76 
4.2.7.5 Regression Analysis ................................................................................ 78 
4.3 Results ................................................................................................................. 78 
viii 
 
4.3.1 Validation of analytical methods and liposome characterization ..................... 78 
4.3.2 Spectrometric determination of the TPT A-ring phenol (pKa1) ...................... 81 
4.3.3 TPT lactone-carboxylate interconversion kinetics .......................................... 83 
4.3.4 pH Sensitive release of TPT ........................................................................... 85 
4.4 Discussion ............................................................................................................ 87 
4.4.1 Effect of TPT ring-opening on pH sensitive release kinetics........................... 87 
4.4.2 Comparison of kinetic and equilibrium models of lactone ring-opening/closing
 ............................................................................................................................... 89 
4.4.3 Determination of species permeability coefficients ........................................ 91 
4.5 Conclusions .......................................................................................................... 94 
CHAPTER FIVE .......................................................................................................... 95 
Insights Into Accelerated Liposomal Release of Topotecan in Plasma Monitored by a 
Non-invasive Fluorescence Spectroscopic Method ..................................................... 95 
5.1  Introduction ......................................................................................................... 95 
5.2  Materials and Methods ........................................................................................ 97 
5.2.1  Materials ....................................................................................................... 97 
5.2.2  Liposome preparation ................................................................................... 98 
5.2.3  Active loading of TPT into ammonium besylate liposomes ........................... 98 
5.2.4  Liposome characterization ............................................................................ 99 
5.2.5  Fluorescence method development and validation ....................................... 100 
5.2.5.1  TPT Excitation Spectra ......................................................................... 100 
5.2.5.2  TPT release studies by fluorescence ..................................................... 100 
5.2.6  TPT release by HPLC ................................................................................. 101 
5.2.7  TPT degradation kinetics in the presence/absence of ammonia .................... 102 
5.2.8  Ammonia analyses ...................................................................................... 103 
ix 
 
5.2.9  General mathematical model for actively-loaded liposomal TPT release under 
non-sink conditions .............................................................................................. 103 
5.3  Results .............................................................................................................. 107 
5.3.1  Differences in fluorescence spectra and quantitation of extravesicular TPT . 107 
5.3.2  TPT degradation in the presence and absence of ammonia .......................... 109 
5.3.3  Comparison of fluorescence and HPLC methods to monitor release ............ 109 
5.3.4  Release experiments in human plasma and plasma ultrafiltrate .................... 112 
5.4  Discussion ......................................................................................................... 114 
5.4.1  Differences in liposome concentration led to changes in intravesicular 
ammonia, pH, and subsequent release kinetics ...................................................... 114 
5.4.2  Effects of ammonia concentration in physiological samples and implications 
on liposomal TPT release ..................................................................................... 119 
5.4.3  Adaptation of method for other nanoparticles and drugs .............................. 122 
5.5  Conclusion ........................................................................................................ 123 
CHAPTER SIX ........................................................................................................... 125 
Mechanistic Evaluation of Self-association, Ion-pairing, Ammonia, and Precipitation 
Effects on Active Loading and Release of Liposomal Topotecan ................................. 125 
6.1 Introduction ........................................................................................................ 125 
6.2 Materials and methods ........................................................................................ 127 
6.2.1 Materials ...................................................................................................... 127 
6.2.2 Liposome preparation and characterization .................................................. 128 
6.2.3 Active loading of TPT ................................................................................. 129 
6.2.4 Release of passively-loaded TPT ................................................................. 130 
6.2.5 Release of actively-loaded TPT in the presence of extravesicular ammonia .. 131 
6.2.6 Isolation of intravesicular TPT by ultrafiltration ........................................... 131 
6.2.7 HPLC analyses ............................................................................................ 132 
x 
 
6.2.8 Ammonia analyses ....................................................................................... 133 
6.2.9 Loading and release models of liposomal TPT ............................................. 134 
6.2.9.1 TPT rate equations governing loading kinetics....................................... 136 
6.2.9.2 Generation of pH gradient ..................................................................... 138 
6.2.9.3 Loading Model #1:  TPT dimerization and ion-pairing .......................... 140 
6.2.9.4 Loading Model #2: Ion-pairing without dimerization ............................. 144 
6.2.9.5 Loading Model #3: Dimerization with no ion-pairing ............................ 144 
6.2.9.6 Equations describing PLLT release ........................................................ 145 
6.2.9.7 Equations describing release of liposomal TPT loaded at 37 °C ............. 145 
6.2.9.8 Equations describing release of liposomal TPT loaded at 60 °C ............. 148 
6.3 Results ............................................................................................................... 152 
6.3.1 Active loading of TPT at 37 °C .................................................................... 152 
6.3.2 PLLT release studies .................................................................................... 157 
6.3.3 ALLT release studies ................................................................................... 159 
6.3.3.1 Effect of chloride permeability on ALLT release ................................... 159 
6.3.3.2 Effect of ammonia transport on ALLT release ....................................... 163 
6.3.3.3  Effect of loading at high temperature (60 °C) on ALLT release ............ 169 
6.4  Discussion ......................................................................................................... 174 
6.4.1  Effect of TPT ion-pairing, dimerization, and intravesicular pH on active 
loading and subsequent release kinetics ................................................................ 174 
6.4.2 Significance of loading temperature and precipitate identity ......................... 179 
6.4.3 Implications of loading conditions on optimizing release kinetics ................ 185 
6.5 Conclusions ........................................................................................................ 185 
CHAPTER SEVEN ..................................................................................................... 187 
Mechanistic Modeling Provides Insights on Doxorubicin Release, Partitioning, and 
Conjugation Stability in Polymeric Micelles ................................................................ 187 
xi 
 
7.1  Introduction ....................................................................................................... 187 
7.2  Materials and methods ....................................................................................... 190 
7.2.1  Materials ..................................................................................................... 190 
7.2.2  Preparation and characterization of polymeric micelles ............................... 190 
7.2.2.1  BLA-NCA monomer synthesis ............................................................. 191 
7.2.2.2  PEG-pBLA synthesis ............................................................................ 191 
7.2.2.3  PEG-p(Asp-Hyd) functionalization ....................................................... 191 
7.2.2.4  Synthesis of PEG-p(Asp-Gly-Hyd) and PEG-p(Asp-Abz-Hyd) block 
copolymers ....................................................................................................... 192 
7.2.2.5  DOX conjugation via hydrazone bond .................................................. 192 
7.2.2.6  Block copolymer micelle characterization ............................................ 193 
7.2.3  Drug release studies .................................................................................... 193 
7.2.3.1  DOX release monitored by dynamic dialysis:  sink conditions .............. 194 
7.2.3.2  DOX release monitored by ultrafiltration:  non-sink conditions ............ 194 
7.2.4  Determination of unconjugated drug produced during storage ..................... 195 
7.2.5  Model Development.................................................................................... 195 
7.2.5.1  Release studies monitored by ultrafiltration: non-sink conditions .......... 197 
7.2.5.2  Release studies monitored by dynamic dialysis: sink conditions ........... 199 
7.3  Results .............................................................................................................. 202 
7.3.1  Micelle characterization .............................................................................. 202 
7.3.2  Validation of free DOX removal for methods used to monitor release ......... 202 
7.3.3  Model-predicted micelle instability during storage confirmed by other 
experimental methods ........................................................................................... 203 
7.3.4  Characterization of release kinetics of HYD DOX-conjugated block 
copolymer micelles ............................................................................................... 205 
xii 
 
7.3.5  Characterization of release kinetics of DOX-conjugated block copolymer 
micelles with GLY and ABZ spacers .................................................................... 208 
7.4  Discussion ......................................................................................................... 212 
7.4.1  Strengths and limitations of micelle release model and methods used .......... 212 
7.4.1.1  Instability of hydrazone bond under storage conditions identified with 
mathematical modeling ..................................................................................... 212 
7.4.1.2  Probing contributions of DOX partitioning and DOX hydrolysis kinetics 
on release using sink and non-sink conditions ................................................... 214 
7.4.1.3  Concentration effects of conjugated and unconjugated DOX on 
partitioning ....................................................................................................... 214 
7.4.2  Effect of unconjugated DOX partitioning into micelle on observed drug 
release under non-sink and sink conditions ........................................................... 216 
7.4.3  Intrinsic factors governing micellar DOX release ........................................ 221 
7.4.3.1  pH-dependent DOX partitioning ........................................................... 221 
7.4.3.2  Biphasic hydrazone hydrolysis kinetics ................................................ 222 
7.5  Conclusions ....................................................................................................... 224 
CHAPTER EIGHT ...................................................................................................... 226 
Conclusions and Future Directions .............................................................................. 226 
References ................................................................................................................... 236 
VITA ........................................................................................................................... 248 
 
  
xiii 
 
LIST OF TABLES 
Table 3.1. Volume parameters used when comparing release studies of liposome 
suspensions under non-sink and sink-conditions……………...…………………………43 
Table 3.2.  Values used to calculate the intrinsic DSPC bilayer/water partition 
coefficients for TPT species at pH 4 and 37 °C……………………………………........ 47 
Table 4.1.  Volume parameters used in TPT release studies...........……………………. 80 
Table 5.1.  Release parameters obtained from HPLC and fluorescence methods…...... 110 
Table 5.2.  Parameters used to simulate 𝐻𝑖
+ profiles at different lipid concentrations... 117 
Table 6.1.  Parameters used to model release and loading kinetics of liposomal TPT that 
are independent of the experiment.……………………………………………………. 151 
Table 6.2.  Parameters used to model release and loading kinetics of liposomal TPT that 
are experiment-specific.……………………………………………………………….. 151 
Table 6.3.  Values of release parameters and goodness-of-fit for the various loading 
models developed.......…………………………………………………………………. 153 
Table 6.4.  Initial conditions used for modeling ALLT release…………………….......160 
Table 7.1.  Volume parameters used for mathematical modeling of DOX release from 
block copolymer micelles………………………………………………….......……… 198 
Table 7.2.  Values of release parameters fitted to mathematical model to describe DOX 
release from micelle formulations at pH 5.0 and 7.4...………………………………... 206 
  
xiv 
 
LIST OF SCHEMES 
Scheme 3.1.  Illustration of the relevant kinetic and equilibrium processes applicable in 
developing a mathematical model for liposomal drug release as determined by dynamic 
dialysis…...........…………………………………………………………………………27 
Scheme 4.1.  The major species of TPT in solution in the low to neutral pH range.........59 
Scheme 4.2.  A schematic of the associated equilibria and kinetics governing liposomal 
release of TPT………………………………………………………………....………....66 
Scheme 4.3.  Phenol ionization on the A ring of TPT is governed by the acid dissociation 
constant, 𝐾𝑎1…………………………………………………....………………………..73 
Scheme 4.4.  The proposed mechanism for reversible, pH dependent ring opening of TPT 
from its lactone, 𝐿, to carboxylate, 𝐶𝐶𝑂𝑂−, form…………………………………………76 
Scheme 4.5.  The equilibrium between TPT’s carboxylate zwitterion and neutral, 
unionized  form is governed by 𝐾0,𝐶……………………………………………………..93 
Scheme 5.1.  Physicochemical properties of TPT considered in modeling liposomal 
release kinetics……………………………………………………………………….....104 
Scheme 6.1. A mechanistic illustration of the equilibria and kinetic processes that govern 
active loading of TPT in the presence of pH and chloride gradients…………………...135 
Scheme 7.1.  An illustrated schematic of the mathematical model used to describe DOX 
release from the three different micelle formulations studied………………………….196 
Scheme 7.2.  The ionization states of DOX are governed by its acid dissociation constant 
(KA) and the pH of the solution…………………………………………………………222  
xv 
 
LIST OF FIGURES 
Figure 2.1.  An illustration of a liposome used in this thesis…..………….....……..…......7 
Figure 2.2  Phospholipids used for liposomal formulations used within this thesis………9 
Figure 2.3  An illustration of the active loading process for weakly basic drugs………..12 
Figure 2.4  An illustration of a polymeric micelle…………………………….................13 
Figure 2.5.  TPT undergoes reversible, pH dependent intervonversion between its lactone 
(left) and carboxylate (right) froms………………………………………………………16 
Figure 2.6.  The ionization states of DOX are governed by its acid dissociation constant 
(KA) and the pH of the solution…………………………………………………………..16 
Figure 2.7  An illustration of the effect of non-sink conditions on release profiles……..18 
Figure 3.1.  Elution profiles of free or liposomal TPT analyzed by HPLC……………...37 
Figure 3.2. Lipid content was monitored during non-sink release studies………………38 
Figure 3.3.  The rate of dialysis tube swelling was monitored and used to determine a 
swelling rate constant for the dialysis tubes used in dynamic dialysis studies…………..41 
Figure 3.4.  A comparison of the release profiles of TPT from DSPC/mPEG-DSPE 
liposomes obtained from ultrafiltration (A) and dynamic dialysis (B) methods at pH 4.0, 
37 °C............................................................................................................................. .....43 
Figure 3.5.  Determiniation of TPT dimerization in solution (A) and TPT binding to 
liposomes as a function of TPT suspension concentration (B)…………………………..49 
Figure 3.6. The effect of experimental parameters on total drug release at equilibrium...53 
Figure 4.1.  The fraction of DSPC remaining during release studies conducted at pH 3.35 
and 4.01…………………………………………………………………………………..81 
Figure 4.2.  Determination of TPT phenol pKA1………………………………………...82 
Figure 4.3.  Ring opening/closing kinetics of TPT as a function of pH………………....84 
xvi 
 
Figure 4.4.  Fraction of TPT retained in DSPC/DSPE-PEG2K liposomes vs. time at 
varying pH (right panel displays only the first 6 hrs)……………………………………86 
Figure 4.5.  Liposomal TPT release profiles at pH 6.33 (A) and 7.04 (B)……………....88 
Figure 4.6.  Comparison of the experimental pH profile of TPT release half-lives to 
model fits that account for the kinetics of lactone-carboxylate interconversion or 
assuming lactone-carboxylate equilibrium………………………………………………90 
Figure 5.1.  Illustration of differences in normalized excitation spectra between free and 
entrapped TPT at 37 °C………………………………………………………………...108 
Figure 5.2. Comparison of release profiles obtained by HPLC and fluorescence 
methods……....................................................................................................................111 
Figure 5.3.  Fluorescence excitation spectra of ALLT in plasma over time……………113 
Figure 5.4.  The simulated profiles of [𝐻𝑖
+] and [𝑁𝑜] versus time in pH 7.4 PBS release 
media that initially contained no extravesicular ammonia or 60 µM NH4Cl…..............118 
Figure 5.5.  The relationship between TPT release half-life and simulated intravesicular 
pH……………………………………………………………………………………….120 
Figure 6.1.  Loading profiles of TPT using loading method #1 with TPT loading 
concentrations of 60, 130, and 180 µM in the extravesicular compartment with lines 
indicating simulated profiles obtained from the fit of loading models…………………154 
Figure 6.2.  Comparison of release profile of PLLT in the presence or absence of chloride 
at 37 °C……………………………………………………………………………........157 
Figure 6.3.  Release at 37 °C in PBS of ALLT formulations loaded at 37 °C………....161 
Figure 6.4.  The effect of ammonia transport on ALLT release at pH 7.4 PBS at             
37 °C............................................................................................................................. ...164 
Figure 6.5  Comparison of the loading efficiencies of TPT at different temperatures and 
suspension conditions………………………………………………………………......169 
xvii 
 
Figure 6.6  The effect of high temperature loading (60 °C) on ALLT release in pH 7.4 
PBS at    37 °C………………………………………………………………………….173 
Figure 6.7  The effects of ion pairing and dimerization on TPT active loading at             
37 °C............................................................................................................................. ...175 
Figure 6.8  The effects of ion-pairing, dimerization, and pH on ALLT release at             
37 °C………....................................................................................................................177 
Figure 6.9.  Changes in the intravesicular Cl:TPT ratio provides insight on the 
mechanism of TPT uptake at 60 °C…………………………………………………….180 
Figure 6.10  The identity of TPT salt affects release…………………………………...183 
Figure 7.1.  The graph above displays the % of DOX conjugated (𝑓𝑐 × 100%) after 15 
months of storage determined by mathematical modeling (under both pH conditions 
DOX release was monitored) and two other experimental methods...............................206 
Figure 7.3.  DOX release profiles obtained for GLY micelles at pH 5.0 (A) and 7.4 (B) 
along with those obtained for ABZ micelles at pH 5.0 (C) and 7.4 (D)………………..210 
Figure 7.4.  Simulation of HYD pH 5.0 release profile under non-sink conditions.  Using 
the rate constants provided in Table 7.2………………………………………………..216 
Figure 7.5.  The effect of unconjugated DOX partitioning is illustrated for dynamic 
dialysis release studies………………………………………………………………….218 
Figure 7.6.  The effect of micelle concentration and partioning of unconjugated DOX 
(Kp) on the effective rate constant, 𝑘′𝑑, (A) and half-life, t1/2, (B) of unconjugated DOX 
transport from the dialysis cassette……………………………………………………..220  
1 
 
CHAPTER ONE   
Statement of Aims 
Much has been made of the potential of nanoparticles as drug delivery vehicles due to 
their unique properties (e.g. size, shape, surface chemistry); however, few nanoparticle 
formulations have been approved for clinical use.  The low percentage of approved 
nanoparticle formulations is partially due to the current trial-by-error approach generally 
used in the development of these formulations.  Such a haphazard way to develop successful 
nanoparticle formulations is time-consuming and expensive and must be improved to 
increase the success of nanomedicines.  Furthermore, most in vitro characterization studies 
of nanoparticle release kinetics do not critically evaluate the factors governing observed 
release let alone provide any idea whether these studies are able to predict release in vivo.     
The application of mechanistic mathematical models supported by experimental studies 
is necessary to rationally optimize nanoparticle drug delivery systems and begin the critical 
task of correlating in vitro release characteristics to in vivo performance.  To this end, the 
use of mechanistic models to characterize in vitro release kinetics must incorporate 
thermodynamic (e.g. drug ionization state, self-association, interfacial binding) and kinetic 
(e.g. drug species’ permeability and/or kinetics of drug degradation of drug, particle, and/or 
drug-particle linkages) properties inherent to the drug/particle system.  Furthermore, these 
models must also account for the specific effects of the method used to monitor release, 
such as drug transport through a dialysis membrane or sink vs. non-sink conditions.  This 
thesis focuses on developing an approach that combines experimental studies with 
supporting mechanistic mathematical models capable of identifying the factors governing 
nanoparticle drug release.  The aims outlined below were pursued to advance 
understanding of factors which affect nanoparticle drug release kinetics and provide 
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examples for future approaches to analyzing drug release kinetics and developing models 
capable of predicting drug release.   
I. Develop and validate a non-sink method to simultaneously determine both 
liposomal release kinetics and apparent binding coefficients of topotecan to 
the lipid bilayer using mathematical modeling.  
An ultrafiltration method was developed and validated to separate encapsulated 
from free drug to monitor liposomal release kinetics under non-sink conditions.  
Using a mathematical model that considered both drug permeability and binding to 
the bilayer-solution interface allowed for both constants to be determined 
simultaneously from the same experiment.  With modification, the model could also 
describe release kinetics under sink conditions maintained by dynamic dialysis.   
II. A mechanistic model to assess the pH-sensitive release of liposomal topotecan 
was developed and experimentally validated   
Using the developed non-sink method, experimental studies were conducted to 
observe the pH-dependent release of passively-loaded liposomal topotecan.  Based 
on these profiles, further studies were conducted to analyze the pKa governing 
topotecan ionization in the low-to-neutral pH region.  The kinetics of reversible, pH-
dependent, ring-opening/closing interconversion of the drug between its lactone 
and ring-opened carboxylate forms was also assessed to clearly determine the 
contribution of the various topotecan species contributing to drug release.  
III. A non-invasive method was developed to monitor liposomal release kinetics 
in human plasma and reveal the effect of ammonia levels on intravesicular pH 
and accelerated release 
A spectroscopic fluorescence method was developed to monitor liposomal 
release kinetics of topotecan in plasma in real-time.  A mathematical model was 
3 
 
developed to compare the release kinetics obtained from this fluorescence method 
with those determined by HPLC.  Lastly, the accelerated release seen in plasma was 
correlated with the ammonia concentration in plasma using simulations to account 
for the effects of transbilayer ammonia transport on intravesicular pH.  
IV. Mechanistic mathematical models were developed to identify the factors 
contributing to experimentally observed loading and release kinetics of 
actively-loaded liposomal formulations of topotecan 
The kinetics of topotecan active loading was monitored at 37 °C and a 
mechanistic model was developed which incorporated transport of ion pairs of 
topotecan with excess chloride in solution.  The model was validated with studies 
that showed slowed release in the absence of excess chloride.  Further studies 
focusing on release from these formulations corroborated these factors using 
mechanistic models developed to describe release.  Lastly, differences in release 
kinetics between formulations loaded at 37 and 60 °C were assessed.  Mechanistic 
modeling of these release profiles implicated precipitation of a HCl salt of topotecan 
as the primary cause of the extended release kinetics observed from liposomal 
topotecan formulations actively-loaded at 60 °C.   
V. A mechanistic model was constructed to characterize the experimental 
release kinetics of doxorubicin-conjugated polymeric micelles using an 
approach similar  to that used to characterize liposomal drug release kinetics 
The approach used to developed mechanistic models for liposomal drug release 
was extended to characterize drug release from polymeric micelle nanoparticles.  
Experimental release studies of doxorubicin conjugated to block copolymers via a 
pH-sensitive hydrazone linkage were mechanistically modeled.  As a result of 
modeling, instability of  the hydrazone linkage during storage and partitioning of 
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unconjugated doxorubicin into the micellar phase were identified as important 
factors in the release kinetics as determined by dynamic dialysis.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Copyright © Kyle Daniel Fugit  
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CHAPTER TWO   
Introduction 
2.1 Nanotechnology and chemotherapy 
 Treating cancer with conventional therapeutic agents presents many challenges from 
both a clinical and physicochemical standpoint.  Many chemotherapeutics result in high 
systemic toxicity due to their nonspecific actions upon DNA repair and/or cell replication.1  
Such toxicity limits the therapeutic doses possible.  High systemic clearance and protein 
binding also limit tumor exposure to many of the anticancer agents already approved or 
currently under development.  Improving clinical efficacy of these chemotherapeutic agents 
requires increasing tumor exposure while reducing systemic toxicity.  From a formulation 
standpoint, strategies to increase drug solubility, shield drugs from rapid clearance (e.g. 
extend release), and/or target the tumor vasculature would increase the effectiveness of 
chemotherapeutic agents.   Nanoparticle delivery systems satisfy many of these 
requirements. 
A wide array of nanoparticles has been extensively explored as drug carriers for the 
treatment of cancer.2-4  These nanoparticulate systems are attractive for pharmaceutical 
applications due to their ability to entrap and release drug payloads in a manner capable of 
altering pharmacokinetics via increased drug solubility or extended release from the 
particle.3, 5  Their unique size is also advantageous for passively targeting the particles and 
their drug payloads to solid tumors due to the enhanced permeation and retention (EPR) 
effect.  This effect is a result of the leaky vasculature within the tumor environment 
produced by rapid tumor angiogenesis.  Fenestrations between endothelial junctions allow 
nanoparticles that cannot penetrate healthy vasculature to reach tumor tissue.6-9  In 
addition to the benefits of nanoparticle size, a multitude of chemical surface modifications 
may further reduce systemic toxicity through active targeting.  Modifying the surface of 
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these particles with various oligomers that are recognized by receptors overexpressed or 
unique to cancer cells provides the means to actively target cancer cells.3-5, 10-13    Active 
targeting in this context has the potential to increase drug accumulation at the tumor site;5, 
14, 15 it may also allow drugs to bypass efflux transporters overexpressed in drug resistant 
cancer cells.7, 16-19  
Many types of nanoformulations have been developed to take advantage of these 
properties but few have had clinical success.20  Part of this low success rate may be 
attributable to differences in release rates observed during in vitro characterization studies 
and those occurring in vivo.  This is supported by investigations that have shown antitumor 
efficacy of drug-loaded nanoparticle formulations is linked to drug release rates.21-24  Many 
physiological factors (i.e. age, gender, dose regimen, type or location of cancer, mononuclear 
phagocyte system)25 have been hypothesized to contribute to a disparity between in vitro 
drug release and the  pharmacokinetics (PK) and pharmacodynamics (PD) frequently seen 
with nanoparticle formulations of anticancer agents.  However, correlations between 
nanoparticle efficacy and these proposed factors remain untested.26, 27  Understanding the 
contributions of these various factors to alterations in drug release kinetics from 
nanoparticles will require a combined approach of experimental techniques and 
mechanism-based mathematical models.  Such an understanding will ultimately aid in the 
design of models capable of reliably predicting in vivo formulation performance and offer 
insights into ways to minimize these physiological effects on nanoformulations. 
2.2  Liposomes 
Liposomal formulations offer several potential advantages for the intravenous delivery 
of antitumor agents due to  their ability to increase drug solubility, reduce drug toxicity, and 
prolong drug release.3  These liposomes are generally composed of an aqueous core 
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surrounded by one or more lipid bilayers.  Most liposomes range between 50 and 600 nm in 
diameter.  Large unilamellar vesicles (LUV’s) (i.e. liposomes with only a single bilayer) 
typically range between 50 and 200 nm in diameter (Figure 2.1).  LUV’s are advantageous 
for developing controlled release strategies and ideal for modeling and studying release 
kinetics because: 1) a single bilayer provides a single barrier domain as opposed to the 
heterogeneous barrier properties of multilamellar vesicles;28 and 2) the bilayer properties 
are minimally altered  by curvature effects that reduce chain order in the bilayer.28, 29 
 
Figure 2.1.  An illustration of a liposome used in this thesis.  The liposome of 
radius R forms a single bilayer composed of phospholipids.  The phospholipids 
comprising the inner and outer leaflet of the bilayer (green and purple, 
respectively) are composed of a hydrophobic fatty acid tail and a hydrophilic 
phosphatidylcholine headgroup.   
Pegylated liposomes have the added benefit of longer systemic circulation due to 
reduced clearance by the mononuclear phagocytic system. 3, 30-32   This prolonged circulation 
time when combined with an appropriate particle size provides enhanced delivery of 
liposomes to solid tumors due to the EPR effect. 3, 8, 31  These properties have led to the FDA-
approved liposomal formulation of doxorubicin (DOXIL®) as well as other drug products, 
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including several currently in clinical trials.33-40  Functionalization of the liposome surface 
with specific moieties also makes possible active targeting strategies utilizing receptors that 
are highly expressed and specific to various cancer types.3, 7, 16, 40-42  
2.2.1  Factors governing liposomal drug release 
The release of drugs from liposomes is dependent upon a multitude of factors.  These 
factors can be divided into two major categories:  properties associated with the bilayer 
structure and those associated with the aqueous compartments.  
The structure of the bilayer is quite complex, with various regions of hydrophobicity 
and 3-dimensional order that may interact with drug molecules in specific ways; however, 
the hydrophobic domain of the inner bilayer is typically viewed as the rate-limiting barrier 
governing drug permeability in bilayers.43-46  The bulk solubility-diffusion model described 
over a century ago by Overton was one of the earliest attempts to account for the properties 
of bilayers that govern permeability47, 48 and is still sometimes used.  The model relates 
permeability, Pm, to the oil-water partition coefficient of the solute, K, the diffusion 
coefficient of said solute through this oil phase, and the thickness of the bilayer, h.  This 
relationship is illustrated by the equation below. 
𝑃𝑚 =
𝐾𝐷
ℎ
          (1) 
This equation clearly illustrates the dependence of permeability upon both the ability of the 
solute to partition into the bilayer and its diffusivity through the bilayer.  The dependence 
on partitioning qualitatively explains why ionized compounds are generally impermeable to 
bilayer membranes as the free energy for charged species to partition into the bilayer are 
much higher than those of neutral compounds.28, 49-51 
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This model is overly simplistic, however. It fails to account for the differences in 
permeability seen with different bilayer compositions and the drastic reductions in 
permeability seen as the size of the solute increases.  The bulk solubility-diffusion model is 
unable to capture the effects of the ordered structure of the bilayer’s fatty acid tails.  This 
chain ordering effect provides an additional resistance to drug diffusion and an entropic 
barrier to solute (i.e. drug) partitioning, which is also required for transport across the 
bilayer.28, 51, 52  This free-surface-area theory explains why lipids that form rigid gel phases 
(and higher surface densities) result in lower permeabilities for larger molecules.49, 52  Even 
the sudden and large increases seen in transport when the bilayer undergoes a phase 
transition from its more rigid gel phase to a liquid crystalline environment with increases in 
temperature may be explained by the more loosely-packed structure of the bilayer..50, 53  
The longer-chain phospholipids used here (see Figure 2.2) exist in the gel phase under 
physiological conditions and are used to slow release.49, 50  Further study of the bilayer 
properties was not a focus of this thesis. 
 
Figure 2.2  Phospholipids used for liposomal formulations used within this 
thesis. 
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When considering release kinetics, determination of the various drug species that are 
permeable and subsequently their respective permeabilities is crucial.  As mentioned 
previously, the ionization state of drugs and small molecules has been shown to alter 
release kinetics,49, 50, 52  Permeability determinations for each ionization state of the drug are 
therefore crucial to developing mechanistic models governing liposomal drug release.  The 
populations of these ionization states and other equilibria or kinetic events in solution may 
alter the driving force governing the kinetics of drug release.  These factors may include 
drug self-association, complexation, precipitation, and/or kinetic events which reduce the 
amount of permeable specie(s) present in solution. The studies conducted in this thesis 
focus heavily on the physiochemical properties of the drug in the aqueous compartments. 
In addition to these physicochemical properties, physiological processes and/or 
conditions may also affect liposomal drug release.  Bilayer integrity may be compromised 
by the particles’ interactions with proteins (e.g. vesicle binding and particle opsonization)54-
57 or osmotic stresses58, 59 while in circulation or at the tumor site.  Other factors such as the 
influx of other permeable species may alter the conditions of the aqueous compartment in 
vivo and accelerate release.60  Some of these effects are observed and identified within this 
thesis.  
With a thorough understanding of the physiochemical and biological phenomena that 
affect liposomal drug release, predictable and tunable drug release may be engineered for 
these types of formulations.  Developing models that incorporate these properties and 
mechanistically describe their effect on drug release kinetics is vital to a rational 
development process and one of the principal subjects of this thesis.   
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2.2.2  Loading Strategies 
Implementation of mechanistic models requires an understanding of the loading 
methods used to entrap drug within the intravesicular compartment.  This is important as 
the environmental conditions dictating drug loading (i.e. loading solution) may have vastly 
different effects on the intravesicular environment and consequently result in different drug 
release kinetics.  Two of the main methods used to entrap or load drug within a liposome 
(both used within this thesis) are passive and active loading.  Passive loading is quite 
simple.  The lipid films used to form the bilayer are hydrated with a solution containing the 
drug of interest.  Drug loading efficiencies can vary greatly using this method as highly 
lipophilic drugs will have a great affinity for the bilayer49, 61 while more hydrophilic drugs 
will mostly remain within the aqueous phase, leaving much of the drug unencapsulated.62, 63 
Active loading of drug is more complex, as illustrated in Figure 2.3.  Many liposomal 
formulations of amine-containing (or weakly basic) anticancer agents are actively-loaded by 
establishing an acidic intravesicular compartment relative to the extravesicular pH of the 
loading solution.  This pH gradient is generated by the release of a small, highly permeable 
base (ammonia in this case) once it has been removed from the extravesicular solution.  As 
ammonia is released, protons are generated in the intravesicular compartment and the pH 
is lowered.  When a weakly basic drug is exposed to this low intravesicular pH, the drug 
ionizes and typically becomes impermeable.  This maintains the gradient for the permeable 
form of the drug to continue driving the loading process.  This process results in high drug 
loading efficiencies that often prolong drug retention in aqueous buffers.23, 62, 64  However, 
many of these formulations may exhibit accelerated release in vivo or ex vivo.23, 62  A 
mechanistic understanding of the loading process should aid in deciphering the factors that 
contribute to these differences in release kinetics and are investigated in this thesis. 
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Figure 2.3  An illustration of the active loading process for weakly basic drugs.  
The rates of drug and ammonia transport are governed by their permeabilities 
𝑃𝐷𝑟𝑢𝑔
𝑚  and 𝑃𝑁𝐻3
𝑚 , respectively. 
2.3  Polymeric micelles 
Polymeric micelles are amphipathic block copolymers which self-associate to form a 
hydrophobic core surrounded by a hydrophilic shell when dispersed in aqueous solutions.5, 
65  This is illustrated by Figure 2.4.  One of the most common examples of these formulations 
are Pluronic block copolymer micelles.  These triblock copolymers possess a hydrophobic 
poly(propylene oxide) chain sandwiched between more hydrophilic poly(ethylene oxide) 
chains.65, 66  The ratio of these copolymers may be changed to improve the partitioning of a 
particular drug.66  These types of micelles are generally between 10-100 nm in diameter, 
allowing them to take advantage of passive targeting due to the EPR effect65 and overcome 
multidrug resistant cancers.19, 65  These initial polymer micelle formulations primarily 
focused upon increasing the solubility of many highly lipophilic anticancer agents while 
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reducing the systemic toxicities encountered using other excipients as solubilizing agents.67-
70 
 
Figure 2.4  An illustration of a polymeric micelle.  The nanoparticle forms as the 
amphipathic block copolymers self-associate in aqueous solution.  The more 
hydrophobic polymer block resides in the core and the more hydrophilic 
polymer block forms the shell.  
Further development of polymeric micelles using more elaborate copolymers has led to 
many more exotic versions.  These more advanced delivery systems are designed to possess 
unique structures capable of providing a plethora of characteristics exploitable for altering 
drug release.  Some of these designs alter characteristics intrinsic to the formulation (e.g. 
particle size, charge, hydrophobicity).  While these properties may be advantageous for 
altering drug release kinetics, they may also result in a complicated drug release 
mechanism.  The partitioning of drug payloads may be due to the drug’s affinity for a micelle 
with a highly-charged core rather than the typical hydrophobic core.5, 65, 66  Over time, drug 
may be released from these various polymeric micelles due to a combination of kinetic 
factors (i.e. drug diffusion and/or stability of drug-polymer linkage) and thermodynamic 
factors (i.e. complexation/absorption to the micelle core, CMC) intrinsic to the 
drug/polymer system and independent of the release environment.5, 66  Further complexity 
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is added when nanoparticles are engineered to respond to external stimuli such as heat, 
electromagnetic waves, enzymatic activity, or pH5, 63, 65, 71-79 while active targeting strategies 
to alter the micelle surface may subsequently alter the mechanism or kinetics of release.5, 19, 
65, 68, 70 
Chemically conjugating drugs to the block copolymers is another way to alter drug 
release kinetics and adds another dimension to the mechanism of drug release.  In several 
instances, these drug-conjugated micelles exhibit a biphasic drug release pattern (i.e. burst 
drug release followed by an extremely slow drug release phase) that varies depending upon 
the pH of the release medium.80-83 This thesis examines the factors governing release from 
this type of polymer micelle formulation. 
2.4 Topoisomerase inhibitors 
2.4.1  Topotecan 
Topotecan (TPT) is a topoisomerase I inhibitor currently approved to treat cervical, 
ovarian, and small cell lung cancers as an oral capsule or an injectable solution.  
Furthermore, TPT is also used in multiple clinical trials as the sole medication or in 
conjunction with other medications and/or radiation.84-88  TPT is one of several 
camptothecin analogues which stabilize single-strand breaks produced by the DNA-
topoisomerase I complex, preventing further DNA replication and eventually resulting in 
cell death.89  Due to its dimethylethylamine group, TPT is also weakly basic and 
subsequently its active lactone conformation is highly soluble under mildly acidic 
conditions.90  As such, an injectable solution of the hydrochloride salt is readily made and 
approved for use;88, 91 however, TPT undergoes pH-dependent ring-opening hydrolysis from 
its active lactone to a less-active carboxylate form as pH is increased (see scheme 2.5).92  
This results in the carboxylate form dominating at physiological pH.  The ring-opening 
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combined with base-catalyzed degradation and binding of the carboxylate to serum 
albumin90, 91, 93 significantly lowers TPT’s effectiveness upon systemic administration. 
 
Figure 2.5.  TPT undergoes reversible, pH dependent interconversion between 
its lactone (left) and carboxylate (right) forms that results in the lactone form 
dominating under acidic conditions while the carboxylate form dominates at 
neutral or basic pH. 
These issues may be circumvented upon TPT encapsulation in liposomes with a low 
intravesicular pH.94  Like other weakly basic drugs, TPT can achieve high encapsulation 
efficiency in liposomal formulations utilizing active loading strategies to generate a 
transbilayer gradient of lower intravesicular pH relative to the extravesicular loading 
solution.21, 42, 61, 73, 95-97  Considerable work has focused on such loading strategies for TPT; 
however, the subsequent release of TPT from these formulations is poorly understood.24, 42, 
62, 64, 97 Moreover, observations of accelerated release from studies conducted in plasma 
have not been explained.62  Part of the work in this thesis focuses on mechanistically 
determining the critical parameters attributable to liposomal TPT loading and release 
kinetics.  
2.4.2  Doxorubicin 
Doxorubicin (DOX) is a topoisomerase II inhibitor currently approved to treat several 
hematological malignancies in addition to many solid tumors including gastric, ovarian, 
thyroid, and small cell lung cancers as an injectable solution.98  DOX is also extensively used 
pH 
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in preclinical and clinical trials with a wide array of nanoparticle formulations.36, 40, 99-104  
The weakly basic anthracycline stabilizes the topoisomerase II cleavage complex (Top2cc) 
formed during unwinding of supercoiled DNA during replication.  In the case of DOX, both 
single and double strand breaks formed by the Top2cc prevent DNA replication and 
eventually triggers cell death.105  At higher DOX concentrations, DOX may suppress Top2cc 
altogether by altering DNA structure.105, 106  DOX may be administered as its hydrochloride 
salt as a soluble injection due to the weakly basic nature (pKa ~ 8.2)107 of the 
anthracycline’s aminogylcosidic side chain (see Scheme 2.6); however, cardiotoxicity 
typically occurs in over half the patients that receive chronic treatment.108  The generation 
of free oxygen radicals in response to DOX is the likely cause108-110 (although the 
mechanisms leading to this are numerous and still debated).108  
 
Figure 2.6.  The ionization states of DOX are governed by its acid dissociation 
constant (KA) and the pH of the solution.  At higher pH, the neutral base form 
dominates (left) while its cationic form (right) dominates at lower pH. 
 Reducing this cardiotoxicity through formulation is of great clinical interest.110  The 
nanoparticle formulation marketed as DOXIL (liposomal doxorubicin) reduces DOX’s 
cardiotoxicity due to its slow release from liposomes and preferential accumulation of these 
nanoparticles in solid tumors.30, 73, 111-113 Even so, the liposomal formulations have led to 
other side effects including hand-foot syndrome (i.e. blistering and skin necrosis typically in 
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the extremities), likely due to a combination of the prolonged circulation and slow DOX 
release from the liposome delivery vehicle in combination with the rich capillary beds of the 
skin.30, 114  This has led to much research on other nanoparticle formulations with various 
release rates in an attempt to find formulations which may not share in this same toxicity.  
The factors governing DOX release from a polymeric micelle formulation are explored as 
part of this thesis. 
2.5 Characterization of nanoparticle drug release 
The characterization of nanoparticle drug release requires methods to monitor either 
the loss of drug from the nanoparticle or the accumulations of drug in the release media.  
There are many methods employed to monitor nanoparticle drug release under these 
constraints;115-117 however, few consider the impact of environmental conditions (particular 
to the selected characterization method) which may alter observed in vitro drug release 
kinetics.  One popular method used to monitor in vitro drug release from nanoparticles that 
exhibits several of these method-specific effects is dynamic dialysis.  Dynamic dialysis uses 
a large reservoir in an attempt to provide the sink conditions necessary to drive release to 
completion.  Meanwhile, the nanoparticles remain concentrated within a small volume 
compartment separated from the reservoir by a semi-permeable membrane.19, 60, 63, 64, 118-120  
A large reservoir volume, however, does not necessarily ensure sink conditions within the 
dialysis chamber itself.  Depending on the nanoparticle release kinetics and the extent of 
drug binding to the nanoparticle, transport across the dialysis membrane may become rate-
limiting.3,8 Corrections for drug binding to the nanoparticles and the barrier properties of 
the dialysis membrane are therefore crucial when interpreting kinetic data collected with 
dynamic dialysis.49, 61, 63, 118   
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Most other methods used to monitor nanoparticle drug release typically use a physical 
separation (e.g. size-exclusion chromatography, ultrafiltration)51, 121 or spectral 
differences78, 79 between free and entrapped drug.  Validation of the separation 
efficiency/recovery or spectral deconvolution63 is obviously required for interpretation of 
release kinetics using these methods.  Just as important as this validation and frequently 
overlooked during release characterization is evaluation of “sink” or “non-sink” conditions. 
If non-sink conditions are present, evaluation of release kinetics becomes problematic.  For 
example, changes in the extent of release from nanoparticle formulations due to changes in 
pH or temperature do not necessarily translate into differences in release rates (i.e. 
thermodynamics vs. kinetics).81, 122, 123  Figure 2.7 provides a general illustration of this 
effect.  Without a way to quantify these distinctions, assessing the eventual in vivo 
performance becomes challenging.  
 
Figure 2.7  An illustration of the effect of non-sink conditions on release 
profiles.  In this illustration, the initial rate of release is the same; however, the 
final % of drug released is different due to a different equilibrium.  Interpreting 
both factors during nanoparticle release characterization is necessary to 
evaluate the effect of different conditions (e.g. pH and/or temperature) on 
altering the rate of release rather than the equilibrium. 
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Mathematical modeling of release profiles obtained from these methods may provide 
the ability to validate such release methods and subsequently determine release 
parameters intrinsic to the drug/nanoparticle system of interest.  At a minimum, these 
models can distinguish the kinetic and thermodynamic quantities intrinsic to the 
drug/particle system and those from the experimental environment contributing to the 
observed release profiles.49, 60, 63, 124-126  This thesis provides validation of several non-sink 
methods with the aid of mathematical models capable of quantifying the kinetics and 
approach to equilibrium exhibited by release studies conducted with such methods.  
With validated methods, studies that systematically examine release kinetics under a 
variety of conditions can be used for the development of mechanistic models which will 
provide insights on further optimization and control of drug release from these 
nanoparticle drug delivery systems.  These mechanistic models will contain the 
physicochemical principles governing drug release from the nanoparticle of interest.  They 
may require other studies in conjunction with release studies to validate the 
physicochemical principles affecting release kinetics.49, 53, 60, 63, 124 
 Once these mechanistic models are capable of describing nanoparticle drug release in 
vitro, the incorporation of in vivo conditions will be possible and ultimately lead to accurate 
in vitro/in vivo correlations.  Such correlations would reduce much of the costs incurred 
during preclinical development due to extensive animal testing and unguided formulation 
optimization. Mathematical models for assessing in vitro drug release and predicting in vivo 
drug release from nanoparticle formulations would be useful both in the design phase and 
during preclinical testing where avoiding the extensive use of animals would be highly 
desirable.  Such models would facilitate the design of formulations with adjustable and 
predictable drug release rates for patient-specific treatment regimens.  The work within 
20 
 
this thesis is intended to develop mechanistic models that are adequate enough to describe 
drug release kinetics from nanoparticle formulations in vitro.  The approach used here along 
with its subsequent findings will guide the design of future studies used to characterize 
nanoparticle drug release kinetics, optimize the loading and release of the formulations 
studied, and explore the mechanistic changes in release kinetics due to various 
physiological factors.       
 
 
 
 
 
 
 
 
 
 
 
 
Copyright © Kyle Daniel Fugit   
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CHAPTER THREE 
  Dynamic Non-sink Method for the Simultaneous Determination of Drug 
Permeability and Binding Coefficients in Liposomes 
3.1  Introduction 
Mathematical models for assessing drug permeability and predicting in vivo drug 
release from nanoparticle formulations would be useful both in the design phase and during 
preclinical testing where avoiding the extensive use of animals would be highly desirable.  
Such models would facilitate the design of formulations with adjustable and predictable 
drug release rates for patient-specific treatment regimens.  Mechanism-based models 
applicable to liposomal systems would need to account for three main factors affecting drug 
release: 1) the escaping tendency or effective concentration of the entrapped (permeable) 
drug species which serves as the driving force for liposomal release; 2) drug speciation and 
species permeability-area products for lipid bilayer transport;44, 49, 52, 53, 63, 127, 128 and 3)  the 
environmental conditions in which drug release occurs both during the in vitro release 
characterization and in vivo.49, 118  The intraliposomal driving force for transport likely 
depends on such factors as pH-dependent drug speciation, self-association, complexation, 
precipitate formation, membrane binding, and drug degradation/interconversion kinetics.  
The driving force for liposomal release and the membrane permeability-area product are 
closely linked and dependent on which drug species account for the release.49, 60, 129, 130  The 
environmental conditions (e.g., temperature, pH, sink conditions or lack thereof, presence of 
permeable buffer species, lipid-bilayer perturbing components, etc.) also impact both the 
driving forces and permeability coefficients.  Thus, robust mechanism-based models for 
predicting liposomal drug release may be quite complex.  Translation of release parameters 
generated in vitro to the prediction of drug release in vivo may be particularly challenging.  
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The necessary corrections will likely vary depending on the in vitro method employed to 
study drug release. 
A number of methods currently exist to monitor in vitro drug release from 
nanoparticles115, 117, 131 but extrapolation to predict in vivo release often requires an 
adjustment for the absence of sink conditions in the in vitro experiments as well as other 
possible environmental differences.  For example, one popular method to monitor in vitro 
drug release from nanoparticles is dynamic dialysis. Dynamic dialysis uses a large reservoir 
in an attempt to provide the sink conditions necessary to drive the process to completion.  
Meanwhile, the nanoparticles remain concentrated within the small volume compartment 
and separated from the reservoir by a semi-permeable membrane.19, 60, 63, 64, 118-120  
Unfortunately, a large reservoir volume does not ensure sink conditions within the dialysis 
chamber itself.  Depending on the nanoparticle release kinetics and the extent of drug 
binding to the nanoparticle, transport across the dialysis membrane may become rate-
limiting.3,8 Corrections for drug binding to the nanoparticles and the barrier properties of 
the dialysis membrane are therefore crucial when employing dynamic dialysis for 
predictive modeling.49, 61, 63, 118  In some cases, incomplete release has been observed even 
though approximate sink conditions (based on overall drug concentration gradients) were 
maintained due to factors such as pH differences or drug binding phenomena.  Such factors 
reduce the thermodynamic activity gradient for the permeable species, resulting in the 
achievement of equilibrium and subsequently incomplete release.72, 132-134 Finally, even if 
the above concerns relating to sink conditions are properly taken into account, a separate 
set of experiments in addition to dynamic dialysis would be needed.  These additional 
experiments would be required to quantify the species-dependent membrane binding of the 
drug and its influence on observed release kinetics for the construction of a mechanism-
based release model. 63, 119     
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A method to evaluate drug release kinetics under well-defined non-sink conditions when 
combined with the appropriate mechanistic release model would allow simultaneous 
determination of the kinetic and thermodynamic parameters governing release kinetics.  
This method would also provide a more robust assessment of nanoparticle formulations.  
This study demonstrates the utility of a novel ultrafiltration method to analyze drug release 
from nanoliposomal formulations under non-sink conditions using the model anti-cancer 
agent topotecan (TPT).  With the appropriate mathematical models, the liposomal drug 
release parameters generated under non-sink conditions were shown to be comparable 
with those obtained from dynamic dialysis.  This non-sink method was also used to 
simultaneously characterize membrane binding of the drug and its dependence on both 
drug and lipid concentrations in suspension. 
3.2  Experimental 
3.2.1  Materials   
Powders of 1,2-distearoyl-sn-glycero-3-phosphatidylcholine (DSPC, >99% purity) and 
1,2-distearoyl-sn-glycero-3-phosphoethanolamine-N-[methoxy(polyethyleneglycol)-2000] 
(m-PEG DSPE, MW = 2806, >99% purity) were purchased from Avanti Polar Lipids 
(Alabaster, AL).  Topotecan hydrochloride was purchased from AK Scientific (Union City, 
CA).  Float-A-Lyzer® G2 dialysis tubes (100,000 MWCO) were purchased from Spectrum 
Labs (Rancho Dominguez, CA).  Millipore semi-micro ultrafiltration centrifugation devices 
(regenerated cellulose, NMWL: 30,000), 100 nm pore size Nuclepore polycarbonate 
membranes, solvents, and buffer salts were purchased from Fisher Scientific (Florence, KY).  
All solvents were HPLC grade.   
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3.2.2  Preparation and characterization of DSPC/m-PEG DSPE liposomes 
Large unilamellar vesicles were formed using a film hydration and extrusion process as 
reported previously with slight modifications.28, 49, 62  Briefly, DSPC and m-PEG DSPE (95:5 
mol:mol) lipids were weighed, dissolved in chloroform, and aliquots of the resulting 
solutions were distributed into separate vials. Chloroform was subsequently evaporated 
under a stream of nitrogen gas and the residue was vacuum-dried at 40°C for 6 hours.  For 
release studies, TPT was passively loaded into liposomes by hydrating the dried lipid film 
with TPT solutions (0.25 mM in pH 4.0, 50 mM formate buffer adjusted to an ionic strength 
of 0.3 with NaCl) to achieve 40 or 90 mg lipid/mL suspensions.  These suspensions were 
extruded 10 times through two stacked 100 nm pore size Nuclepore® polycarbonate 
membranes using a Liposofast® extrusion device at 60°C to obtain unilamellar vesicles with 
encapsulated  TPT in the intra-vesicular solution.  Blank liposome suspensions (40 mg 
lipid/mL) used in spiking experiments for dynamic dialysis and ultrafiltration validation 
were made under the same conditions as passively loaded liposomes without TPT present 
in the hydrating solution. 
Liposome characterization included particle size measurements by dynamic light 
scattering (DLS) and lipid content analyses using HPLC with evaporative light scattering 
detection (ELSD) as previously reported.130  Particle size data were used to monitor 
liposome stability and in combination with information on the number of vesicles in 
suspension (based on lipid content) and bilayer surface density data from the literature to 
calculate liposomal volumes necessary for the mathematical models.49, 50, 84, 135  
3.2.3  Release of TPT from DSPC/m-PEG DSPE liposomes 
All release studies were conducted in a water-jacketed incubator maintained at 37 °C.   
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3.2.3.1  Sephadex® column removal of unencapsulated drug from passively loaded liposome 
suspensions 
To compare release studies using dynamic dialysis (sink conditions) and ultrafiltration 
(non-sink conditions), 0.7 mL of 40 mg lipid/mL suspensions was passed through a 
Sephadex® PD-10 column to separate liposomes from unencapsulated drug.  The first 4.75 
mL was collected and diluted to 15 mL of suspension using the same buffer used for lipid 
hydration (without drug).  Next, 4.5 mL of this suspension was either transferred to dialysis 
tubes or 7 mL glass vials with a rubber stopper.  Release studies under either sink or non-
sink conditions were performed in triplicate.  Additional studies of the concentration 
dependence of binding to the DSPC bilayer utilized 90 mg lipid/mL suspensions and 0.25 or 
0.7 mL aliquots passed through a Sephadex® column.  In these instances, the first 1.5 mL of 
eluent was discarded and the next 3.25 mL containing the liposome suspension was 
collected and transferred to 7 mL glass vials with a rubber stopper.   
3.2.3.2  Non-sink release studies measured by ultrafiltration 
Glass vials containing the liposome suspensions were placed on a Thermo Cimerac iPoly 
15 multipoint stirrer insulated with 1.5 inches of Styrofoam® to minimize heating from the 
stir plate and subsequently maintained a suspension temperature of 37.4 ± 0.6 °C.  
Liposome suspensions were stirred at 200 rpm over the time course of the release study (~ 
96 hours) using 10 x 5 mm Teflon® stir bars. Encapsulated drug was monitored by ultrafiltration 
of 100 µL samples taken throughout the duration of the release studies.   
Ultrafiltration was chosen as it has been used in previous studies with liposomes as a 
method in which encapsulated drug may be separated from released drug.121, 130  Each 
sample was diluted with chilled (4 °C) buffer to 450 µL to quench drug release and ultrafiltered 
using an Amicon® Ultra 0.5 mL centrifugal filter device with a 30,000 MWCO Ultracel® 
membrane.  Samples were centrifuged in these cartridges at 14,000 rpm for 10 minutes in an 
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Eppendorf 5417R maintained at 4 °C.  During centrifugation, liposome integrity was maintained 
as suspensions were concentrated but not dried completely due to the conical geometry of the 
ultrafiltration membrane.  Concentrated suspensions (26 ± 2 µL) were recovered by inverting and 
centrifuging the cartridge at 2000 rpm for another 2 minutes.  After recovery of the concentrate, 
400 µL of chilled buffer was added and the process was repeated to ensure complete removal of 
membrane-bound extravesicular drug.  The final concentrate from this second cycle was analyzed 
by HPLC after dilution into the calibration range of TPT standards.  Chilled methanol (-20 °C) 
was used to disrupt the vesicles and minimize solvent evaporation during sample dilution.  
Samples that had not been ultrafiltered (20–100 uL) were also taken and immediately 
diluted in chilled methanol to determine the total amount of TPT and any extravesicular 
drug present at the beginning of the release study. 
3.2.3.3  Dynamic dialysis under sink conditions 
Dialysis tubes (Float-A-Lyzer® G2, 100,000 MWCO) containing 4.5 mL of liposome 
suspension were placed in 900 mL reservoirs containing pH 4.0 formate buffer pre-
equilibrated at 37 °C.  Aliquots (20 uL) were removed from the dialysis tube over a 48 hour 
period and immediately diluted in chilled methanol for TPT analysis by HPLC.    
3.2.4  Dialysis tube swelling studies 
Changes in the suspension volume within the dialysis tube during release studies may 
produce errors in the observed loss of drug during dynamic dialysis.  To correct for this, the 
rate of swelling as measured by the volume of sample within the dialysis tubes at 
equilibrium must be determined.  Fresh dialysis tubes of the same make as those used in 
dynamic dialysis studies were filled with 4 mL of the same buffer as that in the reservoir.  
These tubes were then allowed to sit in reservoirs at the same conditions used in dynamic 
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dialysis studies.  The volume in these tubes was monitored over time using a 10 mL 
graduated cylinder.   
3.2.5  TPT dimerization 
Several reports have indicated that TPT self-associates to form dimers,136-138 the tendency 
of which may be pH dependent.138  Self-association of TPT may result in liposomal 
membrane binding coefficients that are concentration dependent if only the monomeric 
form is involved in binding.  Since previous characterization of TPT self-association has 
been in the neutral pH range,136-138 studies were conducted to assess TPT dimerization at 
the conditions release studies were performed.  Apparent extinction coefficients were 
calculated for varying concentrations of TPT (1 – 250 µM) dissolved in the same buffer 
employed for release studies.  Absorbance was measured at wavelengths of 360, 376, 378, 
380, 382, 384, 386, and 388 nm using a Varian Cary 50 UV-Vis spectrophotometer.  NSG 
quartz cuvettes (NSG Precision Cells, Farmingdale, NY) with 2 and 10 mm path lengths were 
used to stay within the analytical range of the instrument. 
3.2.6  HPLC analyses 
Samples from release and validation studies were analyzed for TPT and lipid 
concentration by HPLC as reported previously.49, 130  TPT samples were analyzed with a 
previously developed HPLC method utilizing fluorescence detection.130  TPT lactone 
standards were prepared in chilled, acidified methanol over a concentration range of 20-
200 nM. Samples were diluted to within this concentration range using chilled methanol.  
Samples were either immediately injected or stored at -20 °C for no more than 48 hours 
before analysis. 
Lipid analysis was performed using an HPLC coupled to an ELSD (Sedere, Inc., 
Lawrenceville, NJ) as previously reported.49, 130  DSPC standards and samples were dissolved 
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in 80% chloroform:19.5% methanol:0.5%(v/v) of 30% (vol) NH4OH solution.  Standards 
spanned the concentration range of 0.05 – 0.3 mg DSPC/mL.  Lipid samples from release 
studies (50 – 150 µL) were dried at room temperature under N2.  Once dried, samples were 
redissolved in the above-mentioned solvent mixture to be within the calibration range of 
DSPC standards. 
3.2.7  Model Development and Data Analysis  
Previously, mechanistic models for liposomal release have been developed to account for 
the additional resistance contributed by the dialysis membrane in dynamic dialysis 
studies.49, 60, 118  The general concepts applicable to liposomal systems are depicted in 
Scheme 3.1.  By developing appropriate models, the rate of drug release applicable to sink 
conditions can be extracted from a variety of release methods.  Such a case is illustrated 
here by using mathematical models to analyze and compare the kinetics of liposomal 
release of TPT under sink and non-sink conditions.  All fitting of release kinetics and 
dimerization data was performed using Micromath® Scientist® non-linear regression 
software utilizing a weighting factor of two. 
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Scheme 3.1.  Illustration of the relevant kinetic and equilibrium processes 
applicable in developing a mathematical model for liposomal drug release as 
determined by dynamic dialysis.  The volume compartments of a liposome with 
radius, r, are highlighted along with the kinetic and binding components 
governing drug release.  The blue core is the inner aqueous volume, 𝑽𝒊
𝒘, while 
the green and purple sections refer to the inner, 𝑽𝒊
𝒎, and outer, 𝑽𝒐
𝒎, membrane 
volumes, respectively.  The rate of liposomal drug release depends on the rate 
constant, km’, and the difference in the unbound inner and outer aqueous drug 
concentrations, Tiw and Tow, respectively, while the apparent intravesicular, Ki’, 
and extravesicular, Ko’, binding coefficients govern the equilibrium between 
drug bound to the inner or outer lipid membrane, Tim and Tom, respectively, and 
the corresponding unbound drug in the intravesicular or extravesicular 
compartments, respectively.  The rate constant kd reflects the diffusion of drug 
across the dialysis membrane driven by the concentration gradient Tow -Tr.  All 
notations in red refer to aspects unique to dynamic dialysis conditions.   
3.2.7.1  Mathematical model of TPT release from unilamellar liposomes: non-sink conditions   
A mechanistic, mathematical model is required to obtain both drug permeability and 
membrane- binding from release studies.  Several models describing drug loading and 
release have already been developed;49, 60, 124, 127, 128, 139, 140 however, only a few have been 
tested and these studies have only examined release under sink conditions.49, 60, 124   
The apparent rate constant governing drug release from a liposome is a function of the 
drug’s apparent permeability coefficient, 𝑃𝑚′, through the bilayer and the radius, r, of the 
particle.  This is shown below in equation 1.49, 50 
𝑘𝑚
′ =
3
𝑟
𝑃𝑚′          (1) 
While 𝑘𝑚
′  may be dependent on the respective permeabilities of each species of drug 
present in solution, such a distinction cannot be made here as multiple conditions (e.g. pH) 
must be explored to determine each specie’s contribution.  Therefore, the 𝑘𝑚
′  determined 
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here applies to the specific pH chosen for these experiments (which is satisfactory for 
comparing these different release methods).   
Liposomal drug release is dependent on the driving force developed by the effective 
concentration gradient between unbound, intra- and extra-vesicular drug concentrations 
(𝑇𝑖
𝑤  and 𝑇𝑜
𝑤 , respectively).  This is expressed by equations 2a and b.    
     
𝑑𝑇𝑖
𝑑𝑡
= −𝑘𝑚
′ (𝑇𝑖
𝑤 − 𝑇𝑜
𝑤)        (2a) 
𝑑𝑇𝑜
𝑑𝑡
=
𝑛𝑉𝑖
𝑇
𝑉0
𝑇 𝑘𝑚
′ (𝑇𝑖
𝑤 − 𝑇𝑜
𝑤) = 𝑓𝑣𝑘𝑚
′ (𝑇𝑖
𝑤 − 𝑇𝑜
𝑤)     (2b) 
These differential equations describe bilayer-limited Fickian diffusion at a pseudo steady-
state.  The term 𝑓𝑣  symbolizes the ratio of total entrapped volume (the product of the total 
number of vesicles, n, and intravesicular volume of a single liposome, 𝑉𝑖
𝑇) to total 
extravesicular volume, 𝑉0
𝑇 , thus accounting for the difference in volumes of the inner and 
outer compartments. Derivation of the concentrations of unbound drug in the intra- and 
extra-vesicular compartments in terms of total intra- and extra-vesicular drug 
concentrations (𝑇𝑖  and 𝑇𝑜, respectively) will be described in a later section.  
For non-sink release studies, both the initial concentrations of intra- and extra-vesicular 
drug were determined by analyzing total suspension concentration of drug, T, and drug 
concentration after ultrafiltration of suspension when the release study began, Ti,0.  This is 
shown by the equations below: 
   𝑇𝑖(0) = 𝑇𝑖,0          (3a) 
𝑇𝑜(0) = 𝑇𝑜,0 = 𝑇 − 𝑓𝑣𝑇𝑖,0       (3b) 
3.2.7.2  Dynamic dialysis model of drug release from unilamellar liposomes: sink conditions 
Dynamic dialysis is advantageous for maintaining sink conditions as it provides a large 
reservoir capable of maintaining the driving force for drug release.  Because nanoparticles 
cannot cross the dialysis membrane, significant dilution of the nanoparticle suspension 
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during drug release is avoided and the concentration of drug remaining in the suspension 
versus time can be quantified.  This is depicted in Scheme 1.  Mathematically, the differential 
equation governing transport in the vesicle is the same as equation 2a, where 𝑇𝑜
𝑤  refers to 
the unbound extravesicular TPT within the dialysis tube.  A release rate constant for 
transport of liposomally-released drug from the dialysis tube, 𝑘𝑑 , must be added to eqn. 2b 
to describe transport from the extravesicular compartment of the dialysis tube into the 
reservoir compartment.  This is expressed by equation 4 with portions in red identifying the 
term unique to dynamic dialysis.  
   
𝑑𝑇𝑜
𝑑𝑡
= 𝑘𝑚
′ 𝑓𝑣(𝑇𝑖
𝑤 − 𝑇𝑜
𝑤) − 𝑘𝑑𝑇𝑜
𝑤        (4) 
In these studies, the suspension concentration of TPT within the dialysis tube at any time 
(𝑇𝑑) is sampled.  This concentration would naturally be composed of intra- and 
extravesicular TPT as shown by equation 5.  
  𝑇𝑑 = 𝑓𝑣𝑇𝑖 + 𝑇𝑜          (5) 
Derivation of the unbound drug concentrations in dynamic dialysis is the same as in the 
non-sink condition case (see next section).   
For sink conditions using the dynamic dialysis method, the initial conditions are 
dependent on the loading condition of the liposome suspension.  For passively-loaded 
liposomes, the initial conditions are as follows: 
  𝑇𝑖(0) =
𝑆
𝑓𝑣
         (6a) 
  𝑇𝑜(0) = 0         (6b) 
where S is the initial suspension concentration of TPT within the dialysis tube.  To 
accurately discern the rate of transport of drug through the dialysis membrane, a 
suspension of blank liposomes spiked with free TPT was used.  While the rate equations are 
the same as for passively-loaded drug, the initial conditions are not and are expressed 
below:  
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𝑇𝑖(0) = 0         (7a) 
𝑇𝑜(0) = 𝑆         (7b) 
3.2.7.3  Derivation of unbound drug concentration for modeling of release studies at sink and 
non-sink conditions  
Binding of drug to the phospholipid membrane interface has been reported previously 
with other chemotherapeutics and lipophilic drugs.49, 53, 61, 63, 118, 141  Such binding will reduce 
the driving force for drug transport, resulting in the need for a mathematical model that 
includes this effect on release kinetics.  Such a model was developed based on previous 
models (which account for drug binding) to describe the concentration of unbound drug in 
terms of total intra-and extravesicular drug concentration and its subsequent effect on 
release kinetics.49, 60  The relationship is the same for release studies conducted under non-
sink and sink conditions and is derived below. 
The total amount of drug inside (𝑀𝑖,𝑇) and outside (𝑀𝑜,𝑇) the vesicle can be expressed in 
terms of the contributions of aqueous and membrane bound components.  Equations 8a and 
b express these mass balances.  
    𝑀𝑖,𝑇 = 𝑀𝑖,𝑇
𝑤 +𝑀𝑖,𝑇
𝑚          (8a) 
                                         𝑀𝑜,𝑇 = 𝑀𝑜,𝑇
𝑤 +𝑀𝑜,𝑇
𝑚         (8b) 
In these equations and from this point on, the superscripts “w” and “m” represent 
unbound drug in the aqueous compartment and membrane bound drug, respectively; the 
subscripts i, and o, refer to the intra- and extra-vesicular compartments.  These mass 
balance equations can be expressed in terms of concentrations using the ratios of the 
aqueous to membrane volume in the inner and outer compartments defined in equations 
9a-e (see Scheme 1) 
     𝑎 =
𝑉𝑖
𝑤
𝑉𝑖
𝑇 , 𝑏 =
𝑉𝑖
𝑚
𝑉𝑖
𝑇 , 𝑐 =
𝑉𝑜
𝑤
𝑉𝑜
𝑇 , 𝑑 =
𝑛𝑉𝑜
𝑚
𝑉𝑜
𝑇 , 𝑓𝑣 =
𝑛𝑉𝑖
𝑇
𝑉𝑜
𝑇      (9a-e) 
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thus producing equations 10a & b for total drug concentration within, 𝑇𝑖 , and outside, 𝑇𝑜, 
the vesicles:  
𝑇𝑖 = 𝑎(𝑇𝑖
𝑤) + 𝑏(𝑇𝑖
𝑚)         (10a) 
𝑇𝑜 = 𝑐(𝑇𝑜
𝑤) + 𝑑(𝑇𝑜
𝑚)        (10b) 
Next, the concentration gradient of aqueous, unbound drug must be solved in terms of 
total drug encapsulated.  This is done by incorporating an apparent volume-normalized 
membrane binding coefficient describing the equilibrium between TPT bound at the 
interface of the bilayer membrane and that in solution for the intravesicular, Ki’, and 
extravesicular, Ko’, compartments. These binding constants may differ if there are 
differences in the intra- versus extra-vesicular environments (e.g. pH gradients, ionic 
strength differences, etc.) or prior to equilibrium when drug concentrations may differ 
dramatically between the inner and outer compartments.  In the present study of passively 
loaded liposomes, the intravesicular and extravesicular compartments were at the same pH 
and buffer concentration throughout the experiment.  At equilibrium both compartments 
contained the same drug concentration.  Under these conditions we found that a single K’ 
could be assumed (Ki’= Ko’) without diminishing the quality of the fit of the model to the 
data.  
With this assumption, the model may refer to both as K’ and,Tiw and Tow may be described 
by equations 11a and b 
𝑇𝑖
𝑤 = 𝑓𝑖
𝑤𝑇𝑖;  𝑓𝑖
𝑤 =
1
𝑎+𝑏𝐾′
        (11a) 
𝑇𝑜
𝑤 = 𝑓𝑜
𝑤𝑇𝑜;  𝑓𝑜
𝑤 =
1
𝑐+𝑑𝐾′
        (11b) 
with 𝐾′ = 𝑇𝑚 𝑇𝑤⁄ .  Using these substitutions, equations 2a, 2b, and 4 can be rewritten in 
terms of total intra- and extra-vesicular drug concentration.  
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3.2.7.4  Concentration corrections for ultrafiltration recovery and dialysis compartment 
volume 
 For non-sink release studies, the recovery of intra- and extra-vesicular drug after 
ultrafiltration must be accounted for to accurately assess release kinetics.  In dialysis 
experiments under sink conditions, the volume of the nanoparticle suspension within the 
dialysis tubes may fluctuate.   
The concentration of TPT determined by HPLC analysis of ultrafiltered samples, while 
mostly composed of intravesicular TPT, may require corrections due to the ultrafiltration 
process.  The observed concentration obtained from ultrafiltration, 𝑇𝑢, must be interpreted 
correctly to accurately model drug release.  This can be accomplished by expressing 𝑇𝑢 with 
equation 12. 
𝑇𝑢 = 𝜔
𝑇𝑖
𝑓𝑣
+𝜑𝑇𝑜          (12) 
Here, the % of intravesicular (𝜔) and extravesicular drug (𝜑) recovered in the 
ultrafiltrate were determined with validation studies. 
Ideally, the concentration in samples from dynamic dialysis studies at any sample time, n, 
would be dependent upon only diffusive transport process.  This suspension concentration, 
Td,n, can be determined from the observed concentration within the dialysis tube, 𝑇𝑑,𝑛
′  , by 
accounting for volume changes due to sample removal and dialysis bag shrinking/swelling.  
These effects are expressed by equation 13. 
 𝑇𝑑,𝑛 = 𝑥𝑣,𝑛𝑥𝑠,𝑛𝑇𝑑,𝑛
′         (13) 
The factors 𝑥𝑣,𝑛 and 𝑥𝑠,𝑛 correct for volume swelling in the dialysis tube and the mass 
removed due to sample collection since the previous time point, respectively.   
The correction factor for volume change in the dialysis tube, 𝑥𝑣,𝑛, is: 
    𝑥𝑣,𝑛 =
𝑉𝑛−1
𝑉𝑛
          (14) 
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where 𝑉𝑛 is the volume present in the dialysis tube at sample time, n, and 𝑉𝑛−1 is the 
volume present after removing sample for analysis at the previous time point (n-1).  The 
following equation describes the volume change occurring between time points:  
  𝑉𝑛 = 𝑉𝑛−1 + (𝑉𝑒𝑞 − 𝑉𝑛−1)(1 − 𝑒
−𝑘𝑣𝑡𝛥𝑛)      (15) 
where 𝑘𝑣  is the rate constant and  𝑉𝑒𝑞  is the volume in the dialysis tube at hydrostatic 
equilibrium.  𝑉𝑛−1 is the volume at the previous sampling time and 𝑡𝛥𝑛  is the time interval 
between the samples. 
In addition to swelling, the mass removed with each sample, while small, could 
cumulatively result in a substantial amount of lipid removal and subsequently encapsulated 
drug removed from the dialysis tube.  Because of volume swelling, the amount of mass 
taken from the previous sampling must be accounted for at each sampling.  The correction 
factors for the first, second, and any later sample (𝑥𝑠,1, 𝑥𝑠,2 , and 𝑥𝑠,𝑛, respectively) are:  
 𝑥𝑠,1 =
𝐿0
𝐿0
          (16a) 
𝑥𝑠,2 =
𝐿0
𝐿0
−
𝐿𝑠,1𝑉𝑠,1
𝐿0𝑉0
         (16b) 
𝑥𝑠,𝑛 =
𝐿0
𝐿0
− (
𝐿𝑠,1𝑉𝑠,1
𝐿0𝑉0
+
𝐿𝑠,2𝑉𝑠,2
𝐿0𝑉0
+⋯
𝐿𝑠,𝑛−1𝑉𝑠,𝑛−1
𝐿0𝑉0
)     (16c) 
Here, 𝐿0 is the lipid concentration in the initial suspension in the dialysis tube, 𝐿𝑠 and 𝑉𝑠 
are the lipid concentration and volume of sample taken, respectively (at the denoted sample 
number), and 𝑉0 is the initial volume of suspension added to the dialysis chamber. 
3.2.7.5  Determination of TPT dimerization constant (K2)  
Self-association of TPT in solution has been previously reported137, 138 and may affect 
observed binding due to the different binding affinities of the drug in its monomeric (T1) 
and dimeric (T2) forms and the effects of binding on the bilayer surface charge.  The two 
forms of TPT in solution can be related by a dimerization constant, K2, as shown by equation 
17.  
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𝐾2 =
𝑇2
𝑇1
2           (17) 
The two forms may also be related by mass balance in which the total concentration of TPT 
in solution, T, may be written as the sum of these species as shown in equation 18. 
 𝑇 = 𝑇1 + 2𝑇2         (18) 
Using these equations, the fraction of monomer present in solution, 𝑓1, can be solved as 
expressed by equation 19. 
𝑓1 =
−1+√1+8𝐾2𝑇
4𝐾2𝑇
         (19) 
In solution, both monomeric and dimeric forms of TPT have their own unique extinction 
coefficients (𝜀1,𝑖  and 𝜀2,𝑖, respectively) at any wavelength, i, which contribute to the 
apparent extinction coefficient, 𝜀𝑎𝑝𝑝.  This is shown by equation 20. 
       𝜀𝑎𝑝𝑝,𝑖 = 𝑓1𝜀1,𝑖 + 𝑓2𝜀2,𝑖 = 𝑓1𝜀1,𝑖 + (1 − 𝑓1)𝜀2,𝑖      (20) 
 Using equations 19 and 20, the concentration dependence of 𝜀𝑎𝑝𝑝,𝑖 was fit at multiple 
wavelengths simultaneously to determine K2, 𝜀1,𝑖  and 𝜀2,𝑖. 
3.3  Results 
3.3.1  Validation of Analytical Methods and Liposome Particle 
Characterization 
TPT concentrations were analyzed using a previously validated HPLC method with 
fluorescence detection.130  A linear response for TPT lactone (4.5 min retention time) was 
observed between 20 and 200 nM using excitation and emission wavelengths of 380 nm 
and 550 nm, respectively.  TPT concentrations in samples taken from release studies and 
size exclusion experiments ranging from 0.2 - 2 µM were determined by diluting samples 
with chilled methanol into the concentration range of standards.  
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Phospholipid content was determined using an HPLC method previously developed and 
validated.49, 130  ELSD was employed due to the lack of a chromophore/fluorophore in the 
lipid molecules.  A peak retention time of 7.9 minutes and a linear relationship between the 
logarithm of peak area and DSPC concentration was observed from 0.05 – 0.3 mg 
DSPC/mL,similar to that previously reported.49, 130 
Separation of passively-loaded TPT liposomes from unencapsulated drug was achieved 
with a Sephadex® size exclusion column.  Figure 3.1 compares the elution profiles of an 
aqueous solution of TPT in the absence of liposomes and a suspension of passively-loaded 
TPT-containing liposomes.  Both TPT and liposomes detected using HPLC and DLS, 
respectively, were present in the peak eluting in the 2.5- 5mL range while the solution of 
TPT in the absence of liposomes did not produce a peak in this range.   
 
Figure 3.1.  Elution profiles of free (  ) or liposomal TPT (  ) analyzed by 
HPLC.  The DLS intensity profile generated by liposomes (  ) is also shown to 
indicate separation of free from entrapped drug. 
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Particle size was determined by DLS for the liposomes before and after the conclusion of 
release studies.  The average particle size in five independent release studies (with 95 % 
confidence interval) was 98 ± 2 nm before studies began and 100 ± 3 nm after release 
studies were concluded.  Because phospholipids undergo acid-catalyzed ester hydrolysis, 
142-144 the stability of the phospholipid bilayer under acidic conditions for extended periods 
of time could lead to lipid loss during the release study and alter release kinetics.143  Lipid 
stability was evaluated by monitoring lipid content in solution using HPLC with an ELSD.  
Figure 3.2 demonstrates that liposomal suspensions employed in release studies conducted 
under non-sink conditions exhibited no lipid loss during the 96 hour period in which 
release was monitored.   
 
Figure 3.2. Lipid content was monitored during non-sink release studies.  The 
line indicates the average of all measured lipid concentrations and shows lipid 
content remained constant throughout the release experiments.  Error bars 
represent 95% confidence intervals. 
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3.3.2  Recovery from ultrafiltration and volume changes in dynamic dialysis  
Corrections were required to obtain the true release profiles from changes in drug 
concentration observed by both ultrafiltration and dynamic dialysis methods.  Values for 
the % of TPT and lipid recovered after ultrafiltration have been reported previously under 
similar conditions.130  The % of lipid recovered was used to determine the actual amount of 
intravesicular drug present in samples as trace amounts of extravesicular TPT still present 
after separation by Sephadex®118 would lead to a lower % of TPT recovered.130  
Additionally, any extravesicular drug still present after ultrafiltration could also lead to an 
overestimation in the binding coefficient observed.  To determine the % of extravesicular 
drug present in the retentate after ultrafiltration, blank liposome suspensions were spiked 
with TPT followed by immediate ultrafiltration. Using similar drug and lipid concentrations 
as those employed in release studies, the % of extravesicular TPT recovered during 
ultrafiltration was determined to be 1.5 ± 0.2 %.  This recovery was similar to the 1.4 % that 
would be expected based on the 26 µL of ultrafiltrate suspension that was retained after 
ultrafiltration.  For non-sink release studies, the initial concentration of extravesicular drug 
was never more than 0.2% of the drug concentration used to load the liposomes.  
Dynamic dialysis studies also required corrections in drug concentration due to increases 
or decreases in volume within the dialysis tube.  Additionally, the effect of sample removal 
also needed to be taken into account.  For these dynamic dialysis studies, 4.5 mL of solution 
was initially observed to fill the dialysis tubes to the top of the dialysis membrane.  
However, these tubes swelled during release studies. To correct for the effect of observed 
volume changes on drug concentration, the rate of volume swelling was determined.  This 
was achieved by filling a fresh set of dialysis tubes initially with 4 mL (Vo) of buffer solution, 
then monitoring volume changes over 72 hours at the same conditions used in dynamic 
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dialysis release studies.  The rate of swelling, kv, and tube volume at equilibrium, Veq, could 
be determine using the equation below.   
𝑉 = 𝑉0 + (𝑉𝑒𝑞 − 𝑉0)(1 − 𝑒
−𝑘𝑣𝑡)       (21) 
The resulting swelling profile of the dialysis tubes is shown by Figure 3.3a and resulted in 
a kv of 0.13 ± 0.02 hr-1 while Veq varied greatly between dialysis tubes (ranging from 4.8 – 
5.3 mL.  Using this rate constant and the Veq determined for each dialysis tube, the loss of 
lipid observed in dynamic dialysis studies could be accounted for using the correction 
factors described by equations 13 – 16 and is illustrated by Figure 3.3b.  These equations 
were then applied to TPT concentrations obtained during dynamic dialysis studies to reflect 
drug loss due only to liposomal release. 
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Figure 3.3.  The rate of dialysis tube swelling was monitored and used to 
determine a swelling rate constant for the dialysis tubes used in dynamic 
dialysis studies (A).  Using this swelling rate and accounting for the volume of 
sample removed over time, the loss in lipid observed over time in dynamic 
dialysis studies (  ) could be accounted for (  ) (B). 
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3.3.3  Comparison of release studies under non-sink and sink conditions  
In addition to these corrections, the parameters calculated in Table 3.1 which describe the 
ratio of aqueous and membrane volumes for the intravesicular compartment (a and b 
respectively) and the extravesicular compartment (c and d respectively) along with the 
ratio of entrapped and external volume (fv) were required for model fitting (see Appendix 
for a more detailed explanation) and calculated using previously reported values and 
equations.50, 135 With this information, the kinetic parameters for drug release under non-
sink and sink conditions could be compared.  For simplicity and because equilibrium is 
nearly reached in these non-sink studies, Ki’ and Ko’ are assumed to be equivalent at the end 
of these studies and thus referred to from this point on as K’.  Fitting of release profiles from 
0.48 mg lipid/mL suspensions under non-sink conditions as shown in Figure 3.4a resulted 
in a k’m of 0.51 ± 0.05 hr-1 and K’ of 73 ± 2.  For dialysis studies, drug transport across the 
dialysis membrane may affect observed drug release.49, 118  As such, release profiles from 
passively loaded liposome suspensions and blank liposome suspensions spiked with TPT 
were simultaneously fit to determine both k’m and the rate constant for TPT transport 
across the dialysis membrane (kd).  Because K’ cannot be determined from dynamic dialysis 
studies, it was held constant at the value determined from the non-sink studies.  Using this 
value and the parameters listed in Table 1, k’m and kd were simultaneously fit as shown by 
Figure 3.4b, resulting in values of 0.50 ± 0.04 hr-1 and 0.79 ± 0.13 hr-1 respectively.  The 
release profile of passively-loaded liposomes in Figure 3b also exhibits a lag time consistent 
with accumulation of released drug within the dialysis tube caused by the non-
instantaneous rate of drug transport across the dialysis membrane.49, 118  The values of k’m 
determined from both methods are nearly identical and show that non-sink studies can 
simultaneously provide accurate release rate constants along with drug binding 
information. 
43 
 
Table 3.1. Volume parameters used when comparing release studies of liposome 
suspensions under non-sink and sink-conditions 
Lipid Suspension Concentrations a b c d fv 
0.48 mg/mL (non-sink) 0.85 0.15 0.99982 0.00018 0.00122 
0.51 mg/mL (dialysis) 0.85 0.15 0.99980 0.00020 0.00135 
 
A. 
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Figure 3.4.  A comparison of the release profiles of TPT from DSPC/mPEG-DSPE 
liposomes obtained from ultrafiltration (A) and dynamic dialysis (B) methods at 
pH 4.0, 37 °C.  A) The release profiles of TPT under non-sink conditions are 
shown for suspensions of 0.48 (  ),      5.44 (  ), and 15.3 (  ) mg lipid /mL 
along with the fits of these data to the mathematical model describing release 
under non-sink conditions (represented by the lines of corresponding color).  
The inset at the top right compares the approach to equilibrium occurring under 
non-sink conditions to a simulated profile of release under sink conditions (
).  B) The release profiles of TPT using dynamic dialysis.  After correcting for 
volume swelling and sampling of the dialysis tube, TPT release from passively 
loaded liposomes       (  ) and blank liposome suspensions spiked with free 
drug (  ) were fit simultaneously, producing their respective release profiles 
(  and ).  Error bars indicate the standard deviation at each time point of 
triplicate release experiments. 
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3.3.4  Drug and lipid concentration effects on drug partitioning probed by non-
sink method  
Further validation of the non-sink method to examine release kinetics was performed by 
varying the suspension concentration of lipid.  For these studies, the same initial 
concentration of TPT was used to passively load the three different lipid suspensions.  This 
was done to avoid drug self-association effects on release kinetics (i.e., to maintain the same 
intravescicular driving force between the studies).   
Because equilibrium is achieved with a different extent of drug released due to changes in 
membrane binding of drug, the effects of membrane binding (K’) in addition to TPT 
permeability (k’m) on release may be observed by calculating the half-life to equilibrium 
(𝑡1/2) from these non-sink release studies.  This calculation starts by solving for 𝑡1/2 with 
the rearrangement of equation 2a and substituting for 𝑇𝑜 using the mass balance 𝑇𝑜 =
𝑓𝑣(𝑇𝑖,0 − 𝑇𝑖). 
   −
𝑑𝑇𝑖
𝑑𝑡
= 𝑘𝑚
′ 𝑇𝑖(𝑓𝑖
𝑤 + 𝑓𝑜
𝑤𝑓𝑣) − 𝑘𝑚
′ 𝑓𝑜
𝑤𝑓𝑣𝑇𝑖,0        (22) 
Next, the term 𝑘𝑚
′ 𝑓𝑜
𝑤𝑓𝑣𝑇𝑖,0 may be solved for by assuming equilibrium where 
𝑑𝑇𝑖
𝑑𝑡
= 0 and 
𝑇𝑖 = 𝑇𝑖
𝑒𝑞  and 22 becomes equation 23. 
     𝑘𝑚
′ 𝑓𝑜
𝑤𝑓𝑣𝑇𝑖,0 = 𝑘𝑚
′ 𝑇𝑖
𝑒𝑞(𝑓𝑖
𝑤 + 𝑓𝑜
𝑤𝑓𝑣)       (23) 
Substituting 23 back into 22 and rearrangement provides equation 24. 
  
𝑑𝑇𝑖
𝑑𝑡
= −(𝑘𝑚
′ 𝑓𝑖
𝑤 + 𝑘𝑚
′ 𝑓𝑜
𝑤𝑓𝑣)(𝑇𝑖 − 𝑇𝑖
𝑒𝑞)      (24) 
Equation 24 takes on the general form of a first order reaction.  Upon integration and 
substituting equations A11a & b for 𝑓𝑖
𝑤and 𝑓𝑜
𝑤  respectively, equation 25 is produced by 
solving for 𝑡1/2 as the time at which the amount of drug encapsulated is halfway to 
equilibrium (𝑇𝑖 − 𝑇𝑖
𝑒𝑞 = 0.5(𝑇𝑖,0 − 𝑇𝑖
𝑒𝑞)).   
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    𝑡1/2 =
ln (2)
𝑘′𝑚(
1
𝑎+𝑏𝐾′
+
𝑓𝑣
𝑐+𝑑𝐾′
)
          (25) 
The fitted release profiles for the three suspensions at varying lipid concentration in 
Figure 3.4a resulted in similar release half-lives (see Table 3.2), indicating this method is 
useful over a wide range of lipid concentrations.   Altering the suspension concentration of 
lipid to validate the non-sink method’s ability to determine release kinetics also allowed 
critical evaluation of the membrane binding coefficient determined from these release 
studies.   The apparent binding coefficients (K’) were observed to vary depending on the 
lipid concentration (spanning a 30-fold range).  The resulting fits of K’ were 73 ± 2, 46 ± 6, 
and 23 ± 3 for the 0.48, 5.44, and 15.3 mg lipid/mL suspensions, respectively.   
Because this release model accounts for the differences in aqueous and membrane 
volumes encountered under the various conditions studied, the apparent binding 
coefficients should not be different between these studies.  However, the cationic charge of 
TPT at pH 4.0 in conjunction with the varying suspension concentrations of TPT may have 
an effect on observed binding coefficients.  Both of these variables may be accounted for 
with the consideration of drug self-association and the change in bilayer surface potential 
due to binding of cationic drug.  To assess whether either or both effects contribute toward 
the variation in K’ observed experimentally, TPT dimerization in solution and the varying 
surface potential at the lipid membrane-solution interface were evaluated and used to 
determine intrinsic binding coefficients for the monomeric and dimeric forms of TPT 
binding to the DSPC/m-PEG DSPE bilayer. 
In general, the intrinsic binding coefficient, 𝐾𝑖
0 , for any species “i” (in this case TPT) 
capable of binding to the lipid membrane may be expressed by equation 26. 
    𝐾𝑖
0 =
𝑇𝑖→0
𝑚
𝑇𝑖→0
𝑤            (26) 
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Essentially, 𝐾𝑖
0 represents the equilibrium partition coefficient at infinitely dilute 
concentrations within the membrane and aqueous phases (𝑇𝑖→0
𝑚  and 𝑇𝑖→0
𝑤 , respectively) 
when the membrane surface charge is zero.  These intrinsic partition coefficients can be 
related to the observed partition coefficient at higher TPT concentrations as illustrated by 
equation 27.   
𝐾′ = 𝑓1𝛿1𝐾1
0 + 𝑓2𝛿2𝐾2
0 = 𝑓1𝛿1𝐾1
0 + (1 − 𝑓1)𝛿2𝐾2
0     (27) 
 Here, f1 and f2 account for the fractions of total TPT in the monomeric and dimeric forms, 
respectively, as defined by equation 19.  Values of f1 corresponding to the conditions at the 
end of each release study were calculated from the dimerization constant (K2) obtained by 
fitting the dependence of the TPT extinction coefficient on concentration (Figure 3.5a) to 
the dimer model described by equations 19 and 20. The estimated value of K2 is 6700 ± 600 
M-1. 
Table 3.2.  Values used to calculate the intrinsic DSPC bilayer/water 
partition coefficients for TPT species at pH 4 and 37 °C. 
Parameters 
Lipid suspensions 
0.48 mg/mL 5.44 mg/mL 15.3 mg/mL 
Total TPT (µM) 0.94 4.99 15.44 
t1/2 (hrs) 17 ± 2 19 ± 2 19 ± 3 
𝐾′ 73 ± 2 46 ± 4 23 ± 3 
𝑓1 0.99 0.95 0.83 
∑𝐶𝑖
𝑖
 0.6 0.6 0.6 
𝛿1 1.3 ± 0.1 1.8 2.3 
𝛿2 1.6 ± 0.3 3.2 5.3 
95% confidence intervals are shown where applicable 
The 𝛿 values account for the effects of changes in membrane surface potential on species 
binding with increasing drug concentration.  Because TPT is primarily cationic at pH 4, its 
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ability to bind to the bilayer surface will also depend on the membrane surface potential.  
Using the Gouy-Chapman theory as previously described by Austin and coworkers,141 this 
effect may be calculated for any partitioned species with charge z using the correction factor 
𝛿𝑧.  This correction factor is calculated with the following equation.141 
𝛿𝑧 = [
𝛼+∑ 𝐶𝑖𝑖 +√𝛼
2+2𝛼 ∑ 𝐶𝑖𝑖
∑ 𝐶𝑖𝑖
]
𝑧
        (28) 
Here, 𝛼 = 𝜎/(2000𝑅𝑇𝜖0𝜖𝑟) where 𝜎 is the surface charge density due to the 
concentration of TPT bound to the bilayer, 𝜖0  is the permittivity of a vacuum and 𝜖𝑟  is the 
relative permittivity of water.  This correction is also dependent upon the bulk 
concentration of all electrolytes in solution, ∑ 𝐶𝑖𝑖 , and the charge of the TPT species of 
interest as both monomer (1+) and dimer (2+) forms are present in the concentration range 
studied.138   
Using the values reported in Table 3.2 to account for dimerization and the membrane 
surface potential, 𝐾1
0 was determined to be 80 ± 20 while the partition coefficient for the 
dimer, K20, was found to be negligible. In Figure 3.5b, the profile generated by equation 27 
using the fitted value of 𝐾1
0 along with the dimer constant, K2, correlates well with the 
experimentally-observed apparent binding constants, K’. The inset in 4b also demonstrates 
the non-linearity observed in the plot of bound drug-to-lipid ratio, Tm/L, versus unbound 
monomeric drug concentration conforms to the Gouy-Chapman theory. 
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Figure 3.5.  A) The apparent extinction coefficients of TPT as a function of 
concentration at pH 4 were simultaneously fit to the dimer equations (19 and 
20) to determine a dimerization constant, K2. The plot shows extinction 
coefficients at 380 (blue), 376 (red), 386 (purple), and 388 (green) nm 
wavelengths along with lines of the corresponding color to represent the fit of 
the data to the dimerization model.  Only four of the eight wavelengths used are 
shown above for clarity.  B) Using K2 and correcting for the changes in bilayer 
surface potential described by the Gouy-Chapman theory, the apparent binding 
coefficient, K’, observed at the three lipid concentrations used in non-sink 
release studies  ( ) was used to determine the intrinsic binding coefficient, 𝐾1
0 
with equation 27, and the values provided in Table 3.2.  The resulting fit of K’ to 
equation 27 is shown (solid line) and correlates with the reduction in binding 
experimentally observed with the three TPT suspension concentrations studied.  
The inset to the top right compares the non-linear relationship of bound drug-
to-lipid ratio, Tm/L, with increasing concentration of unbound, monomeric drug, 
f1Tu, predicted by the Gouy-Chapman equation (dotted line) with that 
determined from non-sink release studies ( ). 
3.4  Discussion 
3.4.1  Effect of experimental parameters on extent of drug release under non-
sink conditions 
For the non-sink experiments, the extent of drug release is highly dependent upon two 
primary factors: fraction of volume encapsulated (𝑓𝑣) and the apparent membrane binding 
of drug to the liposomal bilayer (𝐾′).  The effect of these factors can be appreciated by 
examining the percentage of total drug released as defined by the following equation. 
  𝑋 =
𝑀𝑜,∞
𝑀𝑇
× 100%         (29) 
Here, Mo,∞ refers to the total mass of extravesicular drug at equilibrium and MT is the total 
mass of drug in the suspension.   
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Using the non-sink model, X can be simulated under a variety of experimental conditions 
(e.g. different lipid concentrations, particles sizes, drug binding coefficients etc.).  Figures 
3.6a and b illustrate two of the main experimental parameters affecting the total amount of 
drug released.  Here simulations were conducted to determine the expected % of drug 
released, X, for varying values of binding coefficients, K’, in Figure 3.6a and as a function of 
the ratio of entrapped volume, fv (i.e. liposome concentration), in Figure 3.6b.  In Figure 
3.6a, the plot shows that increasing values of K’ result in less drug released into the 
extravesicular compartment due to a higher amount bound to the membrane leaflet.  For 
Figure 3.6b, the increasing values of fv result in less drug released because a larger fraction 
of the total volume is within the intravesicular compartment.   
It would also be convenient to generalize these relationships so that the extent of drug 
release from liposomes under non-sink conditions could be estimated for a wide array of 
experimental conditions.  Such a relationship is illustrated by Figure 3.6c.  This nomograph 
was constructed by noting that at equilibrium, the concentrations of unbound, aqueous 
drug in the intra- and extra-vesicular solution will be equal. 
     𝑇𝑖
𝑤 = 𝑇𝑜
𝑤          (30) 
This relationship can then be rewritten in terms of total concentration of intra- and extra-
vesicular drug using the previous derived fraction of unbound intra- and extra-vesicular 
drug (eqns. 11a & b) and rearranged to the following ratio. 
 
𝑇𝑖
𝑇𝑜
=
𝑓𝑜
𝑤
𝑓𝑖
𝑤 =
𝑎+𝑏𝐾′
𝑐+𝑑𝐾′
         (31) 
Furthermore, one can specify the percent of drug released, 𝑋, in terms of the total 
suspension concentration of drug present in solution, 𝑇,  for 𝑇𝑖  and 𝑇𝑜 as expressed by 
equations 32a and b. 
     𝑇𝑖 =
(100−𝑋)𝑇
𝐸
         (32a) 
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𝑇𝑜 = (1 − 𝐸)𝑋𝑇         (32b) 
Here, the fraction of total volume entrapped, E, may be expressed in terms of the 
previously defined ratio of entrapped to external volume, 𝐸 = 𝑓𝑣 (1 + 𝑓𝑣)⁄ . These equations 
can be substituted into equation 31 and rearranged into the following equation. 
    
(100−𝑋)
𝑋
= [
𝑎+𝑏𝐾′
𝑐+𝑑𝐾′
]
𝐸
1−𝐸
         (15) 
This relationship is linear as shown in Figure 3.6c with 𝐸 (1 − 𝐸)⁄  providing the slope.   
Here, the slopes of lines are shown based on varying values of E, and the horizontal lines 
indicate the percent of drug which would be released at equilibrium.  
The above calculations and simulations assumed that all released drug, whether 
membrane-bound or free in extravesicular solution, was removed during ultrafiltration due 
to the low binding observed in these studies.  This assumption can be assessed based on the 
dilutions made during ultrafiltration and drug binding coefficients.  Based on the highest 
binding coefficient obtained during these experiments (73), there would be less than a 2.5% 
change in the total amount of drug removed over the range of lipid concentrations (0.48 – 
15.3 mg lipid/mL) used in these studies.  For drugs with higher membrane binding, a 
similar analysis shows that a 0.5 mg lipid/mL suspension would have less than a 3% change 
in the amount of drug removed for a lipophilic compound having a binding coefficient of 
2400. 
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Figure 3.6. The effect of experimental parameters on total drug release at 
equilibrium.  A) Keeping the suspension concentration constant at 0.5 mg/mL, 
simulations using the equations describing the non-sink model were used to 
determine the % of released drug, X, as a function of varying values of drug 
binding coefficients, K’.  These simulations are plotted for several common 
diameters of liposomes.  B) To illustrate the effect entrapped volume, fv , has on 
the amount of drug released under non-sink conditions, simulations were 
conducted in which K’ was held constant at 90.  The plot shows increasing fv  (i.e. 
increasing amount of liposomes) reduces the amount of drug released as the 
volume fraction entrapped increases (i.e. the number of liposomes in the 
suspension increase).  The lines illustrate this trend for liposomes of different 
diameters indicated by the legend in the upper right corner of plot. C)  This 
nomograph provides a general method for estimating the amount of released 
drug.  The plot relates all experimental conditions affecting the amount of drug 
released during a non-sink release study including the drug binding coefficient, 
K’, and the volume compartments present in the suspension (a and b for 
intravesicular aqueous and membrane compartments, and c and d for 
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extravesicular aqueous and membrane compartments), to X (as indicated by the 
labeled, horizontal lines).  This relationship is highly dependent upon the 
fraction of entrapped volume, E, as the slope steepens dramatically with 
increasing E (and subsequently higher lipid concentration).  
3.4.2  Applicability to drug release characterization for other drugs and/or 
nanoparticle formulations 
The mathematical model described here should be adaptable to other drugs and 
nanoparticle formulations. For every drug-nanoparticle combination, careful consideration 
should be given to which components of the current model are relevant and whether 
additional terms are necessary.  For example, an evaluation of the effect of pH on release 
requires consideration of drug speciation as the ionization of the drug may have an effect on 
observed release.49, 130  Other effects such as drug precipitation, complexation, or 
degradation may be taken into account by including relevant equilibrium equations to solve 
for the fraction of total drug free to permeate the membrane or by adding relevant kinetic 
terms (e.g. degradation/ineterconversion130 or dissolution rate constant) into the rate 
equation.  More generally, the non-sink method and model may be applicable to other 
agents as well as other types of nanoparticles (e.g., a current application of similar 
methodology underway in this laboratory involves doxorubicin-conjugated polymeric 
micelles).  
Validation of the % recovery and % of free drug removed is critical when considering 
the use of ultrafiltration to isolate drug remaining within the nanoparticle.  Significant 
binding of drug to the ultrafiltration membrane may interfere with removal of released drug 
by a washing step.  In such cases, other methods that can separate (e.g. size-exclusion) or 
distinguish (e.g. spectroscopic techniques) entrapped from released drug may be more 
appropriate yet still amenable to the non-sink mathematical model used here.  
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3.5  Conclusions 
The liposomal release kinetics and lipid bilayer partitioning of the anticancer agent TPT 
were simultaneously determined by ultrafiltering liposomal suspensions under non-sink 
conditions at various times. .  Dynamic dialysis was used to validate these findings by 
providing a nearly identical release rate constant.  The non-sink method was also able to 
probe the concentration dependence of TPT binding to the bilayer and revealed that 
binding was dependent on the surface potential at the bilayer interface and TPT 
dimerization.  The non-sink method provides a reliable way to obtain both kinetic and 
thermodynamic descriptors.  This method may also be useful in future mechanistic studies 
of liposomal drug release kinetics where dynamic dialysis studies are complicated by drug 
binding to the dialysis membrane or observed release is rate-limited by drug transport 
through the dialysis membrane.  The parameter values and methodology provided may 
have utility in the development of models capable of providing in vitro - in vivo correlations; 
however, environmental in vivo factors that may alter release rates would have to be 
investigated and incorporated into mechanistic models to yield useful, predictive 
relationships for liposomal formulations. 
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CHAPTER FOUR   
The Role of pH and Ring-opening Hydrolysis Kinetics on Liposomal 
Release of Topotecan 
4.1 Introduction 
Liposomal formulations offer several potential advantages for the intravenous delivery 
of antitumor agents due to  their ability to increase drug solubility, reduce drug toxicity, and 
prolong drug release.3  Pegylated liposomes have the added benefit of longer systemic 
circulation due to reduced clearance by the mononuclear phagocytic system. 3, 30-32   This 
prolonged circulation time when combined with an appropriate particle size provides 
preferential delivery of liposomes to solid tumors, a result of the well-known enhanced 
permeability and retention of nanoparticles in tumors. 3, 8, 31  These properties have led to 
the FDA-approved liposomal formulation of doxorubicin (DOXIL®) as well as other drug 
products, including several currently in clinical trials.33-40   
When investigated systematically, the antitumor efficacy of drug-loaded liposomal 
formulations has been closely linked to the drug release rate.21-24  Such investigations imply 
that the ability to tailor liposomal drug release rates could enable clinicians to optimize 
efficacy for a specific tumor by selecting the delivery system that produces the optimal 
tumor concentration profile.  Protracted or metronomic dosing regimens have shown such 
promise with enhanced antitumor agent efficacy,1, 145, 146 but these approaches are unable to 
take advantage of the localized intratumoral drug release afforded by liposomes and other 
nanoparticulate systems.  Liposomal systems that provide predictable drug release rates 
would reduce the frequent visits and monitoring currently necessary due to the narrow 
therapeutic window and rapid clearance of many chemotherapeutics.     
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While many models have been developed to describe drug loading,124, 127, 139, 140 few have 
considered release kinetics 49, 60, 128 and even fewer have been validated experimentally. 49, 60, 
124  Mechanistic models that incorporate physicochemical properties of the drug in solution 
including the drug species present as a function of intraliposomal pH, their interactions 
with the lipid bilayer, and their membrane permeabilities would be essential to release rate 
design and optimization.  
Liposomal formulations of topotecan (TPT) serve as a prime example of the need for 
mechanistic models to reliably predict drug release rates under a variety of loading and 
release conditions.  TPT is a topoisomerase I inhibitor currently approved to treat cervical, 
ovarian, and small cell lung cancers as an injectable solution and in multiple clinical trials as 
the sole medication or in conjunction with other medications and/or radiation.84-88 Like 
other weakly basic drugs, TPT exhibits high encapsulation efficiency in liposomal 
formulations utilizing active loading strategies.21, 42, 61, 73, 95-97  Previous work with liposomal 
TPT has mainly focused on encapsulation strategies, while the emphasis on controlled or 
extended release has been limited.24, 42, 62, 64, 97   
Studies that systematically examine various formulation and releasing-media 
parameters are necessary to develop a model capable of understanding and controlling 
release.  Since the generation of a low-intravesicular pH is a prerequisite for active loading 
of weak bases while drug release occurs under physiological conditions near a neutral pH, 
64, 73, 96 evaluating the sensitivity of TPT release to both the intra- and extravesicular pH is 
critical to the development of a mechanistic model having practical utility. Over this pH 
range, TPT is assumed to exist in solution as one of four major species as illustrated in 
Scheme 4.1.   
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Scheme 4.1.  The major species of TPT in solution in the low to neutral pH 
range.  Two lactone forms are present (𝐿𝑝and 𝐿𝑛 ) differing in the state of 
ionization of the phenol on ring A.  Reversible hydrolysis of the lactone E-ring 
may transform these species to their carboxylate counterparts (𝐶𝑛  and 𝐶𝑎  
respectively). 
The aim of the present work was to determine the pH sensitivity of TPT release from 
unilamellar liposomes and develop a mechanism-based mathematical model to account for 
the observed transport rates.  To completely account for the pH-permeability profiles 
obtained experimentally, the mathematical model had to include the effects of TPT 
speciation via ionization, membrane-binding equilibria, drug species’ permeability 
coefficients, and the kinetics and pH dependence of TPT lactone ring-opening/closing.     
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4.2 Materials and Methods 
4.2.1 Materials 
Powders of 1,2-Distearoyl-sn-glycero-3-phosphatidylcholine (DSPC, >99% purity) and 
1,2-distearoyl-sn-glycero-3-phosphoethanolamine-N-[methoxy(polyethyleneglycol)-2000] 
(m-PEG DSPE, MW = 2806, >99% purity) were purchased from Avanti Polar Lipids 
(Alabaster, AL).  Topotecan hydrochloride was purchased from AK Scientific (Union City, 
CA).  Millipore ultrafiltration cartridges (Amicon® Ultra 0.5 mL centrifugal filter device with 
30,000 MWCO Ultracel® membrane), Nuclepore polycarbonate membranes (0.1 µm), 
solvents, and buffer salts were purchased from Fisher Scientific (Florence, KY).  All solvents 
were HPLC grade.   
4.2.2 Preparation and characterization of DSPC/m-PEG DSPE liposomes for 
lactone-carboxylate interconversion and release studies  
Large unilamellar vesicles were formed using the film hydration and extrusion process 
described in several previous reports with slight modifications.49, 62  Briefly, DSPC and m-
PEG DSPE (95:5 mol:mol) lipids were weighed into borosilicate vials, then dissolved in 
chloroform. The chloroform was subsequently evaporated under a stream of N2 and the 
residue was vacuum-dried at 40°C for 6 hours to form a thin lipid film.  Films were hydrated 
and passed 10 times through two stacked Nuclepore polycarbonate membranes (100 nm 
pore) using a Liposofast® extrusion device at 60°C to obtain unilamellar vesicles.  All 
solutions for film hydration were made with a buffer concentration of 50 mM and adjusted 
to an ionic strength of 0.3 with NaCl.  The reported pH was measured at 37 °C.  Liposomes 
used in lactone-carboxylate interconversion studies were composed of lipid films hydrated 
with pH 6.33 (2-(N-morpholino)ethanesulfonic acid (MES)) and pH 7.67 (Tris) to achieve a 
final lipid concentration of 50 mg/mL.  Liposomes for release studies were hydrated with 
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solutions of pH 3.35 (chloroacetate), 4.01 (formate), 5.01 (acetate), 5.92 and 6.33 (MES), 
7.04 and 7.39 (phosphate), and 7.67 (Tris) containing 50 µM TPT, yielding a lipid 
concentration of 40 mg/mL.   
For the calculation of vesicle volume parameters, particle size and lipid content were 
determined.  Liposome particle size was analyzed using a Beckman Delsa™ Nano C Particle 
Sizer with a 70 second accumulation time.  Particle size before and after release studies was 
determined using Cumulants analysis.  Liposome suspensions were diluted by a factor of 10 
before analysis to obtain intensity readings within the detection range of the instrument.  
To avoid interference from dust and other artifacts during size analysis, the buffers used in 
liposome hydration and subsequent release studies were filtered with a 0.22 µm 
nitrocellulose filter.  Samples were stored at 4°C until analysis.  Lipid content was 
determined using HPLC and is described in further detail in the analyses section.  
4.2.3 Fluorescence measurements of aqueous TPT solutions 
 The acid dissociation constant of the TPT A-ring phenol was determined using changes 
in fluorescence excitation spectra with pH.  Solutions of 500 nM TPT were prepared at 
various pH with buffers of formate (pH 3.50), acetate (4.50 and 5.50), MES (pH 6.00 and 
6.27) and phosphate (pH 6.50, 6.80, 7.20, and 7.50) at concentrations of 50 mM while ionic 
strength was kept at 0.3 by adjustment with sodium chloride. Solutions were scanned with 
a FluoroMax-3 (Jobin Yvon Inc., Edison, NJ).  Excitation scans were made over a range of 300 
– 470 nm using an emission wavelength of 560 nm.  The temperature of the sample 
chamber was maintained at 37 °C, and fluorescence intensity was recorded using a 0.5 
second integration time and a 3 nm band pass width.   
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4.2.4 TPT interconversion studies 
Kinetic studies of the reversible and pH dependent ring-opening/closing of TPT were 
conducted with 0.4-0.6 µM TPT solutions at pH 5.92, 6.33, 7.04, 7.39, and 7.67 using the 
same buffers used to hydrate liposomes.  At pH 5.92 and 6.33, solutions were spiked with a 
50 µM stock solution of the ring-opened TPT carboxylate dissolved in 0.1 N NaOH.  Studies 
at higher pH used a 50 µM stock of lactone TPT in DMSO.  To determine the effect (if any) of 
TPT binding to the bilayer, interconversion studies were also conducted in 50 mg/mL 
liposome suspensions at pH 6.33 and 7.67 and compared with profiles obtained in aqueous 
solution.    
At various times, 150 µL samples were withdrawn and interconversion was quenched 
using 300 µL of a chilled (-20 °C) 2:1 (v:v) acetonitrile: methanol solution.  Samples were 
immediately injected and analyzed by HPLC for both ring-opened carboxylate and lactone 
content.  All studies were conducted in a water-jacketed incubator maintained at 37 °C and 
stirred at 200 rpm with a 10 x 5 mm Teflon stir bar using a Thermo Cimerac iPoly 15 
multipoint stirrer. 
4.2.5 Release of TPT from DSPC/DSPE-PEG-2K liposomes 
 Release studies were conducted in a similar manner as reported previously.147  
Unencapsulated TPT present in passively loaded liposome suspensions was removed by 
passing suspensions through a Sephadex G-25 column equilibrated with the same buffer as 
the liposome suspension.  Aliquots of liposome suspension (0.2–0.5 mL) were passed 
through the column and the drug-loaded liposome fraction eluting between 2.5–5 mL was 
collected, yielding liposome suspensions for release studies having lipid concentrations of 
1.0-4.5 mg/mL.  Liposome suspensions were transferred to glass vials capped with a rubber 
stopper and stirred at the same conditions used for interconversion studies within a water-
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jacketed incubator maintained at 37 °C.   Suspension temperature was monitored daily 
using a digital thermometer over the time span of release studies.  
Encapsulated drug was monitored by ultrafiltration of 50–150 µL aliquots of liposome 
suspension taken at various time points.  Each aliquot was diluted with chilled (4 °C) buffer 
to 425 µL and ultrafiltered using an Amicon® Ultra 0.5 mL centrifugal filter device with 
30,000 MWCO Ultracel® membrane.  Cartridges were then centrifuged at 14,000 rpm for 10 
minutes in an Eppendorf 5417R maintained at 4 °C.  The concentrated suspension (50 µL) 
was recovered by inverting the cartridge and centrifuging at 2000 rpm for another 2 
minutes.  Recovered concentrate was resuspended in another 400 µL of chilled buffer and 
the process was repeated.  The final concentrate was dissolved in acidified methanol and 
diluted within the calibration range for HPLC analysis.      
4.2.6 HPLC analyses 
Samples from interconversion studies were analyzed for TPT concentration by HPLC.148 
A Waters Alliance 2695 separation system coupled to a Waters fluorescence detector 
(M474) was employed with excitation and emission wavelengths at 380 and 560 nm, 
respectively.  Interconversion studies measured both lactone and carboxylate forms of TPT 
using a Supelcosil™ ABZ+ column (250 x 4.6 mm, 5 µm) and guard column (20 x 4.0 mm, 5 
µm) with a mobile phase (14% acetonitrile: 86% (v/v) of 5% (pH = 5.5) triethylamine 
acetate, 50 mM tetrabutylammonium hydrogen sulfate (TBAHS) buffer) flow rate of 1.5 
mL/min.  Lactone TPT standards were prepared in chilled, acidified methanol (-20 °C) and 
carboxylate standards were prepared in 10 mM sodium carbonate buffer (pH 10.1) at 20-
200 nM concentrations.  Lactone and carboxylate retention times were 5.5 and 2.1 min, 
respectively. 
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For release studies, samples were diluted in chilled, acidified methanol (0.001 N HCl for 
studies at pH ≤ 5.01 and 0.02 N HCl for studies conducted at higher pH) to convert all TPT to 
its lactone form. Samples were stored at -20 °C until analysis. TPT lactone was then 
analyzed using a Waters Symmetry® C18 column (4.6×150 mm, 5 µm) and guard column 
(3.9 x 20 mm) with a mobile phase (16% acetonitrile: 84% (v/v) of 5% (pH = 5.5) 
triethylamine acetate buffer) flow rate of 1 mL/min.  Sample compartment and column 
were kept at ambient temperature.   The retention time for TPT lactone was 4.5 min and 
response was linear between 20 and 200 nM.   
Lipid analysis was performed with HPLC using an evaporative light scattering detector 
(ELSD, Sedere, Inc., Lawrenceville, NJ) based on a previously described method using an 
Allsphere (Alltech Associates, Inc., Deerfield, IL) silica column (4 x 150 mm, 5 µm) and 
guard column (20 x 4.0 mm, 5 µm).  The elution method employed a linear gradient 
composed of 100% mobile phase A (80% chloroform:19.5% methanol:0.5%(v/v) NH4OH) 
changing to 80% mobile phase A and 20% mobile phase B (80% methanol:19.5% 
water:0.5% (v/v) NH4OH)  at 3 min which was maintained until 7 min, and returned to 
100% mobile phase A at 14 min at a flow rate of 1 mL/min.49 Samples (100 µL) were dried 
at room temperature under N2, then dissolved in chilled mobile phase A before analysis. 
4.2.7 Mechanism-based mathematical model development  
4.2.7.1 Mathematical model for liposomal TPT release including kinetics of lactone ring-
opening/closing 
Scheme 4.2 depicts the equilibria and rate constants that influence the rate of liposomal 
release of TPT as a function of pH.  While the mechanistic approach is similar to those 
employed previously for other compounds,49, 60, 124 the species present and parameter 
values will obviously differ.   Using this scheme, a mathematical model that accounted for 
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the various species of TPT as a function of pH was developed and described in the following 
section.  
  
 
 
6
6
 
 
 
Scheme 4.2.  A schematic of the associated equilibria and kinetics governing liposomal release of TPT.  The liposome depicted 
with radius, r, highlights the volume compartments described in the mathematical model.  The different volume compartments 
are color coded with blue highlighting the inner aqueous volume, 𝑉𝑖
𝑤 , while the green and violet sections refer to the inner, 
𝑉𝑖
𝑚 , and outer, 𝑉𝑜
𝑚 , membrane volumes, respectively.  The transport pathways and binding/ionization equilibria for all species 
illustrated in Scheme 4.1 are also depicted and described in the accompanying table (right).  
Symbols and description 
KA1 Phenol ionization 
w Aqueous species 
m Membrane-bound species 
i Intravesicular  
o Extravesicular 
Partition coefficients 
KL,p Binding for species Lp 
KC,n Binding for species Cn 
Release constants (hr-1) 
km,p For species Lp 
km,n For species Cn 
km,c For species Cn 
Interconversion kinetics 
kcl Ring-closing rate constant (hr-1) 
kop Ring-opening rate constant (hr-1) 
fCOOH Carboxylate fraction 
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Based on Scheme 4.2, the total amount of drug inside and outside liposomes consists of 
various solution and membrane-bound species (Equations 1a and b): 
 𝑀𝑖 = 𝑀𝑖,𝐿
𝑢 +𝑀𝑖,𝐿
𝑚 +𝑀𝑖,𝐶
𝑢 +𝑀𝑖,𝐶
𝑚       (1a) 
𝑀𝑜 = 𝑀𝑜,𝐿
𝑢 +𝑀𝑜,𝐿
𝑚 +𝑀𝑜,𝐶
𝑢 +𝑀𝑜,𝐶
𝑚        (1b) 
In these equations and from this point on, the superscripts u and m represent unbound 
species in the aqueous compartment and phospholipid membrane bound species, 
respectively; the subscripts, i, and, o, refer to the intra- and extravesicular compartments, 
respectively; and L and C refer to the lactone and carboxylate TPT species, respectively.  
These mass balance equations can be transformed to concentrations using volume ratios of 
the aqueous and membrane volumes of the inner and outer compartments.  These are 
expressed below in Equations 2a-e using the same annotations for volume as in Scheme 4.2.  
     𝑎 =
𝑉𝑖
𝑤
𝑉𝑖
𝑇 , 𝑏 =
𝑉𝑖
𝑚
𝑉𝑖
𝑇 , 𝑐 =
𝑉𝑜
𝑤
𝑉𝑜
𝑇 , 𝑑 =
𝑛𝑉𝑜
𝑚
𝑉𝑜
𝑇 , 𝑓𝑣 =
𝑛𝑉𝑖
𝑇
𝑉𝑜
𝑇      (2a-e) 
Combining the mass balance equations with Equations 2a-d produced equations for total 
drug concentration within, 𝑇𝑖 , and outside, 𝑇𝑜, the vesicles as described below. 
        𝑇𝑖 = 𝑎(𝐿𝑖
𝑢 + 𝐶𝑖
𝑢) + 𝑏(𝐿𝑖
𝑚 + 𝐶𝑖
𝑚)      (3a) 
       𝑇𝑜 = 𝑐(𝐿𝑜
𝑢 + 𝐶𝑜
𝑢) + 𝑑(𝐿𝑜
𝑚 + 𝐶𝑜
𝑚)      (3b) 
Total drug release within a liposome suspension may be described by the total rate of 
change for both intra- and extravesicular concentrations of TPT (
𝑑𝑇𝑖
𝑑𝑡
 and 
𝑑𝑇𝑜
𝑑𝑡
, respectively).  
This total rate of change is the sum of the rates of change for both the lactone, 
𝑑𝐿𝑖
𝑑𝑡
 & 
𝑑𝐿𝑜
𝑑𝑡
, and 
carboxylate, 
𝑑𝐶𝑖
𝑑𝑡
 & 
𝑑𝐶𝑜
𝑑𝑡
, forms of TPT in the intra- and extravesicular compartments.  This is 
expressed in Equations 4a and b.  
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𝑑𝑇𝑖
𝑑𝑡
=
𝑑𝐿𝑖
𝑑𝑡
+
𝑑𝐶𝑖
𝑑𝑡
          (4a) 
𝑑𝑇𝑜
𝑑𝑡
=
𝑑𝐿𝑜
𝑑𝑡
+
𝑑𝐶𝑜
𝑑𝑡
          (4b) 
The driving force governing liposomal drug release is the concentration gradient 
between the unbound, intra- and extra-vesicular concentrations of the permeable species. 
In the case of TPT, pH-dependent ring-closure may become the rate-limiting step for drug 
release under certain conditions.  Thus, the rates of change of the intravesicular lactone and 
carboxylate concentrations are determined by both diffusive and chemical kinetic 
contributions as depicted in Equation 5. 
          𝑟𝑎𝑡𝑒 = 𝑑𝑖𝑓𝑓𝑢𝑠𝑖𝑜𝑛 + 𝑖𝑛𝑡𝑒𝑟𝑐𝑜𝑛𝑣𝑒𝑟𝑠𝑖𝑜𝑛       (5)  
These terms can be explicitly written for the rates of both the lactone and carboxylate 
forms of TPT as shown by Equations 6a-d.    
𝑑𝐿𝑖
𝑑𝑡
 = −𝑘𝑚,𝐿
′ (𝐿𝑖
𝑢 − 𝐿𝑜
𝑢) − 𝑘𝑐𝑙𝐾0𝐿𝑖 + 𝑘𝑐𝑙𝑓𝐶𝑂𝑂𝐻𝐶𝑖      (6a) 
𝑑𝐶𝑖
𝑑𝑡
 = −𝑘𝑚,𝐶
′ (𝐶𝑖
𝑢 − 𝐶𝑜
𝑢) + 𝑘𝑐𝑙𝐾0𝐿𝑖 − 𝑘𝑐𝑙𝑓𝐶𝑂𝑂𝐻𝐶𝑖      (6b) 
𝑑𝐿𝑜
𝑑𝑡
 = 𝑘𝑚,𝐿
′ 𝑓𝑣(𝐿𝑖
𝑢 − 𝐿𝑜
𝑢) − 𝑘𝑐𝑙𝐾0𝐿𝑜 + 𝑘𝑐𝑙𝑓𝐶𝑂𝑂𝐻𝐶𝑜     (6c) 
𝑑𝐶𝑜
𝑑𝑡
 = 𝑘𝑚,𝐶
′ 𝑓𝑣(𝐶𝑖
𝑢 − 𝐶𝑜
𝑢) + 𝑘𝑐𝑙𝐾0𝐿𝑜 − 𝑘𝑐𝑙𝑓𝐶𝑂𝑂𝐻𝐶𝑜    (6d) 
The colors highlighting the various terms in Equations 6a-d correspond to those in 
Equation 5.  In these equations, the rates of change of intravesicular lactone and carboxylate 
(highlighted green) are composed of diffusive (yellow) and chemical kinetic components 
(blue) describing interconversion of TPT between its lactone and carboxylate forms. The 
diffusive term describes bilayer-limited Fickian diffusion using a pseudo steady-state 
 69 
 
approximation (based on the absence of a lag time in the observed drug release profiles).  
The two terms to the right reflect the reversible kinetics of TPT lactone ring opening and 
closing.   The term 𝑓𝑣  accounts for the ratio of total entrapped volume to total volume as 
defined by Equation 2e.   
In the diffusion term, 𝑘𝑚,𝐿
′  and 𝑘𝑚,𝐶
′  are effective transport rate constants for the lactone 
and carboxylate species, respectively.  These constants are pH dependent, as determined by 
the various ionization states of the lactone and carboxylate species (Scheme 4.1) and their 
permeability coefficients.  The superscript, u, indicates that only lactone and carboxylate 
species not bound to the membrane contribute to the diffusive driving force governing 
release.   
The transport rate constants for the lactone and carboxylate forms of TPT are 
dependent upon their ionization states and will vary depending upon the pH.  These factors 
are accounted for by Equations 7a and b for both the lactone, 𝑘𝑚,𝐿
′ , and carboxylate, 𝑘𝑚,𝐶
′ , 
respectively: 
𝑘𝑚,𝐿
′ = 𝑓𝐿𝑝
𝑢 𝑘𝑚,𝐿𝑝
0 + 𝑓𝐿𝑛
𝑢 𝑘𝑚,𝐿𝑛
0        (7a) 
𝑘𝑚,𝐶
′ = 𝑓𝐶𝑛
𝑢 𝑘𝑚,𝐶𝑛
0 + 𝑓𝐶𝑎
𝑢 𝑘𝑚,𝐶𝑎
0        (7b) 
Lactone transport is a function of the fraction of the protonated species and its transport 
coefficient, 𝑘𝑚,𝐿𝑝
0 , and the fraction of zwitterionic phenolate and its transport coefficient, 
𝑘𝑚,𝐿𝑛
0 .  Similarly, carboxylate transport is governed by the fraction of the zwitterionic form 
and 𝑘𝑚,𝐶𝑛
0 , and the anionic phenolate fraction and 𝑘𝑚,𝐶𝑎
0 .  The lactone and carboxylate forms 
were assumed to have the same phenol group pKa because of the separation of the A-ring 
phenolic –OH from the lactone ring. Therefore, 
 70 
 
𝑓𝐿𝑝
𝑢 = 𝑓𝐶𝑛
𝑢 =
𝐻+
𝐻++𝐾𝑎1
; 𝑓𝐿𝑛
𝑢 = 𝑓𝐶𝑎
𝑢 =
𝐾𝑎1
𝐻++𝐾𝑎1
     (8a;b) 
Next, the concentration gradient of aqueous, unbound drug must be solved in terms of 
total drug encapsulated for both lactone and carboxylate.  This is accomplished by 
incorporating the apparent volume-based membrane partition coefficients for the lactone, 
𝐾𝐿
′ , and the carboxylate, 𝐾𝐶
′ , as shown in Equations 9a and b. 
      𝐿𝑖
𝑢 = 𝑓𝑖,𝐿
𝑢 𝐿𝑖,𝑇;  𝑓𝑖,𝐿
𝑢 =
1
𝑎+𝑏𝐾𝐿
′       (9a) 
     𝐶𝑖
𝑢 = 𝑓𝑖,𝐶
𝑢 𝐶𝑖,𝑇;  𝑓𝑖,𝐶
𝑢 =
1
𝑎+𝑏𝐾𝐶
′        (9b) 
Similar substitutions can be made for the extra-vesicular fraction unbound for lactone, 𝑓𝑜,𝐿
𝑢 , 
and carboxylate, 𝑓𝑜,𝐶
𝑢 , using the ratios for extra-vesicular membrane, c, and aqueous, d, 
volume.   
As before with permeability, ionization of these species may also affect binding.  The 
apparent partition coefficients may then be written in terms of the intrinsic partition 
coefficients of each ionization state. 
      𝐾𝐿
′ = 𝑓𝐿𝑝
𝑢𝐾𝐿𝑝
0 + 𝑓𝐿𝑛
𝑢 𝐾𝐿𝑛
0         (10a) 
     𝐾𝐶
′ = 𝑓𝐿𝑝
𝑢𝐾𝐶𝑛
0 + 𝑓𝐿𝑛
𝑢 𝐾𝐶𝑎
0         (10b) 
By substituting the expressions in Equations 7 and 9 into Equations 6a-d, the differential 
equations may be solved in terms of total intra- and extra-vesicular concentrations of 
lactone and carboxylate species. 
𝑑𝐿𝑖
𝑑𝑡
= −(𝑓𝐿𝑝
𝑢 𝑘𝑚,𝐿𝑝
0 + 𝑓𝐿𝑛
𝑢 𝑘𝑚,𝐿𝑛
0 )(𝑓𝑖,𝐿
𝑢 𝐿𝑖
𝑢 − 𝑓𝑜,𝐿
𝑢 𝐿𝑜
𝑢) − 𝑘𝑐𝑙𝐾0𝐿𝑖 + 𝑘𝑐𝑙𝑓𝐶𝑂𝑂𝐻𝐶𝑖    (11a) 
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𝑑𝐶𝑖
𝑑𝑡
= −(𝑓𝐿𝑝
𝑢 𝑘𝑚,𝐶𝑛
0 + 𝑓𝐿𝑛
𝑢 𝑘𝑚,𝐶𝑎
0 )(𝑓𝑖,𝐿
𝑢 𝐶𝑖
𝑢 − 𝑓𝑜,𝐿
𝑢 𝐶𝑜
𝑢) + 𝑘𝑐𝑙𝐾0𝐿𝑖 − 𝑘𝑐𝑙𝑓𝐶𝑂𝑂𝐻𝐶𝑖   (11b) 
𝑑𝐿𝑜
𝑑𝑡
= 𝑓𝑣(𝑓𝐿𝑝
𝑢 𝑘𝑚,𝐿𝑝
0 + 𝑓𝐿𝑛
𝑢 𝑘𝑚,𝐿𝑛
0 )(𝑓𝑖,𝐿
𝑢 𝐿𝑖
𝑢 − 𝑓𝑜,𝐿
𝑢 𝐿𝑜
𝑢) − 𝑘𝑐𝑙𝐾0𝐿𝑜 + 𝑘𝑐𝑙𝑓𝐶𝑂𝑂𝐻𝐶𝑜   (11c) 
𝑑𝐶𝑜
𝑑𝑡
= 𝑓𝑣(𝑓𝐿𝑝
𝑢 𝑘𝑚,𝐶𝑛
0 + 𝑓𝐿𝑛
𝑢 𝑘𝑚,𝐶𝑎
0 )(𝑓𝑖,𝐿
𝑢 𝐶𝑖
𝑢 − 𝑓𝑜,𝐿
𝑢 𝐶𝑜
𝑢) + 𝑘𝑐𝑙𝐾0𝐿𝑜 − 𝑘𝑐𝑙𝑓𝐶𝑂𝑂𝐻𝐶𝑜   (11d) 
While this provides a valid set of equations to solve, initial conditions must include the 
initial fractions of lactone and carboxylate.  These were determined from the pH, assuming 
initial equilibrium between the two forms.   Because the fraction of ring-opened carboxylic 
acid is negligible due to the dominance of lactone at low pH for camptothecins,92 an 
apparent acid dissociation constant, 𝐾𝑎2, relating the lactone to carboxylate form can be 
described in terms of the ring-opening constant (𝐾0) and the ionization constant for the 
carboxylic acid (𝐾𝐶𝑂𝑂𝐻).  This relationship is expressed by Equation 12. 
𝐾𝑎2 =
[𝐻+][𝐶𝑇
𝑤]
[𝐿𝑇
𝑤]
= 𝐾𝐶𝑂𝑂𝐻𝐾0       (12) 
Using Equation 12, the initial concentrations of lactone and carboxylate were solved as 
shown below. 
𝐿𝑖(0) =
𝑇𝑖𝐻
+(𝑎+𝑏𝐾𝐿
′)
𝐻+(𝑎+𝑏𝐾𝐿
′)+𝐾𝑎2(𝑎+𝑏𝐾𝐶
′ )
       (13a) 
𝐶𝑖(0) =
𝑇𝑖𝐾𝑎2(𝑎+𝑏𝐾𝐶
′ )
𝐻+(𝑎+𝑏𝐾𝐿
′)+𝐾𝑎2(𝑎+𝑏𝐾𝐶
′ )
       (13b) 
𝐿𝑜(0) =
𝑇𝑜𝐻
+(𝑐+𝑏𝐾𝐿
′)
𝐻+(𝑐+𝑏𝐾𝐿
′)+𝐾𝑎2(𝑑+𝑏𝐾𝐶
′ )
       (13c) 
𝐶𝑜(0) =
𝑇𝑜𝐾𝑎2(𝑑+𝑏𝐾𝐶
′ )
𝐻+(𝑐+𝑏𝐾𝐿
′)+𝐾𝑎2(𝑑+𝑏𝐾𝐶
′ )
       (13d) 
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Additionally, observed suspension concentrations obtained from HPLC samples after 
ultrafiltration, 𝑇𝑖
′ , were related to the total intravesicular concentration of entrapped TPT as 
only a small fraction of total suspension volume was encapsulated.  The ratio of entrapped 
to extra-vesicular volume is 𝑓𝑣 . 
     𝑇𝑖
′ = 𝑓𝑣𝑇𝑖         (14) 
To avoid over-estimation of binding from release studies, any extra-vesicular drug at 
the beginning of the experiment was incorporated into the initial conditions when solving 
the model.  Determination of the extra-vesicular concentration (if any), 𝑇𝑜, at the beginning 
of the experiment was done with the following equation: 
     𝑇𝑜 = 𝑇 − 𝑇𝑖
′         (15) 
where 𝑇 is the total TPT concentration in suspension before ultrafiltration.  The equations 
above were then used to fit the release data obtained at pH 3.35 – 7.67.  By incorporating 
pKa1,kcl, and Ko (constants previously determined in other experiments), all release data 
were fit simultaneously to determine the partition coefficients and rate constants of each 
TPT species in solution.   
Using this mechanistic model to obtain release rate constants for each TPT species from 
transport studies also required separate experiments to generate parameters governing the 
ionization state of the TPT A-ring phenol and the lactone-carboxylate interconversion 
kinetics.  These determinations are described in the following sections.   
4.2.7.2 Spectrometric determination of the TPT A-ring phenol (pKa1) 
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The ionization state of drugs and small molecules has been shown to alter release 
kinetics, typically due to the likelihood that the neutral form is more permeable than 
charged species.49, 50, 52  In the case of TPT, the phenolic -OH group ortho to the dimethyl-
aminomethyl substituent on the A ring may ionize and alter the charge of TPT as depicted in 
Scheme 4.3.   
Scheme 4.3.  Phenol ionization on the A ring of TPT is governed by the acid 
dissociation constant, 𝐾𝑎1. 
The relationship between the phenol and the phenolate depicted in Scheme 4.3 and its 
pH dependence is governed by the acid dissociation constant, 𝐾𝑎1, as expressed in Equation 
16. 
         𝐾𝑎1 =
[𝐻+][𝑃𝑂−]
[𝑃𝑂𝐻]
         (16) 
where [𝑃𝑂−] is the total concentration of TPT species with an ionized phenolate moiety and 
[𝑃𝑂𝐻] is the concentration of all TPT species with the unionized phenol moiety.   
At any given excitation wavelength, j, the fluorescence intensity in aqueous solution 
emitted at wavelength, 𝐼𝑗 , can be described as the sum of the phenol species, 𝐼𝑗,𝑂𝐻, and 
phenolate species, 𝐼𝑗,𝑂−  (Equation 17).   
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          𝐼𝑗 = 𝐼𝑗,𝑂𝐻 + 𝐼𝑗,𝑂−           (17) 
These intensities can be related to the concentrations of each species by their respective 
specific intensities, 𝜖𝑂𝐻 , and  𝜖𝑂− , and the fractions of the phenol, 𝑓𝑂𝐻 , and phenolate, 𝑓𝑂− , 
forms in solution containing a total concentration, T.  Equation 17 can be rewritten in terms 
of the fractions of each species present. 
            𝐼𝑗 = 𝑇[𝑓𝑂𝐻𝜖𝑗,𝑂𝐻 + 𝑓𝑂−𝜖𝑗,𝑂−]        (18) 
Here, the fraction of drug in each form may be expressed by mass balance and 
rearrangement of Equation 16 as illustrated below in Equations 19a and b. 
    𝑓𝑂𝐻 =
𝐻+
𝐻++𝐾𝑎1
; 𝑓𝑂− =
𝐾𝑎1
𝐻++𝐾𝑎1
       (19a; b) 
For spectrometric determination of 𝐾𝑎1, fluorescence emission at 560 nm was fitted to 
the above equations at varying pH (3.5 – 7.5) and a constant TPT concentration of 500 nM 
to determine 𝐾𝑎1 and 𝜖𝑗,𝑂− at excitation wavelengths of 335, 365, 380, and 410 nm.  The 
determination of 𝜖𝑗,𝑂𝐻  was accomplished using the fluorescence intensity at pH 3.5 by 
assuming 𝐼𝑗,𝑂− was negligible at this pH. 
4.2.7.3 TPT lactone-carboxylate interconversion kinetics in solution and in the presence of 
liposomes 
The lactone E-ring in TPT can undergo reversible, base-catalyzed hydrolysis to form its 
ring-opened, carboxylate form via deprotonation of the carboxylic acid intermediate, 𝐶𝐶𝑂𝑂𝐻  
(Scheme 4.4). This process is pH-dependent, similar to other camptothecin analogues, with 
the lactone form, 𝐿, dominating at low pH.  As pH is increased, both ring-opening and 
closing rate constants are base-catalyzed; however, ionization of the ring-opened carboxylic 
acid to form 𝐶𝐶𝑂𝑂− shifts the equilibrium toward the ring-opened species.92, 148 
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Scheme 4.4.  The proposed mechanism for reversible, pH dependent ring 
opening of TPT from its lactone, 𝐿, to carboxylate, 𝐶𝐶𝑂𝑂−, form.  Because ring 
opening proceeds through the carboxylic acid species, 𝐶𝐶𝑂𝑂𝐻 , ring opening 
increases as more carboxylate is formed at higher pH, as governed by the acid 
dissociation constant for the E-ring carboxylic acid, KCOOH. 
Because of its location and the molecule’s rigidity, it is unlikely that the ionization state 
of the phenol would have any effect on the lactone-carboxylate interconversion kinetics.  
With this assumption, the rate equations for ring opening and closing can be expressed in 
terms of total lactone, 𝐿, and carboxylic acid, 𝐶𝐶𝑂𝑂𝐻 , concentrations in solution as shown 
below. 
     
𝑑𝐿
𝑑𝑡
= 𝑘𝑐𝑙[𝑂𝐻
−]𝐶𝐶𝑂𝑂𝐻 − 𝑘𝑜𝑝[𝑂𝐻
−]𝐿       (20a) 
    
𝑑𝐶
𝑑𝑡
= −𝑘𝑐𝑙[𝑂𝐻
−]𝐶𝐶𝑂𝑂𝐻 + 𝑘𝑜𝑝[𝑂𝐻
−]𝐿      (20b) 
Solving for 𝐶𝐶𝑂𝑂𝐻  in terms of total ring-opened species, 𝐶, is needed.  The fraction of 
total ring-opened species present as carboxylic acid at a particular pH, 𝑓𝐶𝑂𝑂𝐻 , can be 
determined from the pKa of the carboxylic acid (Equation 21).     
      𝑓𝐶𝑂𝑂𝐻 =
𝐻+
𝐻++𝐾𝐶𝑂𝑂𝐻
          (21) 
 76 
 
In previous studies, the  𝑝𝐾𝐶𝑂𝑂𝐻  for TPT, camptothecin, and other analogues has been 
assumed to be 3.8 or 4.0.92, 148  Based on those studies and the pKa value of 3.86 for glycolic 
acid, a value of 3.9 was assumed for model fitting. 
To reduce the correlation between the ring-opening, 𝑘𝑜𝑝 , and ring-closing, 𝑘𝑐𝑙 , rate 
constants during model fitting, the equilibrium constant between the ring-opened 
carboxylate acid and ring-closed lactone forms, 𝐾0 , was used.  As seen in Equation 22b, 
𝑘𝑜𝑝  can be rewritten in terms of 𝑘𝑐𝑙  and 𝐾0 . 
           𝐾0 =
𝐶𝐶𝑂𝑂𝐻
𝐿
=
𝑘𝑜𝑝
𝑘𝑐𝑙
; 𝑘𝑜𝑝 = 𝑘𝑐𝑙𝐾0      (22a; b) 
Substituting Equations S21 and 22b into rate Equations 20a and b, 
     
𝑑𝐿
𝑑𝑡
= 𝑘𝑐𝑙[𝑂𝐻
−]𝑓𝐶𝑂𝑂𝐻𝐶 − 𝑘𝑐𝑙𝐾0[𝑂𝐻
−]𝐿      (23a) 
    
𝑑𝐶
𝑑𝑡
= −𝑘𝑐𝑙[𝑂𝐻
−]𝑓𝐶𝑂𝑂𝐻𝐶 + 𝑘𝑐𝑙𝐾0[𝑂𝐻
−]𝐿      (23b) 
To determine 𝐾0 and 𝑘𝑐𝑙  at the same conditions used for release studies, TPT 
interconversion studies were first performed at varying pH (6.33 – 7.67) in the absence of 
liposomes. These studies were fit simultaneously to rate Equations 23a and S8b.  Studies in 
the presence of liposome suspensions (50 mg/mL) prepared in pH 6.33 and pH 7.67 buffers 
were also conducted.  The lactone and carboxylate concentration versus time profiles were 
compared to those obtained at the same pH in the absence of liposomes to evaluate whether 
membrane binding had an effect on the interconversion kinetics. 
4.2.7.4 Mathematical model for liposomal TPT release assuming equilibrium for lactone ring-
opening/closing   
To evaluate the need for lactone/carboxylate interconversion kinetics in the release 
model, the half-life profile of that model was compared to a half-life profile generated by 
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fitting TPT release profiles at varying pH to an equilibrium model.  To determine the half-
life profile for the equilibrium model, 𝑡1/2 may be expressed by Equation 24.  
𝑡1/2 =
ln(2)
𝑘𝑚𝑓
𝑢 =
ln (2)(𝑎+𝑏𝐾′)
𝑘𝑚
        (24) 
Here, the overall release constant, 𝑘𝑚 , and total fraction of unbound intravesicular drug, 𝑓
𝑢 , 
are considered.  Both parameters are a function of pH.  In equation 24, 𝑘𝑚  accounts for the 
fraction of each permeable species found in solution along with their respective transport 
rate constants, where 𝑘𝑚,𝐿𝑝
0  is the transport rate constant for the protonated lactone, 𝑘𝑚,𝐿𝑛
0  
is for the zwitterionic phenolate form of the lactone, and 𝑘𝑚,𝐶𝑛
0 is for the ring-opened 
carboxylate zwitterion.  
 𝑘𝑚 =
𝐻+(𝑓𝐿𝑝
𝑢 𝑘𝑚,𝐿𝑝
0 +𝑓𝐿𝑛
𝑢 𝑘𝑚,𝐿𝑛
0 )+𝐾𝐴2𝑓𝐿𝑝
𝑢 𝑘𝑚,𝐶𝑛
0
𝐻++𝐾𝐴2
     (25) 
The unbound fraction (𝑓𝑢) in Equation 24 varies with pH as it is a function of the 
apparent membrane binding constant, 𝐾’, as illustrated by Equation 25. The binding 
constants obtained previously using the mathematical model for liposomal TPT release that 
included the kinetics of lactone ring-opening/closing were inserted as constants into 
Equation 25. 
𝐾′ =
𝑓𝐿𝑝
𝑢 (𝐻+𝐾𝐿𝑝
0 +𝐾𝐴2𝐾𝐶𝑛
0 )
𝐻++𝐾𝐴2
         (25) 
The release profiles were simultaneously fit to the equilibrium model described by 
Equations S22-24 where the rate constants ( 𝑘𝑚,𝐿𝑝
0 , 𝑘𝑚,𝐿𝑛
0 , 𝑘𝑚,𝐶𝑛
0 , and 𝑘𝑚,𝐶𝑎
0 ) and membrane 
binding constants (𝐾𝐿𝑝
0 , 𝐾𝐿𝑛
0 , 𝐾𝐶𝑛
0 , and 𝐾𝐶𝑎
0 ) were fitted using non-linear regression. 
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4.2.7.5 Regression Analysis 
Data fitting for constants describing the A-ring phenol pKa, ring-opening 
interconversion kinetics, and release kinetics was performed using Scientist® non-linear 
least squares regression software with a weighting factor of two. 
4.3 Results 
4.3.1 Validation of analytical methods and liposome characterization 
 TPT concentrations were analyzed by HPLC with fluorescence detection using excitation 
and emission wavelengths of 380 nm and 550 nm, respectively.  Peak areas varied linearly 
with concentration between 20 and 200 nM for both lactone and carboxylate standards. 
Release studies monitored total TPT concentration by converting all drug to its lactone form 
by diluting samples with chilled acidified methanol into the concentration range of 
standards.  Coefficients of variation for response factors of standards were ±1.4% intraday 
and ±2.6% interday.  Initial TPT concentrations ranged from 0.2-1.0 µM for these 
experiments. Studies monitoring TPT interconversion kinetics were performed with initial 
concentrations of 0.4-0.6 µM and coefficients of variation for response factors were ±2.0% 
intraday and ±7.1% interday for carboxylate standards and ±1.5% intraday and ±2.1% 
interday for lactone standards.  Phospholipid content was determined by a previously 
validated HPLC method with slight modifications.49, 60  ELSD, necessary due to the lack of 
chromophore/fluorophore in the lipid molecules, provided linear log-log plots of the peak 
areas versus DSPC concentration between 0.025 – 0.3 mg/mL and a peak retention time of 
7.9 minutes, similar to that previously reported.49 
 To validate the ultrafiltration procedure as a reliable technique to analyze drug release 
kinetics, the recovery efficiency of TPT and phospholipid after ultrafiltration was 
determined. Sephadex separation of liposomally entrapped TPT from unencapsulated drug 
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was used as previously reported147 to determine this recovery value. By analyzing TPT 
concentrations in liposomal fractions collected immediately after Sephadex purification, the 
percentage of TPT recovered after the ultrafiltration procedure was determined to be 88.0 ± 
2.4%; however, this value may be an underestimation if trace amounts of unentrapped TPT 
were present after Sephadex separation. To further explore this as a possible source of 
error, phospholipid content was also determined in liposome samples after ultrafiltration. 
Phospholipid recovery was determined to be 94.0 ± 3.9%. The slightly higher recovery of 
phospholipid in comparison to TPT after ultrafiltration of freshly purified drug-loaded 
liposomes provides evidence for the presence of a small percentage of unentrapped drug. 
Consequently, phospholipid and TPT recovery were compared at the start of a release 
experiment to estimate the initial amount of TPT in the extra-vesicular solution. During 
these experiments, the initial extra-vesicular TPT was never more than 2.5% of the initial 
intra-vesicular TPT. As a final validation, suspensions of liposomes containing no drug were 
spiked with TPT and then ultrafiltered. Ultrafiltration of these spiked solutions showed only 
trace amounts of TPT present well, below the limit of quantitation (less than 0.3% of initial 
TPT). Because passive loading was used to conduct these experiments, encapsulation 
efficiency was not determined as it was expected to be low (< 3%) and not germane to the 
goals of this study. 
Volume parameters (Table 1) used in model fitting were calculated from particle sizes 
and phospholipid contents determined during release studies.  Particle size was determined 
at each pH (8 measurements) for the suspensions before and after the conclusion of release 
studies.  The average particle size before release studies (with 95 % confidence interval) 
was 96 ± 2 nm and 98 ± 3 nm after release studies were finished, indicating no statistically 
significant change in particle size during the experiments.  Because of the narrow particle 
size distribution, average particle size was used to determine the aqueous/total entrapped 
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volume ratio (a) and membrane/total entrapped volume ratio (b), parameters that were 
necessary for the analysis of the transport data (see Supplementary Data).  Extra-vesicular 
volume ratios (c and d) analogous to a and b were also required for the determination of 
membrane binding constants and subsequently release rate constants because these studies 
were not performed under sink conditions.  The entrapped/unentrapped volume ratio (𝑓𝑣) 
calculated from the lipid content present in suspension was varied in release studies by 
altering the lipid concentration to avoid possible systematic errors in estimation of 
membrane binding constants from release profiles.  Thus, the lipid content determined for 
each release study was used rather than the average of values for all experiments.  The 
values in Table 1 reflect the parameter ranges explored.50, 135, 149  
Table 4.1.  Volume parameters used in TPT release studies 
Parameter Average Range 
a 0.855 NA 
b 0.145 NA 
c 0.9997 0.9995 – 0.9999 
d 0.0003 0.0001 – 0.0005 
𝑓𝑣 0.0067 0.0024 – 0.0110 
 
Phospholipids undergo acid-catalyzed ester hydrolysis142-144 that could lead to hydrolysis-
induced changes in bilayer integrity over longer periods of time.  This possibility was 
examined by monitoring lipid content in solution using HPLC with an ELSD.  No loss of lipid 
was detected in release studies at pH 4.01 over 72 hr but >10% lipid loss was found after 48 
hr at pH 3.35 (Figure 4.1) which is qualitatively consistent with literature data 150. Previous 
literature reports have shown compromised bilayer integrity when 15% or more 
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phospholipid has degraded.143  Consequently, only samples taken before 36 hours from the 
pH 3.35 release study were used in data fitting.  
 
Figure 4.1.  The fraction of DSPC remaining during release studies conducted at 
pH 3.35  and 4.01 .  Error bars at pH 4.01 are the 95 % confidence intervals 
determined by samples taken from four independent experiments. 
4.3.2 Spectrometric determination of the TPT A-ring phenol (pKa1) 
  Because of the high dependency of bilayer permeability on permeant charge,3, 50, 52, 60, 73 
the pKa of the phenolic -OH on the A ring was determined at 37 °C from changes in the TPT 
fluorescence excitation spectra with pH as seen in Figure 4.2a.  Spectral changes as a 
function of pH (Fig. 2b) were used to determine 𝑝𝐾𝑎1 to be 6.56 ± 0.12.  This value is similar 
to those previously reported at lower temperatures.90, 92, 138, 151 
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A.  
B.  
Figure 4.2.  A) TPT excitation spectra at varying pH (3.50, 4.50, 5.50, 6.00, 6.27, 
6.50, 6.80, 7.10, and 7.50) obtained at an emission wavelength of 560 nm.  As pH 
is increased, a red shift occurs with maximum excitation shifting from 380 nm to 
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410 nm. B) Fluorescence intensities at an emission wavelength of 560 nm and at 
excitation wavelengths of 380 (), 365 (), 335 (), and 410 nm () from 
TPT solutions at varying pH and fit to Equations S3 & S4 to determine 𝑝𝐾𝑎1.  The 
lines represent the simultaneous fit of intensities at all wavelengths vs. pH. 
4.3.3 TPT lactone-carboxylate interconversion kinetics 
 The kinetics of interconversion of TPT between its lactone and carboxylate forms was 
monitored as a function of pH by following both carboxylate and lactone species (Figure 
4.3a). A kinetic model based on a ring opening/closing mechanism previously described in 
the literature,92  was able to account for the pH-dependence, resulting in a base-catalyzed 
ring-closing rate constant (𝑘𝑐,𝑂𝐻) of 7.4 ± 0.3 x 108 mol-1hr-1 and a carboxylic acid/lactone 
equilibrium constant (𝐾0) of 1.98 ± 0.07 x 10-3.  Combining the pKa of the ring-opened 
carboxylic acid assumed to be 3.9 (based on values previously assumed for camptothecin 
and its analogues and a pKa of 3.86 for the α-hydroxy acid glycolic acid)with 𝐾0 gave an 
effective pKa for the ring-opening/ionization reaction (𝑝𝐾𝑎2) of 6.60.  This value is similar 
to that reported for camptothecin and other analogues.92, 148 
 Interconversion studies conducted in liposomal suspensions at high lipid content 
revealed no significant changes in the kinetic parameters or value of 𝐾0 from those obtained 
at the same pH in aqueous solutions (Figures 4.3b and c).  This supports the negligible effect 
of membrane binding on interconversion kinetics and the use of 𝑘𝑐𝑙  and 𝐾0 to describe 
inter-conversion kinetics of total intravesicular TPT.   
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Figure 4.3.  Ring opening/closing kinetics of TPT as a function of pH.  A) The 
plots display the fractions of total TPT in the lactone form (closed symbols) or 
carboxylate form (open symbols) versus time at the same pH of 5.92 ( , ), 
6.33( , ), 7.04 ( , ), 7.39 ( , ), or 7.67 ( , x).  The curves of matching 
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color represent simultaneous fits of the kinetic interconversion model to the 
lactone (solid lines) and carboxylate (dashed lines) data.  Most interconversion 
occurred within the first three hours (left) while equilibrium was achieved for 
all studies (right). Interconversion of TPT in liposome suspensions (50 
mg/mL) at pH 6.33 (B) and pH 7.67 (C) is also shown.  The fractions of total 
TPT in the lactone  and carboxylate  form are shown in aqueous solution 
while the open symbols represent studies conducted in liposomal suspensions.  
Solid and dotted lines indicate the simulated interconversion profiles for both 
aqueous and liposome studies simulated by the kinetic parameters previously 
determined from aqueous solution studies. 
4.3.4 pH Sensitive release of TPT 
Transport experiments were performed at varying pH and at a recorded average 
temperature of 38.7 ± 0.1 °C during the time period of the studies.  The fractions of TPT 
retained in DSPC/DSPE-PEG2K liposomes versus time at varying pH are shown in Figure 
4.4.  The curves displayed in Figure 4.4 represent simultaneous fits to the mechanism-based 
mathematical model for TPT release developed in the Supplementary Data using the 
equilibria and chemical kinetic constants determined from spectrometric and 
interconversion studies.  From these data, transport rate constants and partition 
coefficients were obtained for the various ionization states of the lactone and carboxylate 
species (see Scheme 4.1). Transport rate constants of 0.51 ± 0.07 hr-1 and 33.9 ± 4.6 hr-1 
were found for the cationic lactone species (𝐿𝑝) and the zwitterionic lactone (𝐿𝑛), 
respectively, while the ring-opened carboxylate zwitterion (𝐶𝑛) had a rate constant of 5.7 ± 
0.5 hr-1 and its anionic form (Ca) was found to be impermeable.   
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Figure 4.4.  Fraction of TPT retained in DSPC/DSPE-PEG2K liposomes vs. time 
at varying pH (right panel displays only the first 6 hrs).  Release studies were 
conducted at pH 3.35 , 4.10 , 5.10 +, 5.93 , 6.33 , 7.04 , 7.39 , and 7.67 
x. The solid curves of the same color represent the simultaneous fit of the 
mechanism-based mathematical model developed in this paper to the entire 
data set.   
0
0.2
0.4
0.6
0.8
1
0 12 24 36 48 60 72
F
ra
c
ti
o
n
 T
P
T
 R
e
ta
in
e
d
Time (hours)
0
0.2
0.4
0.6
0.8
1
0 1 2 3 4 5 6
F
ra
c
ti
o
n
 T
P
T
 R
e
ta
in
e
d
Time (hours)
 87 
 
The same analysis also indicated that the zwitterionic lactone (𝐿𝑛) and anionic 
carboxylate form 𝐶𝑎  exhibited negligible binding to the phospholipid bilayer.  Both of these 
species have in common a phenolate moiety that evidently disfavors interaction with the 
bilayer.  This and the similar partition coefficients of 62 ± 6 and 42 ± 6 for the lactone and 
carboxylate species in which the phenol is unionized (𝐿𝑝 and 𝐶𝑛 , respectively) suggest that 
binding likely occurs with preferential orientation of the TPT A-ring toward the 
hydrophobic region of the phospholipid bilayer.  Opening of the lactone ring had a negligible 
effect on membrane binding. 
4.4 Discussion  
4.4.1 Effect of TPT ring-opening on pH sensitive release kinetics  
The significantly greater permeability of the zwitterionic lactone species (𝐿𝑛) than any 
of the other TPT species present in the pH range explored (Scheme 4.1) raises the 
possibility that, under certain pH conditions, this species might be depleted from the 
intravesicular compartment due to its slow regeneration from the ring-opened form.  
Simulated profiles of the concentrations of carboxylate and lactone species at pH 6.33 
(where the lactone fraction is greater) and pH 7.04 (where the carboxylate fraction is 
greater) are shown in Figure 4.5 along with the profile of total drug released in Figure 4.4.  
Because interconversion is not instantaneous, the more permeable lactone zwitterion was 
depleted at a faster rate than its carboxylate counterpart, resulting in biphasic release 
profiles at certain pH values such as within the first 30 min of release at pH 7.04 (Figure 
4.5b, see also Figure 4.5b).   
The ratio of lactone to carboxylate species, 𝑅, during release is also depicted in Figure 
4.5.  The profile of 𝑅 initially shows a rapid decrease as the more permeable lactone species 
are depleted during the early phase of release.  During the later phase of release, R 
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approaches its initial equilibrium value as the less permeable carboxylate specie continues 
to release.  Similar trends of 𝑅 are evident for release studies conducted in the neutral pH 
range (Figure 4.5c)  
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C.  
 
Figure 4.5.  Liposomal TPT release profiles at pH 6.33 (A) and 7.04 (B).  The 
observed fraction of total TPT retained  and the resulting fit to the model 
described within this paper ( ) are shown.  The simulated profiles of the 
lactone ( ) and ring-opened ( ) forms are also displayed to illustrate the 
rapid depletion of the lactone.  The lactone to carboxylate ratio, R ( ), is also 
shown to highlight the role of slow carboxylate-> lactone conversion during TPT 
release.  C) Changes in 𝑹 during liposomal TPT release studies for all pH 
studied where interconversion kinetics were not instantaneous (pH 6.33 ( ), 
7.04 ( ), 7.39 ( ), and 7.67 ( )) were also simulated.  All profiles show 
a decrease in 𝑹 as the more permeable lactone is depleted, thus indicating 
non-instantaneous interconversion between the two species. 
4.4.2 Comparison of kinetic and equilibrium models of lactone ring-
opening/closing 
In previous pH-dependent release studies with the camptothecin analogue AR-67, ring-
opening kinetics could be assumed to be instantaneous because the high membrane-binding 
constant for the lactone form reduced the driving force for release and provided a reservoir 
of the lactone species.49, 60, 63  Both of these factors minimized the depletion of lactone.  In 
contrast, the low membrane-partitioning observed for TPT required such an assumption to 
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be tested.  To compare the release model that incorporated the kinetics of ring-opening 
with one that assumed ring-opening/closing equilibrium, the pH profiles for the release 
half-lives (𝑡1/2) generated by the two models as a function of pH were compared in Figure 
4.6 along with the experimentally-observed half-lives.   
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Figure 4.6.  (A) Comparison of the experimental pH profile of TPT release half-
lives ( ) to model fits that account for the kinetics of lactone-carboxylate 
interconversion ( ) or assume lactone-carboxylate equilibrium ( ).  The 
equilibrium model was unable to account for the steep changes in half-life in the 
neutral pH region.  The blue section highlights the pH region in which release 
was slowed by greater than 25% due to rate-limiting ring-closure.  (B) The 
biphasic release profile observed at pH 7.04 and the fits of models that either 
include interconversion kinetics ( ) or assuming interconversion equilibrium 
( ).  
Because the equilibrium model does not account for interconversion kinetics, it tries to 
compensate for the steep change in half-life (resulting from rate-limited ring-closing) seen 
at neutral pH (6.8 – 8.0) by overestimating release in the acidic region and underestimating 
release at higher pH.  Figure 4.6 also demonstrates the inadequate fit of the equilibrium 
model to a single release profile. Here, the equilibrium model underestimated the initial 
phase of drug release as it could not account for biphasic kinetics.  In contrast, the model 
incorporating interconversion kinetics is able to account for the rapid initial phase of drug 
release that leads to lactone depletion followed by subsequent slower release limited by 
intravesicular regeneration of lactone from the carboxylate. 
4.4.3 Determination of species permeability coefficients 
 The apparent permeability coefficient, 𝑃𝑚
0 , is related to the apparent transport rate 
constant at a given pH and the radius of the particle, 𝑟, as expressed by Equation 26. 
𝑃𝑚
0 =
𝑟
3
𝑘𝑚
0           (26) 
Using the release model that included the kinetics of ring-opening/closing, three TPT 
species were determined to contribute to the liposomal transport.  From these release rate 
constants, permeability coefficients could be calculated for these species.   
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Based on the 100 nm liposomes used in these studies, the cationic and zwitterionic 
lactone permeability coefficients were 2.4 × 10−10 𝑐𝑚 𝑠⁄  and 1.5 × 10−8 𝑐𝑚 𝑠⁄  while TPT 
carboxylate zwitterion permeability coefficient was 3.0 × 10−9 𝑐𝑚 𝑠⁄ . Generally, neutral, 
non-ionized species are orders-of-magnitude more permeable than charged species; 
however, few zwitterions have been explored.49, 50, 52  The permeability coefficient for the 
lactone zwitterion determined from this work is similar to one obtained for the neutral, 
unionized lactone species of another camptothecin analogue.49  This is likely due to an 
intramolecular interaction between the A-ring phenolate and dimethyl-ammonium 
substituents.  Because of their close proximity and orientation, the free energy required for 
bilayer partitioning of this specie may be lower due to an electrostatic interaction or an 
intramolecular hydrogen bond between the heteroatoms. This is supported by the large pKa 
shifts observed in aqueous solution for the phenolic –OH (i.e., from 10.0 in phenol to 6.56 in 
TPT) and dimethyl-aminomethyl substituent (from 8.93 in benzyldimethylamine to 10.5 in 
TPT), respectively.  These shifts in pKa are a direct consequence of the stabilization of the 
zwitterionic form in Scheme 4.3.  A similar effect has also been reported for other 
compounds with this same feature,92, 152 and recent studies of TPT fluorescence lifetimes in 
aqueous solution have distinguished intramolecular and bulk solution contributions to 
phenol deprotonation.151  These interactions may help explain the small but significant 
permeability of the cationic species, 𝐿𝑝 , seen in this study.  Partial shielding of the cationic 
charge of 𝐿𝑝  may be through hydrogen bonding with the phenol which may be further 
stabilized by resonance forms that delocalize the charge throughout TPT’s conjugated ring 
structure.  
Unlike the lactone zwitterion, the carboxylate form, 𝐶𝑛 , does not offer the possibility of 
such intramolecular interactions between adjacent charged residues. Without this feature, 
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the observed permeability may reflect the minor fraction of unionized neutral species, 𝐶0 , as 
depicted in Scheme 4.5.   
Scheme 4.5.  The equilibrium between TPT’s carboxylate zwitterion and 
neutral, unionized  form is governed by 𝑲𝟎,𝑪. 
To ascertain whether the observed permeability for the carboxylate could be 
attributable to 𝐶0 , the equilibrium constant between 𝐶𝑛  and 𝐶0 , 𝐾0,𝐶 ,  must be determined.  
This may be written in terms of the fraction of the zwitterion, 𝑓𝑧,𝐶 , and non-ionized, 𝑓0,𝐶 , 
species as expressed in Equation 26. 
𝐾0,𝐶 =
𝐶0
𝐶𝑛
=
𝑓0,𝐶
𝑓𝑧,𝐶
=
𝐾𝑎3
𝐾𝐶𝑂𝑂𝐻
        (26) 
Using this ratio, a maximum permeability for 𝐶0 may be determined if one assumes 𝐶0 is the 
sole specie contributing to the observed permeability of the carboxylate.  Using this 
assumption and a 𝑝𝐾𝑎3 of 10.5 for the dimethyl-amino group,92 the maximum permeability 
coefficient is estimated to be  9.3 × 10−3 𝑐𝑚 𝑠⁄  for 𝐶0 .   
To assess the significance of this permeability coefficient, comparison to the theoretical 
maximum permeability, 𝑃𝑚𝑎𝑥, is needed.  𝑃𝑚𝑎𝑥 can be described by diffusion-limited 
transport through the boundary layer of a spherical particle. This is given by Equation 27. 
𝑃𝑚𝑎𝑥 =
𝐷𝑇𝑃𝑇
𝑟
          (27) 
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Here, the diffusivity of TPT, 𝐷𝑇𝑃𝑇 , was determined by the Stokes-Einstein equation for 
diffusivity in water at 37 °C and a molecular volume of 366.8 Å3 (ACD labs).  Based on this 
information, 𝐷𝑇𝑃𝑇  was calculated to be 7.52 × 10
−6 𝑐𝑚2 𝑠⁄  and  𝑃𝑚𝑎𝑥 was estimated to be 
1.50 𝑐𝑚/𝑠.   While the estimated permeability coefficient of 𝐶0 necessary to account for the 
experimental data is below 𝑃𝑚𝑎𝑥, it is still several orders of magnitude higher than that of 
TPT’s lactone zwitterion and another neutral, non-ionized camptothecin of similar size.49  
This analysis suggests transport of the neutral, unionized ring-opened species is unlikely to 
fully account for the transport observed. Other mechanisms that may stabilize the ring-
opened carboxylate zwitterion as it traverses the bilayer include: long-range intramolecular 
substituent effects on membrane partitioning, formation of water bridges through the 
bilayer, or ion-pairing within the barrier domain during TPT transport.45, 129, 153-155 
4.5 Conclusions 
 The pH dependent release of TPT from DSPC/m-PEG DSPE liposomes was characterized 
and the contribution of the kinetics of the pH-dependent ring-closure reaction to this 
process was assessed.  These factors were incorporated into a mechanism-based 
mathematical model to describe TPT release.  Based on this model, three TPT species were 
determined to be permeable to the membrane with the A-ring zwitterion form being the 
most permeable species.  Within a defined pH region lactone depletion resulted in ring-
closure of the ring-opened carboxylate form becoming at least partially rate-determining.  A 
mathematical model that assumed equilibrium between the lactone and ring-opened 
species was inadequate in accounting for the complete profile for the dependence of t1/2 on 
pH and the biphasic release kinetics observed at certain pH values. The mechanism-based 
model developed in these studies will provide a basis for understanding the loading and 
release kinetics of actively-loaded formulations of TPT.  
Copyright © Kyle Daniel Fugit  
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CHAPTER FIVE   
Insights Into Accelerated Liposomal Release of Topotecan in Plasma 
Monitored by a Non-invasive Fluorescence Spectroscopic Method 
5.1  Introduction 
 Many physiological factors (i.e. age, gender, dose regimen, type or location of cancer, 
mononuclear phagocyte system25) have been proposed to influence the pharmacokinetics 
(PK) and pharmacodynamics (PD) of nanoparticle formulations of anticancer agents.  
Unfortunately, the correlation between these factors and nanoparticle efficacy remain 
largely unknown.26, 27  In liposomal formulations, bilayer integrity may be compromised by 
the particles’ interactions with proteins (e.g. vesicle binding and particle opsonization)54-57 
or osmotic stresses58, 59 while in circulation or at the tumor site.  Other factors may also 
accelerate release of actively-loaded drug by destabilizing the pH gradient in vivo.60  
Actively-loaded liposomal formulations of anticancer agents are numerous21, 42, 62, 73, 95, 156 
and would share in these susceptibilities.  Reports describing the effects of such 
physiological phenomena on release kinetics in vivo have been limited due to the lack of 
available in-situ methods to monitor and distinguish entrapped from free drug.  Methods to 
determine the release kinetics of drug from circulating liposomes and/or at the tumor site 
are crucial to optimizing the efficacy of liposomal-based drug delivery systems.  
 Validation of such a method to quantify release kinetics requires parallel development 
of a mathematical model to interpret observed release profiles.  The model must distinguish 
physicochemical release characteristics intrinsic to the drug/particle system from artifacts 
of the release environment (i.e. kinetic or thermodynamic effects attributable to the 
particular medium within which release is determined).49, 60, 63, 124-126  With such models, the 
in vivo factors that lead to variability in liposomal formulation performance may be 
identified and mechanistically understood. 
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 Topotecan (TPT) is a camptothecin analogue known for its topoisomerase-I inhibitory 
activity and regulation of genes associated with angiogenesis.157  Several preclinical studies 
have demonstrated increased anti-tumorigenic efficacy of liposomal formulations of TPT 
that have reduced systemic clearance, allowing greater uptake and extended tissue 
exposure in murine solid tumors.62, 158, 159 Many of the liposomal formulations of TPT are 
actively loaded by establishing an acidic intravesicular compartment relative to the 
extravesicular pH of the loading solution.  This process provides high drug loading 
efficiencies while ensuring the pharmacologically active lactone form of TPT is delivered to 
the tumor.  While actively loaded liposomal formulations have often shown prolonged 
retention in aqueous buffers,23, 62, 64 the same formulations may exhibit accelerated release 
in plasma.23, 62   
 While the low intravesicular pH persists after active drug loading, 62, 64, 159-161 to the 
authors’ knowledge it has never been used to differentiate between entrapped and free TPT 
during drug release.  Because the fluorescence of TPT is pH-dependent,156, 162 changes in 
TPT fluorescence in aqueous liposomal suspensions and in plasma were explored as a 
potential means of non-invasively monitoring liposomal release in real-time.  Analyses of 
fluorescence spectra confirmed that free TPT exhibits a red shift in its excitation spectrum 
as pH is increased.  Due to this red shift, release of TPT from actively loaded liposomal TPT 
(ALLT) formulations could be monitored using fluorescence at higher wavelengths (410-
430nm) where entrapped drug at low intravesicular pH does not fluoresce.  
 The initial aim of this study was to validate a fluorescence method to non-invasively 
monitor liposomal release of TPT in tissue samples.  During the course of comparing 
apparent liposomal release profiles in different media including PBS buffer, plasma, and 
plasma ultrafiltrate using either the fluorescence method or HPLC it became evident that: a) 
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TPT release is dramatically accelerated in human plasma as initially reported by Liu et al.;62  
and b) similar release kinetics were obtained in plasma ultrafiltrates.  Recognizing that a 
non-filterable plasma component must be responsible for the accelerated release and that 
normal human plasma contains low levels of ammonia,163, 164 additional studies were 
conducted to probe the concentrations of ammonia in the plasma samples and the effect of 
ammonia on TPT release.  To mechanistically rationalize differences in release profiles 
using different analytical methods and media, mathematical models were developed to 
account for the effects of liposome concentration, intravesicular pH, TPT ionization, and 
ammonia concentration on release kinetics.   
5.2  Materials and Methods 
5.2.1  Materials 
 Powders of 1,2-distearoyl-sn-glycero-3-phosphatidylcholine (DSPC, >99% purity) and 
1,2-distearoyl-sn-glycero-3-phosphoethanolamine-N-[methoxy(polyethyleneglycol)-2000] 
(DSPE-PEG2K, MW = 2806, >99% purity) were purchased from Avanti Polar Lipids 
(Alabaster, AL).  Topotecan hydrochloride was purchased from AK Scientific (Union City, 
CA).  Heparinized human plasma samples from three individual donors of different ethnicity 
were purchased from Innovative Research (Novi, MI), aliquoted and stored at -20°C.  
Benzene sulfonic acid sodium salt (sodium besylate) was purchased from Spectrum 
Chemicals (New Brunswick, NJ).  Millipore ultrafiltration cartridges (Amicon® Ultra 0.5 mL 
centrifugal filter device with 3,000 MWCO Ultracel® membrane), Nuclepore polycarbonate 
membranes (0.1 µm), Dowex 50Wx8-200 resin in the H+ form, solvents, and buffer salts 
were purchased from Fisher Scientific (Florence, KY). All solvents were HPLC grade.   
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5.2.2  Liposome preparation 
 Large unilamellar liposomes were prepared based on previously reported methods.49, 50, 
60, 118, 124, 125  Briefly, powders of DSPC and DSPE-PEG2K were dissolved in chloroform at a 
molar ratio of 95:5, then dried under nitrogen, and finally under vacuum (- 30 in Hg) at 35 
°C for 6 hours.  After drying, the films were hydrated in either 0.3 M ammonium besylate, 1 
mM TPT in 50 mM pH 3.75 formate buffer, or pH 7.4 phosphate buffered saline (PBS) 
solutions to produce 30 mg/mL lipid suspensions.  These suspensions were vortexed at 60 
°C, then extruded through two 100 nm polycarbonate membranes 10 times at 40 psig and 
60 °C to yield suspensions of ammonium besylate-loaded liposomes (ABLs), passively-
loaded TPT-containing liposomes, or blank liposomes, respectively.     
 The ammonium besylate solutions (0.3 M) used for liposome hydration were prepared 
in a manner similar to that previously used to make other amino-based salts.21, 42  Solutions 
of sodium besylate (0.6 M) were passed through an ion exchange column loaded with 
Dowex 50Wx8-200 resin in the H+ form.  The eluted solutions were subsequently titrated 
with ammonium hydroxide (3.0 M) to the equivalence point and diluted to the desired 
concentration.   
5.2.3  Active loading of TPT into ammonium besylate liposomes 
 Previous studies have shown that active-loading of weakly basic drugs results in high 
encapsulation efficiency and possibly longer drug retention in vitro and in vivo.62, 159  
Actively- loaded liposomal suspensions of TPT were prepared with the aim of evaluating a 
fluorescence method to analyze drug release in vivo or ex vivo.  Active loading was 
performed by generating a low intravesicular pH via an ammonia gradient.62, 73  This 
gradient was established when extravesicular ammonium besylate was removed by passing 
the suspension through a Sephadex G-25 column similar to previous reports.62  In this case, 
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0.4 mL of the ABL suspension was passed through the column equilibrated with 100 mM 2-
(N-morpholino) ethanesulfonic acid (MES) pH 5.5 buffer and the first 5 mL of eluted 
suspension was collected for loading studies.  Next, 1.5 mL of the eluted suspension was 
added to an equal volume of TPT dissolved in the same pH 5.5 buffer to achieve a total TPT 
suspension concentration of 50 or 200 µM and a lipid concentration of 0.92 mg lipid/mL.  
Loading occurred over a 72 hour period within a 37 °C incubator. 
 Actively-loaded liposomal TPT (ALLT) suspensions were prepared for release studies 
by removing extravesicular buffer and any remaining unloaded drug by applying 0.5 mL of 
ALLT to a Sephadex G-25 column equilibrated with PBS similar to previous reports.60, 63  The 
first 2.5 mL fraction eluted from the column was discarded.  ALLT eluted in the next 2.5 mL 
fraction and was collected for use in release studies monitored by fluorescence or HPLC. 
5.2.4  Liposome characterization 
 Particle size was determined for ALLT and PLLT using dynamic light scattering (DLS) 
using a Beckman Delsa™ Nano C Particle Sizer as previously reported.125, 126  Lipid content 
was monitored by HPLC using an evaporative light scattering detector (ELSD).  A Waters 
Alliance 2695 separations module equipped with an Allsphere (Alltech Associates, Inc., 
Deerfield, IL) silica column (4 x 150 mm, 5 µm) and guard column (20 x 4.0 mm, 5 µm) and 
a mobile phase consisting of 80% of solvent A (80% chloroform:19.5% methanol:0.5%(v/v) 
NH4OH)  and 20% of solvent B (80% methanol:19.5% water:0.5% (v/v) NH4OH) flowing at 
1 mL/min was used to quantify DSPC in conjunction with an ELSD (Sedere, Inc., 
Lawrenceville, NJ) operated at 40 psig and 40 °C.  Standards of DSPC were dissolved in 
mobile phase A (0.05 – 0.3 mg DSPC/mL).  Log-log plots of peak area versus concentration 
were linear over this concentration range.  Samples (100 – 250 µL) were dried at room 
temperature under N2, then dissolved in chilled solvent A before analysis. 
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5.2.5  Fluorescence method development and validation 
5.2.5.1  TPT Excitation Spectra 
 Samples and standards from validation and release studies were placed in 1 ml quartz 
cuvettes (NSG Precision Cells, Inc. Farmingdale, NY) for spectrometric analysis.  
Fluorescence excitation spectra (290-500nm) were collected with a FluoroMax-3 
spectrofluorometer (Jobin Yvon Inc. Edison, NJ) operating at a constant emission 
wavelength of 550 nm, slit width of 1.5 nm, and a 0.5 second integration time.  The 
temperature of the sample chamber was maintained at 37 °C.   
 Excitation spectra of free TPT (2.5 µM) and PLLT (2.5 µM total suspension 
concentration of TPT after Sephadex removal of unentrapped drug) in pH 3.75 formate 
buffer were analyzed to compare the excitation spectra of free and entrapped TPT under 
acidic conditions.  Excitation spectra were obtained by Dr. Amar Jyoti.  These spectra were 
compared to excitation spectra of free TPT (2.5 µM) at pH 7.4 and ALLT suspensions in pH 
7.4 PBS (2.5 µM suspension TPT, 37 ug lipid/mL) to determine if ALLT spectra were 
indicative of an acidic intravesicular environment and whether spectra of entrapped and 
unentrapped drug were different.    
5.2.5.2  TPT release studies by fluorescence 
 Release of liposomal TPT in the presence of extravesicular ammonia may be particularly 
important, as it is present in physiological fluids and tissues and may have an effect on 
intravesicular pH and subsequently on release kinetics.  To observe these effects, release 
studies of ALLT were conducted at 37 °C in pH 7.4, phosphate buffered saline (PBS) solution 
and in PBS containing 60 µM of NH4Cl.     
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 For release studies monitored by fluorescence, 100 uL aliquots of the liposomal 
suspension collected after Sephadex purification were diluted to 1 mL with either PBS, 
human plasma (from three individual donors), or plasma ultrafiltrate (obtained from the 
donors’ plasma used in release studies) to achieve suspension concentrations of 19.2 µg/mL 
lipid and 3.2 µM TPT (as determined by HPLC).  Excitation spectra were collected over time 
and compared to spectra for TPT standards (0.5-5 µM) in the same sample matrix analyzed 
at the same time to quantify the accumulation of free TPT released into the extravesicular 
solution. 
 TPT release was monitored by Dr. Jyoti using the increase of fluorescence intensity at an 
excitation wavelength of 410 nm for PBS and plasma ultrafiltrate while intensities at 420 
nm were used for human plasma studies. TPT standard calibration curves were constructed 
using Equation 14 to adjust for fluctuations in lamp intensity at each sample time, 𝐼0(𝑡), and 
TPT dimerization in solution:137, 138   
𝐼(𝑡) = (𝑖1𝑇1 + 𝑖2𝑇2)𝐼0(𝑡)       (14) 
where T1 and T2 are the solution concentrations of TPT monomer and dimer, respectively, 
and i1 and i2 are the corresponding response factors for these species.  Using a mass balance 
equation for total TPT in solution (𝑇𝑜 = 𝑇1 + 2𝑇2), the TPT dimerization constant ( 𝐾2 =
𝑇2/𝑇1
2), and Equation 11, fitted values for 𝑖1, 𝑖2, 𝐼0(𝑡), and 𝐾2 were obtained from these 
calibration curves and used to calculate the concentration of extravesicular TPT at each 
time point.   
5.2.6  TPT release by HPLC 
 TPT release was monitored by HPLC in suspensions prepared by diluting 0.2 mL of the 
suspension collected after Sephadex to 4 mL with pH 7.4 PBS containing either no added 
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ammonia or 60 µM NH4Cl. The resulting TPT and lipid suspension concentrations were 240 
nM and 6.4 µg/mL, respectively.  Aliquots (150 µL) withdrawn at various times were 
diluted with chilled methanol (-20 °C) to disrupt the liposomes and quench the 
lactone/carboxylate interconversion of TPT.   Samples were immediately analyzed by HPLC 
to quantify both the lactone and carboxylate forms of TPT.  A previously published HPLC 
method was employed with slight modifications.125  Briefly, a Waters Alliance 2695 
separation system with a Waters Symmetry® C18 column (3.9×150 mm, 5 µm) and guard 
column (3.9 x 20 mm) was used to separate lactone and carboxylate TPT using a mobile 
phase of 11.5% acetonitrile: 88.5% (v/v) of a 5% (pH = 5.5) triethylamine acetate, 50 mM 
tetrabutylammonium hydrogen sulfate (TBAHS) buffer at a flow rate of 1 mL/min. TPT 
lactone and carboxylate standards (20-200 nM) were prepared in chilled, acidified 
methanol (-20 °C) and 10 mM sodium carbonate buffer (pH 10.1), respectively.  Lactone and 
carboxylate retention times were 6.1 and 2.7 min, respectively.  A Waters M474 
fluorescence detector (operating at excitation and emission wavelengths of 380 and 560 
nm, respectively) was used to analyze the fractions of lactone and carboxylate TPT after 
separation.   
5.2.7  TPT degradation kinetics in the presence/absence of ammonia 
 Significant TPT degradation would affect the observed concentration of extravesicular 
TPT and must be incorporated into models describing liposomal TPT release.  TPT (0.5 - 5 
µM) degradation was assessed in pH 7.4 PBS with or without 60 µM NH4Cl at 37°C.  
Degradation of TPT was measured by Dr. Jyoti in the presence of ammonia due to its 
presence in release studies and previous reports indicating that increasing concentrations 
of ammonia promote TPT degradation via formation of 9-amino methyl degradants.91  
Aliquots (25 - 40µL) of TPT solutions taken over a 5 day period were diluted to a final 
volume of 1 mL with acidified methanol (0.001 N HCl) to convert all TPT to its lactone form 
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and analyzed by the HPLC method used to monitor release.  TPT concentrations versus time 
(t) were fit to a first-order kinetic model as shown below in Equation 12 where 𝑘𝑑  is the 
first-order degradation rate constant and X is the fraction of initial TPT remaining in 
solution. 
   𝑋 = 𝑒−𝑘𝑑𝑡         (12) 
5.2.8  Ammonia analyses 
 Potentiometric measurements of ammonia content in plasma were performed before 
and after release studies by Dr. Jyoti using an Orion ammonia electrode in conjunction with 
a Thermo Scientific Orion Star A214 pH, ISE, mV, temperature meter.  Ammonia standards 
were prepared between 0.01-0.3 ppm in Milli-Q H2O.  Immediately before ammonia 
analysis, 100 μL of NaOH reagent was added to 10 mL of standards to raise pH and convert 
any ammonium to ammonia.  Solutions were allowed to equilibrate for 3-5 minutes under 
mild stirring and the final voltage was recorded.  A Nernst relationship between ammonia 
concentrations and electric potential (mV) was observed and used to make a standard curve 
for the estimation of total ammonia in solution.  Plasma samples (100µL) were analyzed 
after ultrafiltration and subjugation to the same dilution and addition of NaOH as standards 
to obtain ammonia concentrations within the sample. 
5.2.9  General mathematical model for actively-loaded liposomal TPT release 
under non-sink conditions 
 Because of the low intravesicular pH established during the active loading process, 
encapsulated TPT exists solely in its lactone form.62, 97, 165  Under physiological pH, TPT 
undergoes pH-dependent conversion to its carboxylate counterpart as it is released 
(Scheme 5.1A).62, 165  TPT’s ionization state also changes upon release as the unionized 
phenol dominates at low intravesicular pH (pKa = 6.56) while the phenolate anion is the 
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major species at physiological pH (Scheme 5.1B).92, 125, 138  By applying the appropriate 
mathematical model, it is possible to extract the critical release parameters from either the  
time-dependent profiles of TPT lactone and carboxylate generated by HPLC or changes in 
fluorescence excitation spectra.   
 
Scheme 5.1.  Physicochemical properties of TPT considered in modeling 
liposomal release kinetics.  TPT undergoes pH-dependent interconversion 
between its lactone and ring-opened carboxylate forms which can be monitored 
by HPLC (A).  Ionization of the A-ring phenol causes a shift in the fluorescence 
excitation spectrum of TPT which occurs only when drug is exposed to a 
physiological pH upon liposomal release (B). 
  A simple kinetic model describing drug release proceeding to equilibrium under non-
sink conditions was used to quantify the release profiles obtained by both HPLC and 
fluorescence methods.  Because previous studies have shown the lactone form of TPT to be 
the most permeable, this model assumes the intra- and extravesicular lactone species (Li 
and Lo, respectively) govern the rates of change of total intra- and extra-vesicular TPT (
𝑑𝑇𝑖
𝑑𝑡
 
and 
𝑑𝑇𝑜
𝑑𝑡
, respectively).   
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𝑑𝑇𝑖
𝑑𝑡
= −𝑘𝑚𝐿𝑖 + 𝑘𝑚𝐾𝐿𝑜         (1a) 
        
𝑑𝑇𝑜
𝑑𝑡
= 𝑘𝑚𝐿𝑖 − 𝑘𝑚𝐾𝐿𝑜 − 𝑘𝑑𝑇𝑜       (1b) 
where 𝑘𝑚  is the rate constant for bidirectional TPT transport, K is the ratio Li /Lo  at 
equilibrium, and kd is the first-order degradation constant for TPT released into the 
extravesicular solution. 
 Once released, lactone TPT undergoes reversible, pH-dependent lactone hydrolysis to 
form its ring-opened, carboxylate counterpart.  This process may be assumed to be fast 
relative to release and thus in equilibrium.  Assuming this pH-dependent equilibrium, an 
apparent acid dissociation constant (𝐾𝐴′) may be used to solve for the fraction of 
extravesicular TPT in the lactone form (𝑓𝐿 =
𝐻+
𝐻++𝐾𝐴′
).  This expression allows 𝐿𝑜  to be 
written in terms of 𝑇𝑜, and 𝐿𝑖 ≅ 𝑇𝑖  due to the low intravesicular pH resulting from active 
loading.  Using this information, the rate equations can be rewritten as shown below. 
   
𝑑𝑇𝑖
𝑑𝑡
= −𝑘𝑚(𝑇𝑖 − 𝑓𝐿𝐾𝑇𝑜)        (2a) 
𝑑𝑇𝑜
𝑑𝑡
= 𝑘𝑚(𝑇𝑖 − 𝑓𝐿𝐾𝑇𝑜) − 𝑘𝑑𝑇𝑜       (2b) 
𝑇𝑜 was directly monitored by fluorescence while the fractions of total drug remaining in the 
suspension in the lactone and carboxylate forms were  monitored by HPLC. Ti and To could 
be obtained from the total lactone and carboxylate fractions (𝐿(𝑡) and 𝐶(𝑡), respectively) 
and the total suspension concentration of TPT measured at each time point, 𝑇(𝑡):  
       𝐿(𝑡) = 𝑇𝑖+𝑓𝐿𝑇𝑜
𝑇(𝑡)
          (3a) 
       𝐶(𝑡) = (1−𝑓𝐿)𝑇𝑜
𝑇(𝑡)
          (3b) 
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 Initial conditions were required to accurately solve and fit the above differential 
equations to release data.  In fluorescence studies, extravesicular drug present at the 
beginning of the release study (𝑇𝑜
0) was directly analyzed by fluorescence; however, the 
initial intravesicular drug could not be determined directly from fluorescence.  The initial 
concentration of intravesicular drug was determined after subtracting 𝑇𝑜
0 from the total 
initial suspension concentration (𝑇0) obtained by HPLC analysis.   These initial conditions 
are expressed by the equations below.  
     𝑇𝑜(0) = 𝑇𝑜
0          (4a) 
 𝑇𝑖(0) = 𝑇
0 − 𝑇𝑜
0         (4b) 
 HPLC studies had similar initial conditions.  Assuming that any carboxylate in the 
suspensions was attributable to extravesicular drug, the initial fraction of carboxylate 
present in the release suspension (𝐶0) could be related to  𝑇𝑜
0 and subsequently be used in 
conjunction with the initial fraction of lactone (𝐿0) to solve for the initial intra- and extra-
vesicular conditions as shown below. 
 𝑇𝑜(0) = 𝑇𝑜
0 =
𝐶0
(1−𝑓𝐿)
         (5a) 
 𝑇𝑖(0) = 𝐿0 −
𝐶0
(1−𝑓𝐿)
         (5b) 
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5.3  Results 
5.3.1  Differences in fluorescence spectra and quantitation of extravesicular 
TPT 
 Increases in pH result in a red shift in TPT excitation spectra in aqueous solution.125, 138  
Such a shift suggests TPT release from actively-loaded liposomes into a pH 7.4 buffer or 
plasma could be distinguished from entrapped drug. This hypothesis was confirmed by 
comparing the fluorescence excitation spectra obtained for various aqueous solutions and 
liposomal suspensions of TPT.  In Figure 5.1, the excitation spectra of TPT under acidic 
conditions (either in solution or encapsulated) were nearly identical to the excitation 
spectrum obtained for ALLT suspended in pH 7.4 PBS with maximum excitation occurring 
at 380 nm.  These results are indicative of a low intravesicular pH environment remaining 
after the active loading process.21, 42, 62, 64, 73, 95  The red shift observed for free or 
extravesicular TPT in PBS at pH 7.4 resulting in maximum excitation at 410 nm is not 
altered in the presence of blank liposomes (Figure 5.1). Determination of extravesicular 
TPT is possible without significant interference from encapsulated drug because TPT under 
these more acidic conditions is not excitable at this higher wavelength.  
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Figure 5.1.  Illustration of differences in normalized excitation spectra between 
free and entrapped TPT at 37 °C.  Excitation spectra of free TPT at pH 3.75, 
passively-loaded liposomal TPT (PLLT) at the same pH, and actively-loaded 
liposomal TPT (ALLT) suspensions in pH 7.4 buffer have identical spectra, 
indicating an acidic intraliposomal pH within ALLT..  At pH 7.4, spectra of free 
TPT solutions and suspensions of blank liposomes spiked with free TPT (i.e., 
spiked TPT pH 7.4) exhibit a red shift in the excitation spectrum (denoted by the 
arrow).  The identical spectra of spiked and free TPT indicates that drug binding 
to the outer bilayer leaflet or particle scattering have no effect on the spectra of 
extravesicular TPT.  All the spectra displayed contained total TPT 
concentrations of ~ 2.5 µM.  The lipid concentration in liposome suspensions 
was ~ 37 µg lipid/mL. 
 Calibration curves for quantifying extravesicular TPT were constructed from excitation 
spectra at varying concentrations (0.2-5 µM) of TPT in pH 7.4 PBS, human plasma, and 
plasma ultrafiltrate.    Fluorescence intensity versus TPT concentration was nearly linear 
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with slight quenching of fluorescence at higher concentrations (~ 5 µM).  This quenching 
was due to TPT dimerization and accounted for in the calibration curve (see Methods).138  
Quantitation of intravesicular TPT was not possible due to self-association and collisional 
quenching effects at the high intravesicular TPT concentrations (~ 15 mM) present as a 
consequence of the active loading process.  
5.3.2  TPT degradation in the presence and absence of ammonia 
 TPT degradation was monitored by HPLC at pH 7.4 and 37 C in PBS and PBS containing 
60 M NH4Cl (data not shown).  The degradation was first-order and independent of the 
presence of ammonia.  The rate constant for degradation was determined to be 1.15 ± 0.08 x 
10-2 hr-1 (95% CI).  This value was incorporated into the models used to fit release data. 
5.3.3  Comparison of fluorescence and HPLC methods to monitor release 
 Release studies were conducted in PBS with or without added ammonia and analyzed 
by HPLC and fluorescence methods to validate the use of fluorescence for determining 
release.  Degradation of topotecan at pH 7.4 limited the time frame for release studies by 
fluorescence to ~ 24 h.  However, because longer times were necessary to establish 
equilibrium, both HPLC and fluorescence release data in PBS with and without ammonia 
were fit simultaneously to determine values for K (Ti /𝑓𝐿To at equilibrium).  The resulting 
fits indicated that K decreases with the addition of extravesicular ammonia to the release 
media.   
 While K was assumed to be independent of the method of analysis, separate km values 
were determined for each method and condition.  The values obtained are shown in Table 
5.1, and the resulting fits of the data from both methods are illustrated in Figure 5.2.  Half-
lives to equilibrium, 𝑡1/2
𝑒𝑞 , were also calculated for easier comparison.  This 𝑡1/2
𝑒𝑞  is defined by 
the equation below. 
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𝑡1/2
𝑒𝑞 =
ln (2)
𝑘𝑚(1+𝐾𝑓𝐿)
         (6) 
 Both methods show similar trends in km, with faster release in PBS containing 60 µM 
NH4Cl than that in PBS alone.  In PBS containing 60 µM NH4Cl, the 95% confidence limits of 
the km values determined from both methods overlapped.  However, in PBS without 
ammonia km values differed significantly depending on the monitoring method, with TPT 
release monitored by fluorescence being faster than that obtained by HPLC.  This was 
attributed to the lower concentration of liposomes in the experiments monitored by HPLC 
which resulted in more ammonia release.  Reduction in the intravesicular concentration of 
ammonia lowered the intravesicular pH, thus slowing TPT release.125  A detailed analysis of 
the differences in ammonia release and subsequent effects on intravesicular pH is provided 
in a later section.  
Table 5.1.  Release parameters obtained from HPLC and fluorescence methods.b 
 PBS only PBS w/ 60 µM NH4Cl Plasma & 
Ultrafiltrate Constant HPLC Fluorescence HPLC Fluorescence 
𝑘𝑚(hr -1) 0.037 ± 0.004 0.053 ± 0.008 0.15 ± 0.02 0.18 ± 0.04 1.5 ± 0.4 
𝐾 4.1 ± 0.6 0.5 ± 0.2 0 
𝑡1/2
𝑒𝑞 (hr) 10 ± 1 6.9 ± 0.9 4.6 ± 0.6 3.8 ± 0.8 0.54 ± 0.2 
𝑘𝑑(hr -1) 0.0115 0.0115 0.0115 0.0115 0.1 
  b ± 95 % confidence intervals 
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Figure 5.2.  Comparison of release profiles obtained by HPLC and fluorescence 
methods.  A) Changes in the fraction of TPT carboxylate versus time obtained by 
HPLC in release studies at 37 °C in pH 7.4 PBS with 60 µM NH4Cl and without 
ammonia (  and  , respectively) are shown along with fits of the carboxylate 
fraction to the release model (  and ).  The open symbols in the inset 
reflect the change in the fraction of lactone over the same time frame with  
and  reflecting their respective fits to the release model.  B) The fraction of 
TPT in the extravesicular compartment relative to the initial total suspension 
concentration of TPT (To/T0) versus time determined by the fluorescence 
method in pH 7.4 PBS in the presence or absence of ammonia (  and  , 
respectively).  Solid lines (  and )  represent fits to the release model .  The 
short-dashed  lines (  and ) reflect simulated profiles using the 
parameters obtained from release data monitored by HPLC for comparison.  
Release rates were accelerated to the same degree in plasma ( ) and plasma 
ultrafiltrates ( ).  The long-dashed line ( ) is representative of the 
simultaneous fits of all six data sets (i.e. plasma and plasma ultrafiltrate from 
three separate donors) from which the parameters listed in Table 5.1 were 
obtained. 
5.3.4  Release experiments in human plasma and plasma ultrafiltrate  
 Red shifts in excitation spectra were also observed during release studies in plasma.  
These shifts were again used to monitor TPT release.  This is illustrated in Figure 5.3.  Rate 
constants for release in plasma were ~30-fold greater than in PBS (Figure 5.2b and Table 
5.1) alone.  To assess possible contributions of colloidal lipoprotein particles that might 
participate in lipid exchange with the lipid bilayer or protein effects such as opsonization,93, 
156, 166-168 plasma samples were ultrafiltered and the ultrafiltrates were then used in release 
experiments.   TPT release in plasma ultrafiltrates was indistinguishable from the plasma 
release profiles (see Figure 5.2b) and the release rate constants in both plasma and plasma 
ultrafiltrates were ~10-fold greater than in PBS containing 60 M NH4Cl.  These 
observations provided motivation to measure ammonia concentrations in plasma to 
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determine whether the accelerated release rates seen in plasma and plasma ultrafiltrates 
were related to higher ammonia concentrations in these samples. The ammonia 
concentrations, analyzed using an ammonia selective electrode, were 180, 185, and 355  µM 
for these three plasma samples (each from a different donor) and their respective 
ultrafiltrates.  These levels were much higher than those reported in normal human blood 
(15-60 µM). 163, 164  These higher levels were likely due to protein degradation during 
storage, even under the -20 °C temperatures employed.169 
 
Figure 5.3.  Fluorescence excitation spectra of ALLT in plasma over time.  The 
change in fluorescence at 420 nm was used to monitor extravesicular TPT and 
subsequently liposomal release kinetics.  
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5.4  Discussion 
5.4.1  Differences in liposome concentration led to changes in intravesicular 
ammonia, pH, and subsequent release kinetics 
 While attempts were made to keep the release media consistent between experiments 
analyzed by HPLC and fluorescence, the liposome suspension concentrations differed 
between the two methods.  This was necessary for maintaining TPT concentrations in an 
optimal range for quantification by each method.  Simulations indicated that this seemingly 
minor difference could be important.    
 A preliminary estimate of the intravesicular pH under the different conditions in these 
experiments was obtained by simulating the effects of ammonia transport across the 
bilayer.  The first-order rate constant for ammonia bilayer transport, 𝑘𝑚,𝑛, is related to the 
permeability coefficient for ammonia transport, 𝑃𝑁𝐻3
𝑚 , and liposome diameter d:50  
d
P
k
m
NH
nm
3
6
, 
          (7) 
 The differential equations that govern ammonia transport are then: 
  
𝑑𝑁𝑖
𝑑𝑡
= −𝑘𝑚,𝑛(𝑁𝐻3,𝑖 −𝑁𝐻3,𝑜)       (8a) 
 
𝑑𝑁𝑜
𝑑𝑡
= 𝑓𝑣𝑘𝑚,𝑛(𝑁𝐻3,𝑖 − 𝑁𝐻3,𝑜)       (8b) 
Because the free base form of ammonia is the permeable species,170 the rates of change in 
the total concentration of ammonia in the intra- and extra-vesicular compartments (Ni and 
No respectively) are dependent on the concentration gradient between neutral ammonia in 
the intra- and extra-vesicular compartments (NH3,i and NH3,o respectively), the rate constant 
for neutral ammonia transport (𝑘𝑚,𝑛), and the ratio of liposomally-entrapped to 
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unentrapped volume (fv).  The latter quantity, fv, can be calculated from the particle size and 
lipid content in the liposome suspension with knowledge of the lipid surface density.50  
NH3,I and NH3,o may be written in terms of Ni and No by solving for the fractions of neutral 
ammonia in the intra- and extra-vesicular phases (𝑓𝑖
𝑁  and 𝑓𝑜
𝑁):  
𝑓𝑖
𝑁 = 
𝐾𝐴𝑁
𝐻𝑖
++𝐾𝐴𝑁
          (9a) 
𝑓𝑜
𝑁 = 
𝐾𝐴𝑁
𝐻𝑜
++𝐾𝐴𝑁
          (9b) 
 These fractions are dependent on the acid dissociation constant for ammonia, 𝐾𝐴𝑁 , and 
the acidity or hydrogen ion concentrations in the intra-or extra-vesicular compartments 
(𝐻𝑖
+ and 𝐻𝑜
+, respectively).  Using these fractions, equations 8a and b can be rewritten to 
yield: 
 
𝑑𝑁𝑖
𝑑𝑡
= −𝑘𝑚,𝑛(𝑓𝑖
𝑁𝑁𝑖 − 𝑓𝑜
𝑁𝑁𝑜)       (10a) 
 
𝑑𝑁𝑜
𝑑𝑡
= 𝑓𝑣𝑘𝑚,𝑛(𝑓𝑖
𝑁𝑁𝑖 − 𝑓𝑜
𝑁𝑁𝑜)       (10b) 
 The pH in the intravesicular compartment decreases as ammonia release causes 
deprotonation of ammonium to replenish the released ammonia.  This process governs the 
acidity of the intravesicular compartment by satisfying the charge balance equation: 
      𝐻𝑖
+ = 𝐵− +𝑂𝐻𝑖
− − (𝑁𝐻4,𝑖
+ + 𝑇𝑃𝑇𝐻𝑖
+)      (11) 
where B- is the ammonium salt counterion (besylate) concentration and 𝑇𝑃𝑇𝐻𝑖
+ is the 
concentration of  the cationic form of topotecan.  The ammonium (𝑁𝐻4,𝑖
+ ) and 𝑇𝑃𝑇𝐻𝑖
+ 
concentrations can be expressed in terms of total intravesicular concentration of ammonia 
(Ni) and topotecan (Ti) while 𝑂𝐻𝑖
− can be rewritten in terms of 𝐻𝑖
+and the ion product of 
water, Kw. 
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𝐻𝑖
+ = 𝐵− +
𝐾𝑤
𝐻𝑖
+⁄ − [(1 − 𝑓𝑖
𝑁)𝑁𝑖 + 𝑓𝑖
𝑇𝑇𝑖]      (12) 
At low pH, the fraction of intravesicular TPT in its protonated form, 𝑓𝑖
𝑇 , is a function of 𝐻𝑖
+ 
and the TPT phenol acid dissociation constant, KA1: 
 𝑓𝑖
𝑇 =
𝐻𝑖
+
𝐻𝑖
++𝐾𝐴1
           (13) 
 Simulations were performed using these equations and the values in Table 5.2 to 
calculate 𝐻𝑖
+ concentration versus time when the extravesicular solution initially contained 
either no ammonia (Figure 5.4A) or 60 µM of NH4Cl (Figure 5.4B) using the lipid 
concentrations measured in this study.  From these simulations, it is apparent that the 
entrapped volume can have a significant impact on intravesicular pH depending on the 
concentration of extravesicular ammonia present.  In solutions that initially contained no 
buffer, the higher lipid concentration (i.e. large entrapped volume) allows more ammonia 
release while the intravesicular ammonia is depleted to a lesser extent.  Because of the 
resulting higher intravesicular ammonia concentration, the increase in 𝐻𝑖
+ is less for the 
liposome suspensions used in the fluorescence method.  TPT release is pH-dependent and 
slower as 𝐻𝑖
+ increases.125 The higher rate of TPT release determined by the fluorescence 
method compared to that observed by HPLC is consistent with this difference in 𝐻𝑖
+.  
 This effect, however, is not apparent in the release studies conducted in PBS solutions 
which initially had ammonia present.  At 60 µM NH4Cl, the extravesicular concentration of 
ammonia is sufficiently high and the volume entrapped low enough that the extravesicular 
concentration essentially remained constant.  This normalized the ammonia concentration 
gradient to be the same and independent of the entrapped volume (Figure 5.5b).  This 
results in nearly identical 𝐻𝑖
+ profiles for both methods and subsequently the same release 
kinetics for both methods.   
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 For these simulations, the initial 𝐻𝑖
+ was calculated assuming a 1:1 exchange between 
ammonia and TPT during the active loading process (i.e. 𝑁𝑜(0) = 0.3 − 𝑇𝑖).  While this can 
only be a rough estimation of the initial 𝐻𝑖
+, simulations at a higher or lower initial 𝐻𝑖
+ (10-
2.5 and 10-5.5 or pH of 2.5 and 5.5, respectively) also resulted in similar trends in the 
terminal 𝐻𝑖
+ simulated in Figure 5.4. 
Table 5.2.  Parameters used to simulate 𝐻𝑖
+ profiles at different lipid concentrations 
Parameters Values 
km,n 2.88 × 104 𝑠−1 c 
KA1 2.8 × 10−7 d 
KAN 9.40 × 10−10 e 
Kw 2.12 × 10−14 e 
Ho 3.98 × 10−8𝑀  
Ti 1.45 × 10−2𝑀  
Bi 0.3 𝑀 
fv – HPLC conditions 
       (6.4 µg lipid/mL) 
1.66 × 10−5 f 
fv – Fluorescence conditions 
       (19.2 µg lipid/mL) 
5.19 × 10−5 f 
c Calculated from a previously reported ammonia permeability coefficient of 
𝑃𝑁𝐻3
𝑚 = 48 × 10−3 𝑐𝑚 𝑠⁄   171 
d   Obtained from a previous study125 
e    Values adjusted to reflect conditions at 37 °C and 0.3 I 
f   Calculated based on particle size, lipid content, and lipid surface density 
calculations previously reported50, 135  
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Figure 5.4.  The simulated profiles of [𝐻𝑖
+] and [𝑁𝑜] versus time in pH 7.4 PBS 
release media that initially contained no extravesicular ammonia (A) or 60 µM 
NH4Cl (B).  [𝐻𝑖
+] simulations shown are at the lipid concentrations at which 
release studies by HPLC ( ) and fluorescence methods ( ) were conducted.  
The dotted lines of corresponding color reflect the total extravesicular ammonia 
present over this time period for HPLC and fluorescence methods, respectively.   
5.4.2  Effects of ammonia concentration in physiological samples and 
implications on liposomal TPT release 
 Initial simulations of intravesicular pH showed that the presence of extravesicular 
ammonia in the release media partially dissipated the pH gradient.  Such an effect may also 
be possible in the release studies in plasma and plasma ultrafiltrates as relatively high levels 
of ammonia were detected in these samples.  This was explored further in simulations of the 
intravesicular pH after accounting for the extravesicular ammonia present in the various 
release media studied (buffer, plasma, or plasma ultrafiltrate).  These simulations, shown in 
Figure 5.5, indicate a negative correlation between the release half-life and the 
intravesicular pH.  This relationship provides further evidence that the presence of 
extravesicular ammonia raises intravesicular pH, given the pH-sensitive release of 
liposomal TPT previously reported.125 
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Figure 5.5.  The relationship between TPT release half-life and simulated 
intravesicular pH.  Release studies performed in PBS ( ), plasma ( ), and 
ultrafiltrate obtained from plasma ( ) are shown.  In some instances, the 
plasma ultrafiltrate data are difficult to observe due to overlap with data points 
from plasma studies.  The resulting trend line along with its R2 are shown to 
illustrate the negative correlation between TPT retention and intravesicular pH. 
While further studies are necessary to fully understand the effect of ammonia transport 
on actively-loaded liposomal systems (e.g. in formulations with drug 
precipitation/complexation within the intravesicular environment), the potential 
implications are considerable.  Many liposomal drug loading strategies rely on the 
generation of a pH gradient using ammonia,62, 73 an ionophore,64, 96, 97 or another highly 
permeable amine (e.g. di- or tri-methylamine).21, 42  In all of these strategies, the pH 
gradients generated to stabilize drug encapsulation are susceptible to the influx of ammonia 
or other highly permeable basic species present in physiological tissue or fluid.  The 
intravesicular pH in these formulations should be calculable using an equation based on a 
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charge balance similar to Equation 11 with appropriate modifications to account for 
precipitation, self-association, etc.  Under in vivo conditions, the much larger volume of 
physiological fluids, in comparison with the entrapped volume of administered liposomes, 
would also provide constant extravesicular ammonia levels, similar in manner to the 
conditions studied within this chapter. 
While it is likely that ammonia is the primary basic-permeable species present in 
physiological fluids and tissues, other low molecular weight amines (e.g. di- and tri-
methylamine) are also present at levels which vary from patient to patient.172-174  Other 
effects have been suggested to account for variability of liposomal release kinetics in plasma 
such as destabilization of the bilayer due to protein interactions.32, 55, 57, 166, 167, 175  However, 
these theories could not explain the effects seen here as release kinetics obtained in plasma 
would have been significantly different from release kinetics obtained in studies performed 
in an ultrafiltrate of the same plasma (which was not the case). 
Lastly, the storage conditions and history of the plasma may also have a considerable 
effect on release rates from actively loaded liposomes.  Previous reports on the production 
of ammonia under a wide variety of conditions typically encountered during the processing 
and storage of plasma are considerable.169, 173  Furthermore, these studies indicate that 
ammonia production is significant at room temperature and even when samples have been 
frozen.  This may account for the higher ammonia levels in these plasma studies than those 
reported in the literature for fresh plasma and blood samples.163, 164  Such an issue could 
lead to overestimations of drug release in vivo.  Characterization of the ammonia content 
and possibly other protein degradants in release studies performed in plasma should be 
considered.  Furthermore, ammonia generation during release studies may also affect 
release kinetics.  In the present study, ammonia levels in plasma after a 48 hour release 
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experiment were considerably higher (approximately two-fold) than the initial ammonia 
levels.  This is yet another scenario that could lead to possible overestimation of drug 
release based on characterization studies in plasma, as renal excretion of ammonia would 
typically prevent such high levels in patients.  In contrast, however, patients suffering from 
hyperammonemia could present much higher ammonia concentrations (~1 mM).176, 177  
This condition may be quite relevant in cancer patients with diminished liver function,178 
either as a result of the cancer’s pathophysiology, a side effect of a previous treatment,178-181 
or a preexisting condition (e.g. cirrhosis).178  In such cases, further acceleration in liposomal 
drug release may be seen. 
5.4.3  Adaptation of method for other nanoparticles and drugs  
 In the field of nanotechnology-based drug delivery systems, analytical methods to 
quantify in vivo drug release from nanoparticles are needed to develop in vitro-in vivo 
release rate correlations and to ultimately relate anti-tumor efficacy to drug exposure.  
Described herein is a fluorescence technique to non-invasively distinguish free TPT from 
liposomally entrapped drug in tissue (human plasma).  The release profiles generated were 
analyzed using mathematical models to probe the effects of critical experimental variables 
affecting release rates.  The combination of a non-invasive method to analyze liposomal 
drug release and mechanism-based mathematical modeling to interpret release profiles 
represents a powerful new approach for understanding actively-loaded liposomal drug 
release that may ultimately contribute to improved liposomal drug therapy.  
 For these studies, fluorescence spectroscopy is used; however, the general validation 
scheme could be applied to other spectroscopic techniques depending on the spectrometric 
properties of the particular drug and/or nanoparticle.  While qualitative comparisons of 
spectrometric data are initially made to distinguish free from entrapped drug, quantitative 
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analysis and validation of release kinetics requires a mathematical model describing release 
kinetics. 
5.5  Conclusion 
Reliable methods to monitor drug release in physiological fluids and tissues could improve 
predictions of in vivo performance of liposomal drug delivery systems.  To this end, a non-
invasive method was developed to monitor liposomal release kinetics of TPT.  This method 
utilizes the pH-dependent shift in the excitation spectra of TPT to distinguish between drug 
entrapped at the low intravesicular pH in actively-loaded liposomal formulations from 
released drug.  Release kinetics obtained by fluorescence were consistent with results using 
an HPLC method to monitor release. 
Accelerated liposomal TPT release kinetics were observed in human plasma. Additional 
experiments in plasma that was ultrafiltered to remove protein and lipid components that 
have previously been theorized to alter release kinetics indicated similar accelerated 
release rates.  When release studies were performed in PBS buffer at pH 7.4, the addition of 
ammonia to the buffer was also found to dramatically increase release rates.  Analyses of 
ammonia concentrations in the plasma samples employed in release studies were therefore 
undertaken.  Model-based simulations were used to estimate the intravesicular pH in the 
presence or absence of extravesicular ammonia.  The intravesicular pH increased with 
increasing concentrations of extravesicular ammonia. A significant correlation was found 
between TPT release rates and intravesicular pH simulated based on the extravesicular 
ammonia present in the plasma, plasma ultrafiltrates, or PBS buffer in which release studies 
were conducted.   These findings may account for the accelerated release rates typically 
experienced in physiological fluids and potentially some of the preclinical variability 
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observed from ALLTs23 and likely present for other actively-loaded, weakly basic drugs (e.g. 
doxorubicin, irinotecan, and vincristine).21, 73, 95, 96, 112, 182   
Because extensive processing of sample is not required to analyze drug release, the non-
invasive fluorescence method developed in this work has potential applications for 
analyzing release kinetics in real-time for physiological samples.  One such application may 
include analysis of free and entrapped drug in blood samples taken for PK studies.  This 
would allow for both particle clearance and liposomal release kinetics of drug in systemic 
circulation to be analyzed simultaneously.  Currently, adaptation of this method is under 
investigation using two-photon fluorescence for intratumoral imaging of release kinetics in 
mouse xenografts equipped with a dorsal window.  This method may also be adaptable to 
other molecules that exhibit pH dependent fluorescence spectra.   
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CHAPTER SIX  
Mechanistic Evaluation of Self-association, Ion-pairing, Ammonia, and 
Precipitation Effects on Active Loading and Release of Liposomal 
Topotecan 
6.1 Introduction 
 Nanoparticle formulations of anticancer agents are studied intensively for drug delivery 
applications due to their unique ability to passively or actively target their payloads of 
anticancer agents to the tumor site.  Such targeting has the potential to lower systemic 
toxicity while increasing intratumoral concentrations of the pharmaceutical agent of 
interest.6, 7, 42  Liposomes constitute a class of nanoparticles that has shown additional 
benefits in chemotherapy delivery due to their slow systemic clearance allowing greater 
accumulation of the particles (and consequently, the drug) at the tumor site.30, 111, 183, 184   
 Many of the well-studied liposomal formulations incorporate a weakly basic anticancer 
agent due to their ability to achieve high drug-to-lipid ratios21, 42, 62, 73, 94, 95 .  This result is 
beneficial for a variety of reasons including: increased API solubility, smaller infusion 
volume for patients, higher encapsulation efficiency (i.e. high drug loading) resulting in less 
waste of valuable API, and altered exposure profiles of said API due to liposomal release 
kinetics.   While high loading efficiency is desirable, understanding its effect on in vivo 
performance (i.e. release kinetics) has yet to be adequately characterized.   
 Mechanistic modeling constitutes a means to provide such understanding by 
distinguishing physicochemical release characteristics intrinsic to the drug/particles 
system from artifacts of the release environment (i.e. kinetic or thermodynamic effects 
attributable to the particular medium that release is studied within).49, 60, 63, 124, 126, 130  With 
mechanistic models, optimization of drug release profiles may be achieved by rationally 
selecting the proper drug loading conditions (e.g. drug suspension concentration, pH, 
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temperature, counter-ions in solution, etc.).  A model capable of providing predictable 
release rates under a variety of in vitro conditions could be adapted to incorporate 
physiological variables which affect release in vivo.  Such modeling would allow a 
formulator to reasonably predict in vivo formulation performance from in vitro release 
studies and reduce the need for costly preclinical testing. 
One of the anticancer agents extensively researched as an actively-loaded liposomal 
formulation is the anticancer agent topotecan (TPT).  TPT is a camptothecin analogue 
known for its topoisomerase-I inhibitory activity185  and has demonstrated increased anti-
tumorigenic efficacy as a liposomal formulation.62, 158, 159  Many liposomal TPT formulations 
utilize active loading of the anticancer agent via the establishment of a pH gradient.  
Generating an acidic intravesicular environment relative to the extravesicular loading 
solution preserves the active lactone form of the drug while achieving high drug loading 
efficiencies.  Furthermore, this active loading strategy has been shown to result in 
prolonged retention in release studies conducted in aqueous solution.62, 64 Unfortunately, 
these same formulations have shown accelerated release in plasma.62  Understanding what 
underlying mechanisms lead to these differences, whether physiological or 
physicochemical, requires rigorous studies of the active loading process of liposomal TPT.  
Understanding the kinetic and thermodynamic factors that drive loading will not only allow 
for optimization of the active loading process, but also help decipher the subsequent release 
of TPT from these formulations.  
This study develops and evaluates several models to describe active loading of TPT 
based on physicochemical properties of the drug and the liposomal environment.  All of 
these models accounted for the generation of low intravesicular pH in addition to other 
factors, including TPT self-association and/or ion-pairing transport across the bilayer.  The 
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validity of these models was assessed by fitting experimentally observed uptake profiles of 
TPT undergoing active loading into liposomes containing ammonium besylate 
[NH4C6H6SO3] or sulfate [(NH4)2SO4].  A loading model which incorporated ion-paired 
transport of cationic TPT with chloride and TPT dimerization was found to describe drug 
loading best.  Further validation of this model was performed by assessing the model’s 
ability to predict TPT release under varying chloride conditions.  Lastly, the influence of 
chloride on TPT loading at higher temperature was also demonstrated experimentally, 
showing much higher encapsulation efficiencies and slower release than formulations 
loaded at lower temperatures.  These effects were rationalized by the development of a 
mechanistic release model which suggests the prolonged release from these high-
temperature-loaded liposomes was due to the precipitation of intravesicular TPTHCl.  These 
findings suggest that tunable drug release of liposomal TPT could be achieved through 
manipulation of chloride during active loading.  This work also provides a general approach 
for mechanistically characterizing active loading and release kinetics of liposomal 
formulations. 
6.2 Materials and methods 
6.2.1 Materials 
Powders of 1,2-distearoyl-sn-glycero-3-phosphatidylcholine (DSPC, >99% purity) and 
1,2-distearoyl-sn-glycero-3-phosphoethanolamine-N-[methoxy(polyethyleneglycol)-2000] 
(m-PEG DSPE, MW = 2806, >99% purity) were purchased from Avanti Polar Lipids 
(Alabaster, AL).  Topotecan hydrochloride was purchased from AK Scientific (Union City, 
CA).  Benzene sulfonic acid sodium salt (sodium besylate) was purchased from Spectrum 
Chemicals.  Millipore ultrafiltration cartridges (Amicon® Ultra 0.5 mL centrifugal filter 
device with 30,000 MWCO Ultracel® membrane), Nuclepore polycarbonate membranes 
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(0.1 µm), Dowex 50Wx8-200 resin in the H+ form, solvents, and buffer salts were purchased 
from Fisher Scientific (Florence, KY). All solvents were HPLC grade.   
6.2.2 Liposome preparation and characterization 
Large unilamellar liposomes were prepared based on previously reported methods.49, 50, 
60, 118, 124, 130  Briefly, powders of DSPC and DSPE-PEG2K were dissolved in chloroform at a 
ratio of 95:5 mol:mol, then dried under nitrogen, then under vacuum (- 30 in Hg) at 35 °C 
for 6 hours.  After drying, the films were hydrated with ammonium besylate solutions (0.3 
M), 0.3 M (NH4)2SO4, or a solution of 50 uM TPT in pH 4.1 50 mM sodium formate (adjusted 
to an ionic strength of 0.3 with NaCl) to make 30 mg/mL lipid suspensions.  These 
suspensions were vortexed at 60 °C, then extruded through 2, 100 nm polycarbonate 
membranes 10 times at 40 psig and 60 °C to yield ammonium besylate or sulfate-containing 
liposomes (ABLs and ASLs respectively) for active loading and passively-loaded TPT 
liposomes (PLLT), for separate release studies.  Liposome particle size was determined with 
dynamic light scattering (DLS) as reported previously,126, 130 yielding diameters (with 95% 
CI of 6 independent readings) of 100 ± 4 and 103 ± 2 nm before active loading and release 
studies, respectively.  Lipid content was also determined (see HPLC analyses) for 
calculations of entrapped volume and TPT loading efficiency. 
The ammonium besylate solutions used for ABL hydration were prepared by 
passing solutions of sodium besylate (0.6 M) through an ion exchange column made of 
Dowex 50Wx8-200 resin in the H+ form.  The eluted solutions were subsequently titrated 
with ammonium hydroxide (3.0 M) to the equivalence point and diluted to the desired 
concentration as previously reported for several other amino-based salts.21, 42     
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6.2.3 Active loading of TPT 
 Previous studies have shown that active loading of weakly basic drugs results in high 
encapsulation efficiency and possibly longer drug retention in vitro and in vivo.  Active 
loading was performed by generating low intravesicular pH via an ammonia gradient.62, 73  
Establishing an ammonia (or another small-MW amine) gradient is typically accomplished 
via removal of extravesicular ammonia upon elution of the suspension through a size 
exclusion column.21, 42, 62, 73, 95  In this study, 0.4 mL of the ABL or ASL suspension was passed 
through a Sephadex G-25 column equilibrated with 100 mM 2-(N-
morpholino)ethanesulfonic acid (MES) pH 5.5 buffer containing 0.25 M NaCl to maintain an 
isotonic state between the intra-and extra-vesicular solutions.  The first 5 mL of eluted 
suspension was collected for loading studies.   
Next, 1.5 mL of the eluted suspension was added to an equal volume of TPT dissolved in 
the same pH 5.5 buffer to achieve a total TPT suspension concentration of 60, 130, or 180 
µM and lipid concentration of 0.92 mg lipid/mL.  Loading either occurred over a 72 hour 
period within a 37 °C incubator or over 30 min in a 60 °C oven as previously reported.62  
Loading kinetics was monitored at 37 °C by isolating intravesicular TPT with a previously 
validated ultrafiltration method.126, 130  After ultrafiltration, the obtained suspensions of 
intravesicular TPT were dissolved in chilled (-20 °C) acidified (0.001 N HCl) methanol to 
convert all drug to its lactone form for monitoring of loading with HPLC (see HPLC 
analyses).  The levels of released ammonia were also monitored during loading studies.  
This was achieved by ultrafiltering 0.4 mL of the liposome suspension and analyzing 
ammonia levels in the ultrafiltrate with an ammonia selective ion probe (see ammonia 
analyses section).  
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6.2.4 Release of passively-loaded TPT 
  Passively-loaded liposomal release was used to assess transport of cationic TPT via ion-
pairing with chloride.  This was examined by performing TPT release studies where the 
cationic form of TPT was dominant (pH 4.1) and by examining three different chloride 
conditions including: 1) an excessive amount of chloride present in both the intra- and 
extravesicular compartments, 2) only chloride from the TPTHCl salt present in the 
intravesicular compartment and no chloride present in the extravesicular compartment and 
3) only Cl from the TPTHCl salt present in the intravesicular compartment with a large 
concentration of chloride in the extravesicular compartment.  These conditions were 
achieved using passively-loaded liposomes made in solutions of 50 µM TPTHCl in pH 4.1 50 
mM sodium formate buffer with either 0.25 M NaCl or 0.167 M Na2SO4 to achieve isotonic 
conditions.  Release was monitored after removal of extravesicular TPT by passing 0.35 mL 
of the liposomal suspensions through a Sephadex column.  For liposomes made with 0.25 M 
NaCl solutions, the same buffer was used in the Sephadex column.  For liposomes made in 
the presence of sulfate, the suspensions were passed through columns equilibrated with 
either the same formate buffer or the buffer with 0.25 M NaCl.  After 1.5 mL of buffer had 
been passed through the column, liposomal TPT was eluted in the next 3.5 mL and collected 
to achieve a final suspension concentration of 135 nM TPT and 0.9 mg lipid/mL.  At various 
time points, 150 uL aliquots of the suspension were collected.  Release was monitored by 
isolating intravesicular TPT using ultrafiltration.  After ultrafiltration, intravesicular TPT 
was dissolved in chilled acidified methanol and analyzed by HPLC.  
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6.2.5 Release of actively-loaded TPT in the presence of extravesicular 
ammonia  
 Release of liposomal TPT in the presence of extravesicular ammonia may be particularly 
important, as it is present in physiological fluids and tissues and may have an effect on 
intravesicular pH and subsequently alter release kinetics (as already illustrated in Chapter 
5).  To observe this effect, release studies of actively loaded TPT in ABLs and ASLs were 
conducted at 37 °C in pH 7.4, phosphate buffered saline (PBS) solution and in PBS which 
also contained 12 or 60 µM of NH4Cl.  Removal of extravesicular buffer and any unloaded 
drug from the loading phase was accomplished by applying 0.5 mL of actively-loaded 
liposome suspensions to a Sephadex G-25 column equilibrated with PBS similar to previous 
reports.60, 63  The first 2.5 mL fraction eluted from the column was discarded and the next 
2.5 mL fraction was collected and used in release studies. Release studies were performed 
by diluting 0.2 mL of the actively-loaded liposomal suspension of TPT obtained from 
Sephadex to a final volume of 4 mL using PBS with NH4Cl to achieve final concentrations of 
0, 12, or 60 µM.  The resulting TPT suspension concentrations ranged between 240 and 600 
nM and had a lipid concentration of 6.4 µg/mL.  Over time, 150 µL aliquots were withdrawn 
from the suspension and diluted with chilled methanol (-20 °C) to disrupt the liposomes 
and quench the lactone/carboxylate ratio of TPT.  These samples were immediately injected 
and analyzed by HPLC to monitor release.  
6.2.6 Isolation of intravesicular TPT by ultrafiltration 
 A previously validated ultrafiltration method was used to separate extravesicular from 
entrapped TPT126, 130 for passively-loaded release studies and active-loading at 37 °C.  
Briefly, an Amicon® Ultra 0.5 mL centrifugal filter device with 30,000 MWCO Ultracel® 
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membrane containing sample was centrifuged at 14,000 rpm for 10 minutes in an 
Eppendorf 5417R maintained at 4 °C.   
For the analysis of intravesicular TPT, samples were diluted to 0.45 mL with chilled (4 
°C) buffer identical to that of the extravesicular solution to quench loading or release before 
centrifugation.  After centrifugation, the resulting concentrate (25 µL) containing the 
liposome suspension was recovered by inverting the cartridge and centrifuging at 2000 rpm 
for another 2 minutes.  Recovered concentrate was resuspended in another 400 µL of 
chilled buffer and the process was repeated.  The final concentrate was dissolved in 
acidified methanol and diluted within the calibration range for HPLC analysis of TPT. 
 Extravesicular ammonia released during loading at 37 °C was also separated with this 
method with some modification.  Here, liposomal suspensions (0.45 mL) were centrifuged 
through the same ultrafiltration cartridges; however, only one cycle of centrifugation (with 
the same conditions used to isolate intravesicular TPT) was used.  After centrifugation, 0.35 
mL of the ultrafiltrate was recovered and used for ammonia analysis.  
6.2.7 HPLC analyses 
 Both the lactone and carboxylate forms of TPT were monitored with HPLC using a 
previous method with slight modifications.130  Briefly, a Waters Alliance 2695 separation 
system running mobile phase (11.5% acetonitrile: 88.5% (v/v) of 5% (pH = 5.5) 
triethylamine acetate, 50 mM tetrabutylammonium hydrogen sulfate (TBAHS) buffer) at a 
flow rate of 1 mL/min used a Waters Symmetry® C18 column (3.9×150 mm, 5 µm) and 
guard column (3.9 x 20 mm) to separate lactone and carboxylate TPT in samples.  A Waters 
fluorescence detector (M474) (operating at excitation and emission wavelengths of 380 and 
560 nm, respectively) was used to analyze the fractions of lactone and carboxylate TPT after 
separation.  Standards containing TPT in its lactone and carboxylate forms were prepared 
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in chilled, acidified methanol (-20 °C) and 10 mM sodium carbonate buffer (pH 10.1), 
respectively.  Standards ranged from 20-200 nM.  Lactone and carboxylate retention times 
were 6.1 and 2.7 min, respectively. 
Lipid content was also monitored by HPLC using an evaporative light scattering 
detector (ELSD).  Using the same separations module as mentioned above, an Allsphere 
(Alltech Associates, Inc., Deerfield, IL) silica column (4 x 150 mm, 5 µm) and guard column 
(20 x 4.0 mm, 5 µm) with a mobile phase consisting of 80% of solvent A (80% 
chloroform:19.5% methanol:0.5%(v/v) NH4OH)  and 20% of solvent B (80% 
methanol:19.5% water:0.5% (v/v) NH4OH) at a flow rate of 1 mL/min were used to 
quantify DSPC using an ELSD (Sedere, Inc., Lawrenceville, NJ) operated at 40 psig and 40 °C.  
Logarithms of peak areas of DSPC standards in mobile phase A (0.05 – 0.3 mg DSPC/mL) 
were linear with respect to the logarithm of concentration. Samples (100 – 250 µL) were 
dried at room temperature under N2, then dissolved in chilled solvent A before analysis. 
6.2.8 Ammonia analyses 
Potentiometric measurements of ammonia released during loading at 37 °C employed 
an Orion ammonia ion selective electrode in conjunction with a Thermo Scientific Orion Star 
A214 pH, ISE, mV, temperature meter.  Ammonia standards were prepared between 0.01-
0.3 ppm in Milli-Q H2O.  Immediately before the ammonia analyses, NaOH reagent was 
added to 10 mL of ammonia standards or samples diluted in Milli-Q H2O (10 – 15 mL total 
volume) at a ratio of 0.01:1 (v/v) to raise pH and convert any ammonium to ammonia.  
Solutions were allowed to equilibrate for 3-5 minutes under mild stirring and the final 
voltage was recorded.  A Nernst relationship between ammonia concentration and electric 
potential (mV) was observed and used to make a standard curve for estimation of ammonia 
concentration in these samples.  Blank solutions of MES buffer diluted with Milli-Q H2O in 
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the same manner as ammonia samples were found to have no effect on the baseline voltage 
and therefore no corrections were necessary. 
6.2.9 Loading and release models of liposomal TPT  
 Models describing the pH-dependent release kinetics of ionizable drugs from liposomes 
exist;49, 60, 124, 127, 128, 130 however, only a few have been experimentally tested49, 60, 124, 130 and 
even fewer have been tested under conditions in which a pH gradient was established via 
transport of another small, highly permeable acid/base entrapped within the intravesicular 
compartment.60, 124  To our knowledge, this is the first mechanistic model used to examine 
active loading of a weakly basic drug.  Furthermore, this model also explores the 
incorporation of drug self-association, ion-pairing, and precipitation to characterize the 
active loading process and subsequent release from these actively-loaded formulations.  An 
illustration of these factors and others already shown to affect the release of liposomal 
TPT130 can be found in Scheme 6.1.    
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Scheme 6.1. A mechanistic illustration of the equilibria and kinetic processes 
that govern active loading of TPT in the presence of pH and chloride gradients.  
Intravesicular pH (i.e. negative logarithm of the proton concentration, 𝐻𝑖
+) is 
lowered as ammonia permeates the lipid bilayer.  This is governed by 
ammonia’s release rate constant, 𝑘𝑚𝑛 , and the concentration gradient between 
intra- and extravesicular ammonia (𝑁𝐻3,𝑖 and 𝑁𝐻3,𝑜 , respectively).  Similar 
release rate constants governing the transport of the zwitterionic lactone 
(𝐿1,𝑖
𝑧 and 𝐿1,𝑜
𝑧 ) and carboxylate (𝐶𝑜
𝑧,𝑤) forms of TPT as well as its ion-pair with 
chloride (𝐿𝐶𝑙𝑖  and 𝐿𝐶𝑙𝑜) are represented by 𝑘𝑚𝑧 , 𝑘𝑚𝑐 , and 𝑘𝑚𝑝 , respectively.  
Equilibria governing dimerization of TPT (𝐾2), partitioning of cationic lactone 
and zwitterionic carboxylate TPT to the bilayer/solution interface (𝐾𝑝  and 𝐾𝑐 ,, 
respectively), and the ionization state of TPT lactone and carboxylate (𝐾𝐴1) are 
shown along with the rate constants governing ring-opening and closing of TPT 
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(𝑘𝑜𝑝  and 𝑘𝑐𝑙 ,.  respectively). The inset at the bottom depicts the ion-pair 
transport of TPT-Cl across the bilayer which is dependent on the association 
constant of the ion-pair (Kip) in addition to kmp.  A TPTHCl salt may also form in 
the intravesicular compartment (TCli) during or after the loading process as 
governed by the salt’s solubility product, Ksp. 
6.2.9.1 TPT rate equations governing loading kinetics 
 The rate equations governing transport of TPT may contain multiple terms to account 
for the permeable species in the intra- and extravesicular compartments (from this point 
on, the subscript “i” and “o” will refer to chemical species in the intra- and extra-vesicular 
compartments respectively.)  This is expressed by Equations 1a and b. 
𝑑𝑇𝑖
𝑑𝑡
=
𝑑𝐿𝑖
𝑧
𝑑𝑡
+
𝑑𝐿𝐶𝑙𝑖
𝑑𝑡
         (1a) 
  
𝑑𝑇𝑜
𝑑𝑡
=
𝑑𝐿𝑜
𝑧
𝑑𝑡
+
𝑑𝐿𝐶𝑙𝑜
𝑑𝑡
+
𝑑𝐶𝑜
𝑑𝑡
        (1b) 
Here, the rates of change of total intra- and extra-vesicular TPT (Ti and To, respectively) 
are a sum of the transport rates of the lactone forms (Li and L,o, respectively), the TPT-Cl 
ion-pair (𝐿𝐶𝑙𝑖  and𝐿𝐶𝑙𝑜, respectively), and extravesicular carboxylate (Co).  Intravesicular 
carboxylate may be ignored as the intravesicular pH is sufficiently low that essentially no 
carboxylate exists inside the liposome as shown in CH. 5.92, 130   
The rates governing transport may be described by pseudo steady-state Fickian 
diffusion through a membrane49, 50, 60, 124, 130 of each drug species (or complex) permeable to 
the bilayer.  These terms are incorporated into the rate equations governing intravesicular 
transport of TPT below. 
   
𝑑𝑇𝑖
𝑑𝑡
= −𝑘𝑚𝑧(𝐿1,𝑖
𝑧 − 𝐿1,𝑜
𝑧 ) − 𝑘𝑚𝑝(𝐿𝐶𝑙𝑖 − 𝐿𝐶𝑙0) + 𝑘𝑚𝑐𝐶𝑜
𝑧,𝑤    (2) 
The concentration gradient governing Fickian diffusion across the membrane is 
between the monomeric forms of the lactone zwitterion (𝐿1,𝑖
𝑧 and 𝐿1,𝑜
𝑧 ).  Because 
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intravesicular carboxylate is negligible at low pH, only unbound extravesicular carboxylate 
zwitterion (𝐶𝑜
𝑧,𝑤) contributes to transport.  In previous studies, such transport was also 
assumed for L+1.  However, those studies were performed in dilute concentrations of TPT 
and high chloride concentrations in both the intra- and extra-vesicular compartments.  Such 
conditions are not present during active loading.  Because several gradients now exist in 
active loading (e.g., pH, TPT, chloride, and ammonia), a more complex process may become 
apparent. 
This complexity regarding the transport of L+1 was hypothesized to proceed through 
ion-pairing of the cationic lactone form of TPT with chloride since it is the smallest and 
most abundant anion present in the extravesicular (i.e. loading) solution.  Transport across 
the bilayer is governed by the release rate constant kmp, and the concentration gradient of 
the TPT-Cl ion pair formed in the intra- and extra-vesicular compartments (𝐿𝐶𝑙𝑖  and 𝐿𝐶𝑙𝑜, 
respectively).   
The rate equation governing the extravesicular compartment is similar to that for the 
intravesicular compartment and shown below. 
𝑑𝑇𝑜
𝑑𝑡
= 𝑓𝑣[𝑘𝑚𝑧(𝐿1,𝑖
𝑧 − 𝐿1,𝑜
𝑧 ) + 𝑘𝑚𝑝(𝐿𝐶𝑙𝑖 − 𝐿𝐶𝑙0) − 𝑘𝑚𝑐𝐶𝑛,𝑜
𝑢 ]    (3) 
Here, the ratio of entrapped volume to extravesicular volume (𝑓𝑣 =
𝑉𝑖
𝑉𝑜
) is used to maintain 
mass balance between the intra-and extra-vesicular compartments.  The calculation of 𝑓𝑣  is 
possible with the aid of lipid surface area densities, particle size, and the concentration of 
lipid as previously defined elsewhere.50, 126, 130, 135   
 Accounting for chloride transport is also necessary due to ion-pairing.  This is achieved 
with rate equations governing intra- and extra-vesicular chloride (𝐶𝑙𝑇,𝑖  and 𝐶𝑙𝑇,𝑜, 
respectively) as shown below. 
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𝑑𝐶𝑙𝑇,𝑖
𝑑𝑡
= −𝑘𝑚𝑝(𝐿𝐶𝑙𝑖 − 𝐿𝐶𝑙0)       (4a) 
 
𝑑𝐶𝑙𝑇,𝑜
𝑑𝑡
= 𝑓𝑣𝑘𝑚𝑝(𝐿𝐶𝑙𝑖 − 𝐿𝐶𝑙0)        (4b) 
Initial conditions are required to solve this system of differential equations.  These 
initial conditions are shown by the equations below for loading studies. 
   𝑇𝑖(0) = 𝐶𝑙𝑇,𝑖(0) = 0       (5a &b) 
𝐶𝑙𝑇,𝑜(0) = 0.25𝑀        (5c) 
   𝑇𝑖
𝑏(0) = 𝐿𝑆         (5d) 
Here, LS is the concentration of TPT in the loading suspension which was varied to examine 
self-association and its effect on loading efficiency. 
Derivation of the concentrations of monomeric species of TPT in terms of Ti and To are 
required to model drug transport during the active loading process.  These derivations will 
be described in the subsequent sections for the different loading models examined. 
6.2.9.2 Generation of pH gradient  
 The release of neutral ammonia from the intravesicular compartment  generates  a low 
intravesicular pH (pHi).170  This is governed by the rate equations below. 
 
𝑑𝑁𝑖
𝑑𝑡
= −𝑘𝑚𝑛(𝑁𝐻3,𝑖 −𝑁𝐻3,𝑜)       (6a) 
 
𝑑𝑁𝑜
𝑑𝑡
= 𝑓𝑣𝑘𝑚𝑛(𝑁𝐻3,𝑖 −𝑁𝐻3,𝑜)       (6b) 
The rates of change in the total concentration of ammonia in the intra- and extra-vesicular 
compartments (Ni and No respectively) are dependent on the concentration gradient 
between neutral ammonia in the intra- and extra-vesicular compartments (NH3,i and NH3,o,, 
respectively), the rate constant for neutral ammonia transport (𝑘𝑚𝑛), and fv.  NH3,i and NH3,o 
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may be written in terms of Ni and No by solving for the fractions of neutral ammonia in the 
intra- and extra-vesicular compartments (𝑓𝑖
𝑁  and 𝑓𝑜
𝑁):  
𝑓𝑖
𝑁 = 
𝐾𝐴𝑁
𝐻𝑖
++𝐾𝐴𝑁
         (7a) 
𝑓𝑜
𝑁 = 
𝐾𝐴𝑁
𝐻𝑜
++𝐾𝐴𝑁
         (7b) 
These fractions are dependent on the acid dissociation constant for ammonia, 𝐾𝐴𝑁 , and the 
acidity or hydrogen ion concentrations in the intra-or extra-vesicular compartments (𝐻𝑖
+ 
and 𝐻𝑜
+, respectively).  Using these fractions, Equations 6a and b can be rewritten to yield: 
 
𝑑𝑁𝑖
𝑑𝑡
= −𝑘𝑚,𝑛(𝑓𝑖
𝑁𝑁𝑖 − 𝑓𝑜
𝑁𝑁𝑜)       (8a) 
𝑑𝑁𝑜
𝑑𝑡
= 𝑓𝑣𝑘𝑚,𝑛(𝑓𝑖
𝑁𝑁𝑖 − 𝑓𝑜
𝑁𝑁𝑜)       (8b) 
The pH in the intravesicular compartment decreases as ammonia release causes 
deprotonation of ammonium to replenish the released ammonia.  This process governs the 
acidity of the intravesicular compartment by satisfying the overall charge balance expressed 
by the following equation: 
𝐻𝑖
+ =
𝐾𝑤
𝐻𝑖
+ + 𝐶𝑙𝑖
− + 𝐵𝑖
− − 𝑁𝐻4,𝑖
+ − 𝐿𝑖
+𝑛      (9) 
The dissociation of water, 𝐾𝑤 , is included along with free chloride, 𝐶𝑙𝑖
−, and besylate, 𝐵𝑖
−, in 
the intravesicular compartment.  The concentration of intravesicular ammonium, 𝑁𝐻4,𝑖
+ , 
may be rewritten in terms of 𝑁𝑖 as shown below. 
𝑁𝐻4,𝑖
+ = (1 − 𝑓𝑖
𝑁)𝑁𝑖        (10) 
Solving for total cationic TPT, 𝐿𝑖
+𝑛, will be discussed in the next section. 
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6.2.9.3 Loading Model #1:  TPT dimerization and ion-pairing 
TPT has been shown to self-associate in solution to form dimers137, 138   The equilibrium 
expression for TPT dimerization may be expressed with the constant 𝐾2 and the expression 
below relating the unbound lactone monomer, 𝐿1
𝑤 , and dimer, 𝐿2 , species. 
 𝐾2 =
𝐿2
(𝐿1
𝑤)2
          (11)   
Only the lactone form of TPT is considered to self-associate as previous studies have 
suggested the carboxylate conformation does not lend itself to stacking.137     
With this information, the total concentration of TPT in both the intra-and extra-
vesicular compartments (𝑇𝑖  and 𝑇𝑜, respectively) may be rewritten in terms of the various 
species present in solution.  These overall mass balances are written in terms of 
concentration using corrections for the differences in volumes of the various compartments.  
   𝑇𝑖 = 𝑎(𝐿1,𝑖
𝑤 + 2𝐿2,𝑖)         (12a) 
𝑇𝑜 = 𝑐(𝐿1,𝑜
𝑤 + 2𝐿2,𝑜 + 𝐶𝑜
𝑢) + 𝑑𝐶𝑜
𝑚       (12b) 
These corrections relate aqueous to total volumes of the intra- and extravesicular 
compartments (a and c, respectively) and the membrane volume of the outer bilayer leaflet 
to total extra-vesicular volume (d) as defined in previous studies of liposomal transport of 
TPT.126, 130  
Previous studies also indicated the lactone zwitterion of TPT does not bind to the 
bilayer while its cationic form does;126, 130 however, the high intravesicular TPT 
concentrations achieved during active loading (>1 mM) and the small surface area-to-
volume ratio of the membrane in the external compartment make binding of the cationic 
species negligible in both compartments.  This is supported by previous studies which show 
only the monomeric species binds, and the cationic species follows the Gouy Chapman 
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theory of diminished binding as the charge on the membrane increases.126, 141 These 
assumptions make intravesicular TPT only a function of the monomer and dimer forms of 
lactone TPT. 
 Using Equation 11, Equation 12a can be rewritten solely in terms of 𝐿1,𝑖
𝑤  and 𝑇𝑖 ,136, 186  
resulting in the equations below. 
𝑇𝑖 = 𝑎(𝐿1,𝑖
𝑤 + 2𝐿1,𝑖
𝑤 2)       (13a) 
  𝐿1,𝑖
𝑤 = −1+√1+8𝐾2𝑇𝑖/𝑎
4𝐾2
       (13b) 
 At the extravesicular pH at which loading studies were conducted, extravesicular 
carboxylate TPT in solution, 𝐶𝑜
𝑢, and bound to the membrane, 𝐶𝑜
𝑚 , must be considered.  This 
makes solving for 𝐿1,𝑜
𝑤  more complex.  Eqn. 12b can be rewritten in terms of 𝐿1,𝑜
𝑤  and takes 
on the general form of a quadratic equation which is illustrated below: 
𝐿1,𝑜
𝑤 =
−𝛽+√𝛽2−4𝛼𝛾
2𝛼
        (14) 
where 𝛽 = 𝑐(𝐻𝑜
+ +𝐾𝐴2
′ ) + 𝑑𝐾𝐶
′𝐾𝐴2
′ , 𝛼 = 2𝑐𝐻𝑜
+𝐾2, and 𝛾 = 𝐻𝑜
+𝑇𝑜.  In these terms, the 
carboxylate species may be rewritten in terms of 𝐿1,𝑜
𝑤  using the apparent acid dissociation 
constant for the equilibrium between the lactone and carboxylate forms, 𝐾𝐴2
′  and the 
apparent binding coefficient for carboxylate, 𝐾𝐶
′ , in addition to other constants already 
defined.  The value of 𝐾𝐶
′  is pH dependent and may be determined using the intrinsic 
binding constant of the zwitterionic carboxylate, 𝐾𝑐 , and the dissociation constant of TPT’s 
phenol, 𝐾𝐴1.  These conditions are incorporated into the following equation based on the 
equilibria scheme described for TPT in Chapter 4.130 
 𝐾𝐶
′ =
𝐻𝑜
+𝐾𝐴2
′ 𝐾𝑐
𝐻𝑜
+2+𝐻𝑜
+𝐾𝐴1+𝐾𝐴1𝐾𝐴2
′
        (15) 
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While total monomer may now be expressed in terms of total drug in both 
compartments, the determination of each permeable species is still required.  This may be 
accomplished using the mass balances below for the aqueous monomeric species in both 
intra- and extra-vesicular compartments. 
𝐿1,𝑖
𝑤 = 𝐿1,𝑖
𝑧 + 𝐿1,𝑖
+1,𝑤 + 𝐿𝐶𝑙𝑖         (16a) 
𝐿1,𝑜
𝑤 = 𝐿1,𝑜
𝑧 + 𝐿1,𝑜
+1,𝑤 + 𝐿𝐶𝑙𝑜         (16b) 
Since 𝐿𝐶𝑙𝑖  and 𝐿𝐶𝑙𝑜 also contain chloride, a mass balance for chloride must be considered 
for each compartment. 
𝐶𝑙𝑇,𝑖 = 𝐶𝑙𝑖
− + 𝐿𝐶𝑙𝑖          (17a) 
𝐶𝑙𝑇,𝑜 = 𝐶𝑙𝑜
− + 𝐿𝐶𝑙𝑜         (17b) 
It is easiest to first solve for 𝐿1,𝑖
+1,𝑤 by combining equations 16a_and 17a in addition to 
the expressions governing the equilibrium constants KIP and KA1.  The resulting equation is 
shown below. 
𝐿1,𝑖
𝑤 =
𝐾𝐴1
𝐻𝑖
+ 𝐿1,𝑖
+1,𝑤 + 𝐿1,𝑖
+1,𝑤 +
𝐾𝐼𝑃𝐶𝑙𝑇,𝑖𝐿1,𝑖
+1,𝑤
1+𝐾𝐼𝑃𝐿1,𝑖
+1,𝑤        (18) 
This equation is quadratic in nature and takes on the general form below when solved for 
𝐿1,𝑖
+1,𝑤: 
𝐿1,𝑖
+1,𝑤 =
−𝐵𝑖+√𝐵𝑖
2−4𝐴𝑖𝐶𝑖
2𝐴𝑖
         (19) 
where 𝐵𝑖 = 𝐾𝐴1 +𝐻𝑖
+(1 + 𝐾𝐼𝑃𝐶𝑙𝑇,𝑖 − 𝐾𝐼𝑃𝐿1,𝑖
𝑤 ), 𝐴𝑖 = 𝐾𝐼𝑃(𝐻𝑖
+ +𝐾𝐴1), and 𝐶𝑖 = −𝐻𝑖
+𝐿1,𝑖
𝑤 .  A 
similar expression for 𝐿1,𝑜
+1,𝑤 may be written where 𝐵𝑜 = 𝐾𝐴1 +𝐻𝑜
+(1 + 𝐾𝐼𝑃𝐶𝑙𝑇,𝑜 −𝐾𝐼𝑃𝐿1,𝑜
𝑤 ), 
𝐴𝑜 = 𝐾𝐼𝑃(𝐻𝑜
+ +𝐾𝐴1), and 𝐶𝑜 = −𝐻𝑜
+𝐿1,𝑜
𝑤 . 
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With 𝐿1,𝑖
+1,𝑤 and 𝐿1,𝑜
+1,𝑤  solved, solutions for 𝐿1,𝑖
𝑧 , 𝐿1,𝑜
𝑧 , 𝐿𝐶𝑙𝑖 , and 𝐿𝐶𝑙𝑜 are straightforward 
and shown below.   
𝐿1,𝑖
𝑧 =
𝐾𝐴1
𝐻𝑖
+ 𝐿1,𝑖
+1,𝑤         (20a) 
𝐿𝐶𝑙𝑖 =
𝐾𝐼𝑃𝐶𝑙𝑇,𝑖𝐿1,𝑖
+1,𝑤
1+𝐾𝐼𝑃𝐿1,𝑖
+1,𝑤         (20b) 
Similar equations for 𝐿1,𝑖
+1,𝑤 and 𝐿1,𝑖
𝑧  use 𝐻𝑖
+ and 𝐿1,𝑖
𝑤  instead of 𝐻𝑜
+ and 𝐿1,𝑜
𝑤 . 
  𝐿1,𝑜
𝑧 =
𝐾𝐴1
𝐻𝑜
+ 𝐿1,𝑜
𝑤          (21a) 
𝐿𝐶𝑙𝑜 =
𝐾𝐼𝑃𝐶𝑙𝑇,𝑜𝐿1,𝑜
+1,𝑤
1+𝐾𝐼𝑃𝐿1,𝑜
+1,𝑤         (21b) 
And the solution for 𝐶𝑜
𝑧,𝑤 is simply the following expression. 
     𝐶𝑜
𝑧,𝑤 =
𝐾𝐴2
′
𝐻𝑜
++𝐾𝐴1
𝐿1,𝑜
𝑤         (21c) 
Equations 20a-b and 21a-c can be substituted back into Equations 13 and 14, 
respectively, so the transport equations governing loading and release of TPT may be 
written in terms of 𝑇𝑖  and 𝑇𝑜, respectively, and of 𝐶𝑙𝑇,𝑖  and 𝐶𝑙𝑇,𝑜, respectively.  These 
equations are also used for the transport equations governing chloride.   
The following equation was used to express the total concentration of intravesicular 
cationic TPT, 𝐿𝑖
+𝑛, for the calculation of intravesicular pH during the loading process  
𝐿𝑖
+𝑛 =
𝐻𝑖
+(𝑇𝑖−𝐿𝐶𝑙𝑖)
𝑎(𝐻𝑖
++𝐾𝐴1)
         (22) 
while 𝐶𝑙𝑖
− was simply calculated with the rearrangement of Eqn. 17a (shown below). 
𝐶𝑙𝑖
− = 𝐶𝑙𝑇,𝑖 − 𝐿𝐶𝑙𝑖          (23) 
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6.2.9.4 Loading Model #2: Ion-pairing without dimerization 
 Without dimerization, 𝑎𝐿1,𝑖
𝑤 = 𝑇𝑖and the subsequent equations solving for the different 
intravesicular species of TPT (Eqns. 18-19b) may be used for this model.  The equations 
governing the extravesicular compartment require more explanation as 𝑇𝑜 is now expressed 
by the following equation. 
𝑇𝑜 = 𝑐(𝐿𝑜
𝑤 + 𝐶𝑜
𝑢) + 𝑑𝐶𝑜
𝑚       (24) 
Now 𝐿𝑜
𝑤  may be expressed using 𝐾𝐴2
′  and 𝐾𝐶
′  yielding the following equation for 𝐿𝑜
𝑤  in terms 
of 𝑇𝑜. 
𝐿𝑜
𝑤 =
𝐻𝑜
+𝑇𝑜
𝑎𝐻𝑜
++𝑎𝐾𝐴2
′ +𝑏𝐾𝐴2
′ 𝐾𝐶
′         (25) 
From this point, Eqns. 19 (substituting 𝐿𝑜
𝑤  and 𝐻𝑜
+ for 𝐿𝑖
𝑤  and 𝐻𝑖
+, respectively) and 20a-c 
can be used to determine the concentrations of 𝐿1,𝑜
+1,𝑤 , 𝐿1,𝑜
𝑧 , 𝐿1,𝑜
𝑧 , and 𝐶𝑜
𝑧,𝑤 , respectively.  
Lastly, the calculation of intravesicular pH can be made assuming 𝐿1,𝑖
+1,𝑤 = 𝐿𝑖
+𝑛. 
6.2.9.5 Loading Model #3: Dimerization with no ion-pairing 
 The rate equations governing TPT transport are the same if one substitutes 𝐿1,𝑖
+1,𝑤 and 
𝐿1,𝑜
+1,𝑤 for 𝐿𝐶𝑙𝑖  and 𝐿𝐶𝑙𝑜, respectively, and neglects the transport equations for Cl.  Solving for 
the monomeric species is the same as Equations 13 and 14 so solving for 𝐿1,𝑖
+1,𝑤 , and 𝐿1,𝑖
𝑧,𝑤 
becomes straightforward, resulting in the equations below. 
𝐿1,𝑖
+1,𝑤 =
𝐻𝑖
+
𝐻𝑖
++𝐾𝐴1
𝐿1,𝑖
𝑤         (26a) 
 𝐿1,𝑖
𝑧,𝑤 =
𝐾𝐴1
𝐻𝑖
++𝐾𝐴1
𝐿1,𝑖
𝑤         (26b) 
The equations for 𝐿1,𝑜
+1,𝑤 , and 𝐿1,𝑜
𝑧,𝑤 are the same as 24 a & b aside from using 𝐻𝑜
+  instead of 
𝐻𝑖
+. 
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6.2.9.6 Equations describing PLLT release 
 The equations describing TPT transport and model #1 were used to simulate the 
release of PLLT.  This is achieved by setting 𝐻𝑖
+ = 𝐻𝑜
+ = 10−4.1 and setting the initial 
conditions to reflect the concentrations of TPT and chloride present in the solution used to 
hydrate these passively-loaded liposomes.  For all PLLT studies, the initial conditions for 
TPT were the same and shown below. 
 𝑇𝑖(0) = 50 µ𝑀         (27a) 
𝑇𝑜(0) = 0         (27b) 
The initial conditions for chloride, however, were varied.  In two release studies, 𝐶𝑙𝑖
−(0) =
𝑇𝑖(0) since its HCl salt was used to make the solutions.  In one of these studies, the 
extravesicular solution contained no chloride (𝐶𝑙𝑖
−(0) = 0) while the other suspension did 
have chloride (𝐶𝑙𝑖
−(0) = 0.25𝑀) present.  The other PLLT suspension contained Cl on both 
sides.  Its initial conditions were 𝐶𝑙𝑜
−(0) = 𝐶𝑙𝑖
−(0) = 0.25𝑀.  The rate equations governing 
ammonia transport were unnecessary since it was not present in any of the buffers used in 
PLLT studies. 
6.2.9.7 Equations describing release of liposomal TPT loaded at 37 °C 
 Equilibrium between the lactone and carboxylate forms of TPT was assumed in loading 
studies as ring-opening/closing kinetics for TPT and other camptothecins have been shown 
to be acid-catalyzed at the pH of the loading solution.92  Because the intravesicular 
compartment retains its low pH, carboxylate is still negligible and Equations 2a and b may 
be used to describe intravesicular transport of TPT.  However, this interconversion has 
previously been shown to have an effect on liposomal TPT release at physiological pH 
(7.4).130  This effect requires the differential equation governing extravesicular TPT (Eqn. 3) 
to be modified as shown below.   
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𝑑𝐿𝑜
𝑑𝑡
= 𝑓𝑣[𝑘𝑚𝑧(𝐿1,𝑖
𝑧 − 𝐿1,𝑜
𝑧 ) + 𝑘𝑚𝑝(𝐿𝐶𝑙𝑖 − 𝐿𝐶𝑙0) − 𝑘𝑚𝑐𝐶𝑛,𝑜
𝑢 ] − 𝑘𝑜𝑝𝑂𝐻𝑜
−𝐿𝑜 + 𝑘𝑐𝑙𝑂𝐻𝑜
−𝑓𝐶𝑂𝑂𝐻𝐶𝑜  (28) 
This equation now reflects the interconversion kinetics previously reported with rate 
constants governing base-catalyzed ring-opening and closing kinetics (𝑘𝑜𝑝 and 𝑘𝑐𝑙 , 
respectively).92, 130  Since the carboxylic acid form of TPT is the only ring-opened species 
involved in ring-closing,92 the term 𝑓𝐶𝑂𝑂𝐻  is introduced to account for this fraction of ring-
opened TPT.130 
      𝑓𝐶𝑂𝑂𝐻 =
𝐻𝑜
+
𝐻𝑜
++𝐾𝐶𝑂𝑂𝐻
         (29) 
The ionization of the carboxylic acid to form carboxylate TPT is pH-sensitive and governed 
by 𝐾𝐶𝑂𝑂𝐻 . 
One should notice that Equation 28 only governs the rate of change of Lo due to non-
instantaneous interconversion.  A differential equation governing 𝐶𝑜  is required. 
 
𝑑𝐶𝑜
𝑑𝑡
= −𝑓𝑣𝑘𝑚𝑐𝐶𝑜
𝑧,𝑤 + 𝑘𝑜𝑝𝑂𝐻𝑜
−𝐿𝑜 − 𝑘𝑐𝑙𝑂𝐻𝑜
−𝑓𝐶𝑂𝑂𝐻𝐶𝑜      (30) 
The permeable, zwitterionic form of carboxylate TPT unbound to the membrane, 𝐶𝑜
𝑧,𝑤 , may 
be defined in terms of 𝐶𝑜 .  This is shown in the equation below. 
𝐶𝑜
𝑧,𝑤 =
𝐻𝑜
+𝐶𝑜
(𝐻𝑜
++𝐾𝐴1)(𝑐+𝑑𝐾𝐶)
         (31) 
 In loading studies, the permeability of chloride alone was not considered since its influx 
into the liposome through this pathway would be much slower than through the ion pair.  
During release studies however, the influx of chloride from the extravesicular solution187-189 
would alter the amount of drug released as it would continue to provide more chloride for 
transport of 𝐿𝐶𝑙𝑖 .  Accounting for this effect requires a release rate constant for chloride, 
kmCl, and modification of the transport equations governing chloride.  These equations are 
shown below. 
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𝑑𝐶𝑙𝑇,𝑖
𝑑𝑡
= −𝑘𝑚𝑝(𝐿𝐶𝑙𝑖 − 𝐿𝐶𝑙0) − 𝑘𝑚𝐶𝑙(𝐶𝑙𝑖
− − 𝐶𝑙0
−)     (32a) 
 
𝑑𝐶𝑙𝑇,𝑜
𝑑𝑡
= 𝑓𝑣[𝑘𝑚𝑝(𝐿𝐶𝑙𝑖 − 𝐿𝐶𝑙0) + 𝑘𝑚𝐶𝑙(𝐶𝑙𝑖
− − 𝐶𝑙0
−)]      (32b) 
The concentration gradient is between the anionic forms of intra- and extra-vesicular 
chloride (𝐶𝑙𝑖
− and 𝐶𝑙0
−, respectively).  These concentrations may be expressed in terms of 
𝐶𝑙𝑇,𝑖  and 𝐶𝑙𝑇,𝑜 using the ion-pairing constant and the equations below. 
𝐶𝑙𝑖
− =
𝐶𝑙𝑇,𝑖
1+𝐾𝐼𝑃𝐿1,𝑖
+1,𝑤         (33a) 
𝐶𝑙𝑜
− =
𝐶𝑙𝑇,𝑜
1+𝐾𝐼𝑃𝐿1,𝑜
+1,𝑤         (33b) 
While the equations above imply that chloride permeability soley involves the chloride 
anion, the identity of this permeable species is a point of contention.  Cl- permeability has 
been argued to behave as an ion-pair, typically suggested to be the HCl pair since protons 
are much smaller than any other cations in solution.  This assumption would indicate Cl- 
flux to be pH-dependent as a pKa exists for the HCl pair and its dissociated ions, and a pH-
dependence in Cl- permeability has been observed.187, 190  However, a pH-independent 
pathway has also been observed.187, 190  This pH-independent pathway suggests Cl- to be the 
permeable species and is supported by molecular dynamics simulations (arguing several 
different transport mechanisms) which illustrate anion transport.153, 188, 191, 192  Because a 
mechanistic evaluation of Cl- was beyond the scope of this study, Cl- co-transport was 
assumed.  Under this assumption, Cl- transport was pH-independent and proton conduction 
across the bilayer was assumed to be fast enough to maintain electroneutrality and prevent 
the generation of an electrical potential across the membrane.  While proton transport 
equations are not used, they are implicitly expressed mathematically by assuming charge is 
conserved within the intravesicular compartment.  This was previously expressed 
mathematically by Equation 9 and in the subsequent calculation of intravesicular pH.    
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 Finally, the concentrations obtained from this release model must be transformed to 
illustrate the fraction of lactone and carboxylate TPT (L(t) and C(t), respectively) in solution 
at each time point.  This is shown by the following equations. 
𝐿(𝑡) =
𝑓𝑣𝐿𝑖+𝐿𝑜
𝑓𝑣𝐿𝑖+𝐿𝑜+𝐶𝑜
         (34a) 
 𝐶(𝑡) =
𝐶𝑜
𝑓𝑣𝐿𝑖+𝐿𝑜+𝐶𝑜
          (34b) 
The initial conditions for the various differential equations for the transport of each 
permeable molecule are shown in Table 6.4 while those of the extravesicular compartment 
were determined based on the concentrations calculated at the end of loading studies. 
6.2.9.8 Equations describing release of liposomal TPT loaded at 60 °C 
At 60 °C, DSPC bilayers are in a more permeable liquid crystalline state as opposed to 
their rigid gel phase below 54 °C.135, 193  Under these conditions, the permeabilities of both 
the zwitterion and ion-paired form of TPT may be much faster and increased to different 
extents, resulting in altered Cl: TPT ratios.  Further alteration of this ratio may be due to the 
the relative change in chloride permeability as well.  These effects may ultimately lead to 
much higher Cl: TPT ratios and possibly supersaturate the intravesicular compartment at 
this higher temperature, resulting in precipitate formation upon cooling. 
The formation of precipitate in the intravesicular aqueous compartment is governed by 
an apparent solubility product, K’sp, as illustrated by the following equation: 
𝐾𝑠𝑝
′ = 𝑇𝑖(𝑎𝑞)𝐶𝑙𝑖(𝑎𝑞)         (35) 
where 𝑇𝑖(𝑎𝑞)  and 𝐶𝑙𝑖(𝑎𝑞) are the concentrations of TPT and chloride still solubilized in 
solution.  Only these soluble species may be considered in the equation used to calculate pH.  
Furthermore, these species along with the precipitate, 𝑇𝐶𝑙𝑖(𝑠), must be incorporated into the 
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rate equations governing drug and chloride transport.  Equations 1a and 4a may be 
modified to reflect these stipulations as shown below. 
   
𝑑𝑇𝑖
𝑑𝑡
=
𝑑𝐿1,𝑖
𝑧
𝑑𝑡
+
𝑑𝐿𝐶𝑙𝑖
𝑑𝑡
+
𝑑𝑇𝐶𝑙𝑖(𝑠)
𝑑𝑡
=
𝑑𝑇𝑖(𝑎𝑞)
𝑑𝑡
+
𝑑𝑇𝐶𝑙𝑖(𝑠)
𝑑𝑡
     (36a) 
𝑑𝐶𝑙𝑇,𝑖
𝑑𝑡
=
𝑑𝐿𝐶𝑙𝑖
𝑑𝑡
+
𝑑𝐶𝑙𝑖
−
𝑑𝑡
+
𝑑𝑇𝐶𝑙𝑖(𝑠)
𝑑𝑡
=
𝑑𝐶𝑙𝑖(𝑎𝑞)
𝑑𝑡
+
𝑑𝑇𝐶𝑙𝑖(𝑠)
𝑑𝑡
    (36b) 
Since both TPT and chloride leave in a 1:1 ratio via transport of their ion pair, the rate of 
precipitate dissolution is simply equal to that of the rate of ion-pair transport as shown by 
the following equation. 
If:  𝐾𝑠𝑝
′ ≥ 𝑇𝑖(𝑎𝑞)𝐶𝑙𝑖(𝑎𝑞)         
𝑑𝑇𝐶𝑙𝑖(𝑠)
𝑑𝑡
=
𝑑𝐿𝐶𝑙𝑖
𝑑𝑡
= 𝑘𝑚𝑝(𝐿𝐶𝑙𝑖 − 𝐿𝐶𝑙0)      (37a) 
When 𝐾𝑠𝑝
′ < 𝑇𝑖(𝑎𝑞)𝐶𝑙𝑖(𝑎𝑞), changes in the amount of 𝑇𝐶𝑙𝑖(𝑠) will be governed by the flux of 
free chloride  as illustrated by the expression below. 
If:  𝐾𝑠𝑝
′ < 𝑇𝑖(𝑎𝑞)𝐶𝑙𝑖(𝑎𝑞)      
𝑑𝑇𝐶𝑙𝑖(𝑠)
𝑑𝑡
= −𝑘𝑚𝐶𝑙(𝐶𝑙𝑖
− − 𝐶𝑙0
−)      (37b) 
With these rate equations, the rate equations already derived for the extravesicular 
compartment during ALLT release, and the expressions already derived for the various 
aqueous TPT and chloride species, these differential equations may be modeled once the 
initial conditions (i.e. how much drug and chloride are in the aqueous and solid phases) are 
determined for the intravesicular compartment.  For this calculation, the mass balances for 
TPT and total chloride in the intravesicular compartment, MTPT and MCl respectively, are 
necessary and shown below. 
𝑀𝑇𝑃𝑇 = 𝑀𝑇𝑃𝑇(𝑎𝑞) +𝑀𝑇𝐶𝑙(𝑠)      (38a) 
𝑀𝐶𝑙 = 𝑀𝐶𝑙(𝑎𝑞) +𝑀𝑇𝐶𝑙(𝑠)       (38b) 
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Assuming the intravesicular volume remains constant, the masses for the aqueous species 
of TPT and Cl may be rewritten in terms of the concentrations used in the rate equations 
(Eqns. 36a and b) as illustrated by the following equations. 
𝑇𝑖 = 𝑇𝑖(𝑎𝑞) + 𝑇𝐶𝑙𝑖(𝑠)       (39a) 
   𝐶𝑙𝑇,𝑖 = 𝐶𝑙𝑖(𝑎𝑞) + 𝑇𝐶𝑙𝑖(𝑠)       (39b) 
This system of equations may be used along with the equation for K’sp to solve for 𝑇𝐶𝑙𝑖(𝑠) in 
terms of the initial amount of total intravesicular TPT and Cl, 𝑇𝑖(0) and 𝐶𝑙𝑇,𝑖(0) respectively.  
The resulting solution is expressed below as the initial condition for 𝑇𝐶𝑙𝑖(𝑠)    
𝑇𝐶𝑙𝑖(𝑠)(0) =
𝑇𝑖(0) + 𝐶𝑙𝑇,𝑖(0) − √[𝑇𝑖(0) + 𝐶𝑙𝑇,𝑖(0)]2 − 4(𝑇𝑖(0)𝐶𝑙𝑇,𝑖(0) − 𝐾𝑠𝑝
′ )
2
 
  (40a) 
          
while the initial conditions for 𝑇𝑖(𝑎𝑞) and 𝐶𝑙𝑖(𝑎𝑞) simply become the following expressions. 
𝑇𝑖(𝑎𝑞)(0) = 𝑇𝑖(0) − 𝑇𝐶𝑙𝑖(𝑠)(0)       (40b) 
   𝐶𝑙𝑖(𝑎𝑞)(0) = 𝐶𝑙𝑇,𝑖(0) − 𝑇𝐶𝑙𝑖(𝑠)(0)      (40c) 
HPLC analysis of carboxylate and lactone forms of TPT can again be used to monitor release 
by modifying the Eqns. 34a and b to the form below.  
𝐿(𝑡) =
𝑓𝑣[𝑇𝑖(𝑎𝑞)+𝑇𝐶𝑙𝑖(𝑠)]+𝐿𝑜
𝑓𝑣[𝑇𝑖(𝑎𝑞)+𝑇𝐶𝑙𝑖(𝑠)]+𝐿𝑜+𝐶𝑜
        (41a) 
 𝐶(𝑡) =
𝐶𝑜
𝑓𝑣[𝑇𝑖(𝑎𝑞)+𝑇𝐶𝑙𝑖(𝑠)]+𝐿𝑜+𝐶𝑜
        (41b) 
This model was used to determine both 𝐾𝑠𝑝
′  and 𝐶𝑙𝑇,𝑖(0) from the release profiles obtained 
after active loading of TPT into liposomes at 60 °C. 
All data fitting to the models described above was performed with MicroMath® 
Scientist® non-linear regression software in conjunction with the values supplied in Tables 
6.1 and 6.2 for the various parameters used in these models.  
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Table 6.1.  Parameters used to model release and loading kinetics of liposomal TPT that are 
independent of the experiment 
Parameters Values 
kmn 2.88 × 104 𝑠−1a 
kmz 43 ℎ𝑟−1  b  
kmc 5.6 ℎ𝑟−1 b  
Kc 42 b 
K’A1 2.8 × 10−7b 
KAN 9.40 × 10−10c 
Kw 2.12 × 10−14c 
Bi 0.3 𝑀  
a 0.15 d 
b 0.85 d 
a Calculated from a previously reported ammonia permeability coefficient of  
𝑃𝑁𝐻3
𝑚 = 48 × 10−3 𝑐𝑚 𝑠⁄  171 
b   Obtained from a previous study125 
c    Values adjusted to reflect conditions at 37 °C and 0.3 I 
d   Calculated based on particle size, lipid content, and lipid surface density calculations 
previously reported50, 135  
 
Table 6.2.  Parameters used to model release and loading kinetics of liposomal TPT that are 
experiment-specific* 
Param-
eters 
Values 
Active Loading #1 
(19.2 µg lipid/mL) 
PLLT  
(19.2 µg lipid/mL) 
ALLT release (6.4 
µg lipid/mL) 
K’A2 2.66 × 10−7 b 2.66 × 10−7 b N/A 
kcl N/A N/A 7.4 x 108 mol-1hr-1b 
kop N/A N/A 1.4 x 106 mol-1hr-1b 
fv  2.40 × 10−3 d 2.40 × 10−3 d 1.66 × 10−5 d 
c 0.9997 d 0.9997 d 0.9999 d 
d 3.44 × 10−4 d 3.44 × 10−4 d 2.58 × 10−6 d 
𝐻𝑜
+  3.16 × 10−6𝑀 7.94 × 10−5𝑀 3.98 × 10−8𝑀 
*  Superscripts same as those used in Table 6.1. 
 152 
 
6.3 Results 
6.3.1 Active loading of TPT at 37 °C 
Multiple loading models were explored and the estimated values for the fitted 
parameters are shown for each model in Table 6.3.  The values for the parameters are quite 
revealing.  The model selection criterion (MSC) generated by the non-linear regression 
software provides an indication of the goodness-of-fit for each model to the data obtained 
from fitting the profiles of TPT during active loading at 37 °C.  The MSC for model #3 is 
drastically lower than the other models as it does not account for ion-pairing effects.  This 
result suggests the importance of ion-pairing transport during active loading of TPT.  The 
differences between the MSC for model #1 and #2 are less drastic; however, closer 
examination of the fitted parameters in Table 6.3 provides further evidence of the validity of 
model #1.  The confidence limits for these parameters are far better for model #1, which is 
in agreement upon comparison of the fitted models to the loading data illustrated by 
Figures 6.1a and b. Furthermore, the value of kmp is nearly identical to the value of kmz.  This 
is reasonable considering the ion-pair is likely not much larger than the TPT zwitterion (i.e. 
similar diffusivity through the bilayer).  This value is much more reasonable than the kmp 
obtained from model # 2 which is 70 fold higher than that of the zwitterion rate constant.  
Figure 6.1c shows the predicted profile of ammonia release from model #1 has a similar 
trend as that experimentally observed for each of the loading conditions studied.  While the 
trends are similar, it does appear that ammonia release is over- and under-predicted at the 
loading conditions using 180 and 60 µM of TPT in the extravesicular solution, respectively.  
This is likely due to a couple of factors.  The first is using an average ratio of entrapped 
volume to extravesicular volume (𝑓𝑣) to calculate uptake rather than an individual 𝑓𝑣  for 
each suspension.  The average 𝑓𝑣  was 4.6 % lower and 2.6 % higher than the actual values 
determined from uptake in the 180 and 60 µM TPT loading solutions, respectively.  The 
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respective over and under-estimations of 𝑓𝑣  would consequently lead to under- and over-
estimations in the amount of ammonia released similar to that shown in Figure 6.1c.  With 
this consideration and the high sensitivity of the ammonia probe’s response to different 
buffers and ions in solution (attempts were made to keep the solution composition of 
ammonia standards as similar as possible to the samples), the differences in observed and 
predicted ammonia release appear to correlate well.   Using the ammonia release in 
conjunction with the chloride and TPT loaded into the intravesicular compartment, the 
profile of intravesicular pH was also calculated and is illustrated by Figure 6.1d.  This drop 
in intravesicular pH agrees with that expected during the active loading process.  
Table 6.3.  Values of release parameters and goodness-of-fit for the various loading models 
developeda 
Loading 
Model 
𝐾2 (M
-1
) 
b
 𝐾𝐼𝑃   𝑘𝑚𝑝  (hr
-1
) 
Model Selection 
Criterion (MSC) 
Model #1 6700 0.9 ± 0.7 49 ± 7 5.2 
Model #2 NA 0.1 ± 2 3400 ± 2000 2.9 
Model #3 6700 NA 0.65c 0.8 
a   ± 95% confidence intervals 
b Previously determined in another study.126 
c Based on a previously reported value of 0.51 hr-1 which assumed kmp referred to 
transport of the cation without a counterion.  This value was altered to reflect the 
fraction of monomer being 0.78  in that study.130 
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Figure 6.1.  Loading profiles at 37 °C with TPT loading concentrations of 60, 
130, and 180 µM in the extravesicular compartment with lines indicating 
simulated profiles obtained from the fit of loading models #1 (A) and #2 (B).  A 
comparison of the fit of these two models to the studied loading conditions 
shows TPT dimerization and ion-pairing affects loading kinetics.  Profiles of 
ammonia released during the loading process were also observed 
experimentally and shown along with the profiles of ammonia release predicted 
by model #1 (C).  Using the amount of ammonia released and TPT and Cl loaded 
based on loading model #1, the intravesicular pH during the time course of the 
loading experiments could be calculated (D) and shows the initial drop in pHi is 
rapid and slowly increases during uptake as illustrated in the legend.  
It should also be noted that during the course of fitting models considering ion-pairing, 
the dissociation constant of TPT’s phenol, KA!, was allowed to change during regression in 
accordance with KIP.  This consideration was made due to the high levels of chloride present 
in previous studies would result in the measurement of an effective dissociation constant, 
K’A1, for TPT if ion-pairing was present in those solutions.130  The effect of ion-pairing on K’A1 
is illustrated with the equation below. 
 𝐾𝐴1
′ =
𝐻+𝐿1
𝑧
𝐿1
++𝐿𝐶𝑙
         (42) 
The value for KA! can be used to calculate KA! to be used during regression of the loading 
studies.  This is done using the following equation. 
𝐾𝐴1 =
𝐾𝐴1
′
1+𝐾𝐼𝑃𝐶𝑙𝑇
         (43) 
The equation above assumes TPT dimerization is negligible and that very little chloride is 
consumed to form the ion-pair (𝐶𝑙𝑇 ≅ 𝐶𝑙
−) as solutions used to spectrometrically 
determined K’A1 contained 500 nM TPT and 225 mM chloride.130  With this correction and 
KIP determined with loading model #1, KA1 was determined to be 3.3 x 10-7.  
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6.3.2 PLLT release studies 
PLLT release studies were conducted at 37 °C in pH 4.1 buffer containing 50 uM 
TPTHCl.  The concentration of intra- and extra-vesicular Cl was altered and the resulting 
release profiles of TPT are shown below in Figure 6.2.  The release studies in which no 
excess Cl was added to the intravesicular buffer agreed well with the profile predicted by 
the parameters obtained from loading studies.  The release profile of TPT in the presence of 
excess Cl (0.25 M) in the intravesicular compartment is over 4 times faster than that of 
these other release profiles.  This supports the hypothesis of bilayer transport via the TPT-
Cl ion pair.   
 
Figure 6.2.  Comparison of release profile of PLLT in the presence or absence of 
chloride at 37 °C.  Release when chloride was not added to intravesicular buffer 
and either none ( ) or 0.25 M Cl was added to the extravesicular buffer ( ) are 
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shown.  The profiles predicted based on the fitted values obtained from loading 
studies were the same and are both represented by ( ).  Release when ClT was 
0.25 M in both intra- and extra-vesicular compartments was also observed ( ) 
and compared with the profiles predicted by the loading model under these 
chloride conditions ( ) and when Cli,T was fitted to be 1.1 mM  ( ). 
While TPT release is faster in the presence of 0.25 M Cl, one may also notice that the 
release profile predicted by the values obtained from loading experiments would suggest 
much faster release in the presence of that much Cl.  Part of this discrepancy may be due to 
the method employed to monitor release as the fastest release half-life monitored before 
with this method was ~0.5 hrs.130  The ionic strengths of the two intravesicular solutions 
used in these release studies, while different (0.3 vs. 0.55), are sufficiently high that 
differences in chloride activity would be minimal and therefore an unlikely factor in the 
discrepancy between predicted and observed release kinetics.  Previous reports of chloride 
binding to other gel phosphatidylcholine bilayers would reduce the driving force for ion-
pair formation and release.194   Ion-pairing of chloride with sodium in the aqueous phase or 
at the interface of the bilayer solution could also hinder ion-pair transport of TPT.   
A more likely explanation for the slower release at these high Cl concentrations may be 
related to the differences in PEG density between the intra- and extra-vesicular 
compartments.  The higher PEG density within the aqueous core may create an aqueous 
two-phase system.  Such systems are routinely used for milder separations of more 
hydrophobic solutes by their partitioning into the PEG phase.195  Partitioning of TPT into 
this PEG phase would reduce ion-pair transport in two ways: 1) the amount of TPT available 
to ion-pair with Cl in the aq. salt phase near the bilayer would be reduced and subsequently 
lower the effective driving force for ion-pair transport,196 and 2) the rate of TPT transfer 
from the PEG-phase to the aq. salt phase may become partially rate-limiting to bilayer 
transport due to the increased viscosity (i.e. reduced TPT diffusivity) of the PEG-phase.195  
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This effect would only be present within the intravesicular compartment since the PEG 
density near the bilayer would be much higher due to curvature effects inherent to the 
spherical shape of liposomes. Furthermore, NaCl was never present in the intravesicular 
compartments of liposomal formulations used in active loading studies.  Since drug 
partitioning and liquid viscosity are highly dependent upon the concentration and type of 
salt(s) present in the PEG-salt system,195, 196 it is plausible that the ammonium salts and the 
lower, model-calculated intravesicular Cl concentrations of the actively-loaded systems 
would likely not suffer the same effects during release studies. 
6.3.3 ALLT release studies 
6.3.3.1 Effect of chloride permeability on ALLT release 
After loading at 37 °C, ALLT release was monitored in pH 7.4 PBS at 37 °C with the 
changes in the lactone and carboxylate fractions of TPT in solution.  Simulations of these 
release profiles were made using the fitted values obtained from loading experiments.  The 
initial conditions used in these studies were obtained from the final concentrations of total 
intravesicular chloride, ammonia, and TPT calculated from the loading model and are found 
below in Table 6.4.  Initial simulations did not predict the extent of release seen in the later 
phase of release of these ALLT formulations.  This was likely due to the slight but significant 
permeability of chloride that was not a factor during loading.  With this rationale, these 
ALLT release profiles were used to fit a chloride release rate constant, kmCl, and resulted in 
the fit shown in Figures 6.4a and b.  Based on this fit, kmCl was estimated to be 3.8 ± 0.4 x 10-4 
hr-1.  Based on the 100 nm diameter of these liposomal formulations, the permeability of the 
chloride anion, 𝑃𝑚
𝐶𝑙− , can be estimated by the following equation. 
 𝑃𝑚
𝐶𝑙− =
𝑑
6
𝑘𝑚𝐶𝑙           (44) 
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The resulting permeability coefficient for chloride is 1.8 ± 0.2 x 10-13 cm/s.  This value is 
lower than other values reported for chloride permeability through phosphatidylcholine 
(PC) liposomes and is expected due to the greater rigidity of DSPC bilayers over the PC 
bilayers studied by Toyoshima and Thompson.187  In those studies, PC liposomes were a 
mixture of DSPC and shorter saturated fatty acids that tend to provide less resistance to 
transport and higher permeabilities.50, 53, 187 
Table 6.4  Initial conditions used for modeling ALLT release 
 Ammonium Besylate ALLT (NH4)2SO4 ALLT 
Loading Temp 37 °C 60 °C 60 °C 
Loading TPT 60 µM 130 µM 180 µM 60 µM 180 µM 130 µM 
𝑇𝑖(0) (mM)a 13.7 23.4  29.5  24.6 61.2 42.6 
𝐶𝑙𝑇,𝑖(0) (mM) 5.52b 7.09b 9.12b  68 ± 8c 250± 60c 140 ± 60c 
𝑁𝑖(0) (mM)b 263 257 253 255 220 453 
𝐶𝑙𝑇,𝑜(0) (mM) 0.13 
𝑁𝑜(0) (µM) 0, 12, or 60 
a Values calculated based on initial amount of TPT observed in release study and entrapped 
volume (𝐿𝑖(0) =
𝑇𝑇𝑜𝑡𝑎𝑙(0)
𝑓𝑣
⁄ ) 
b Value obtained from loading model simulation of final experimental loading time point. 
c Fitted value from release profile with 95% CI. 
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C.  
 
Figure 6.3.  Release at 37 °C in PBS of ALLT formulations loaded at 37 °C.  
Release was monitored by the changes in the fractions of lactone (A) and 
carboxylate (B) TPT (L(t) and C(t), respectively) for TPT actively loaded into 
ABLs (loaded with TPT suspension concentrations of 60, 130, and 180 µM TPT 
as designated in the legend).  The lines through the data points represent the fits 
of the profiles to the ALLT release model accounting for chloride permeability.  
Simulations of the interconversion of pure lactone TPT spiked in the pH 7.4 
buffer is also shown to emphasize the retardation in ring-opening due to 
liposomal release kinetics while ALLT loaded in the presence of a 180 µM TPT 
was simulated assuming no Cl permeability to illustrate its effect on release.  
The intravesicular pH was also calculated to reiterate the low intravesicular pH 
maintained during these release studies (C).   
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6.3.3.2 Effect of ammonia transport on ALLT release 
 Preliminary simulations from Chapter 5 indicated the concentration of extravesicular 
ammonia in release media could alter the intravesicular pH and subsequently accelerate 
release with higher ammonia concentrations.  In Figure 6.3c, the intravesicular pH remains 
low as ammonia is continuously released because no ammonia was present in the PBS 
buffer.  The profiles in Figure 6.4, however, show the effect of ammonia influx on 
intravesicular pH and subsequently release kinetics.  As more NH4Cl is added to the pH 7.4 
PBS release media, the rate and extent of release also increases.  Simultaneous fitting of 
release profiles in PBS with varying concentrations of NH4Cl were conducted for ALLT 
suspensions using 60 uM TPT in the loading solution (Figures 6.4a and b).  Fitting these 
profiles identified a shift in the pKA for intravesicular ammonia which was estimated to be 
1.49 ± 0.05.  The change in intravesicular pH due to ammonia influx can be calculated and 
shows the considerable increase in pH resulting in accelerated release (Figure 6.4c).  This 
change in the pKA allows prediction of the release kinetics in the presence of 60 µM NH4Cl 
for the other ALLT formulations studied (Figures 6.4d & e).  
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Figure 6.4.  The effect of ammonia transport on ALLT release at pH 7.4 (PBS) 
and 37 °C.  After active loading in a 60 µM TPT suspension using ABLs, TPT 
release was monitored in PBS with the NH4Cl concentrations displayed in the 
legend.  The changes in L(t) and C(t) are used to monitor release and shown in 
(A) and (B) respectively while intravesicular pH is shown to illustrate the effect 
of ammonia influx (C).  The shift in ammonia pKA fit to these release profiles is 
shown by the plotted lines.  This shift in pKA was able to predict the release 
profiles in 60 µM NH4Cl for the ALLT formulations listed in the legends of (D) 
and (E).  Because ammonia may evaporate over time from solutions, the release 
kinetics of can slow over time as shown in (F) and (G).  The loss of ammonia 
from the PBS buffer over time reduces the influx of ammonia and lessens the 
increase of intravesicular pH (H).         
  Another factor which may impact release profiles is the evaporation of ammonia during 
release studies.  Even through rubber stoppers were used to seal the suspension vials 
during release studies, the gaseous form of ammonia may fill the air space in the vial and 
possibly diffuse through the rubber stopper, and be released when the vials are open for 
sampling.  This appears to have some effect on the release profile of ALLT in the presence of 
PBS with 12 µM NH4Cl (Figure 6.4a & b).  The model expects more TPT to be released than 
that observed at later time points.  Ammonia evaporation could cause such an effect as it 
would effectively lower the intravesicular pH as extravesicular ammonia is depleted.  
Further evidence of ammonia evaporation from the PBS with 12 µM NH4Cl is illustrated by 
the release profiles in Figure 6.4g and h.  Release studies were repeated in the same buffer 7 
and 10 days after it was initially made, clearly showing slower release the longer the buffer 
has aged.  Fitting of the initial extravesicular ammonia concentration for these release 
profiles estimated these concentrations to be 8.6 ± 1 and 1.9 ± 0.6 µM NH4Cl in the buffer 
after 7 and 10 days of aging respectively, further supporting the likelihood of ammonia 
evaporation altering release kinetics.      
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6.3.3.3  Effect of loading at high temperature (60 °C) on ALLT release 
 Loading for 30 minutes at 60 °C achieved higher TPT loading efficiencies than loading 
for 72 hrs at 37 °C (see Figure 6.5).  This is expected due to the bilayer existing in its more 
permeable liquid crystalline phase rather than its more rigid gel phase.135  The ALLT’s made 
with the 60 µM TPT loading solution had the highest encapsulation efficiency, which was 
similar to previous reports of TPT loading with (NH4)2SO4 liposomes.62   
 
Figure 6.5  Comparison of the loading efficiencies of TPT at different 
temperatures and suspension conditions.  Experimental values were calculated 
based on the quotient of the initial TPT suspension concentration and ratio of 
volume entrapped ( 𝐿𝑖(0) =
𝑇𝑇𝑜𝑡𝑎𝑙(0)
𝑓𝑣
⁄ , determined by HPLC) compared to that if 
the entire amount of TPT in the loading suspension had been entrapped in the 
intravesicular volume. 
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Modeling release used the initial conditions in Table 6.4.  Initially, release studies for 
these formulations were conducted in PBS without any NH4Cl; however, no significant 
release was observed (> 96% still lactone after 72 hours).  Release was then studied in PBS 
containing 60 µM NH4Cl to increase release, resulting in the profiles of lactone and 
carboxylate TPT in Figure 6.6a and b respectively.  As expected, the intravesicular pH is 
raised due to the influx of ammonia (Figure 6.6c) to increase release.  The simulation in 
Figure 6.6d of the precipitate dissolution occurring during release from these formulations 
reveals the unique profile of release seen due to the high loading temperatures. Initially, 
𝑇𝑖(𝑎𝑞)𝐶𝑙𝑖(𝑎𝑞) ≤ 𝐾𝑠𝑝
′  and dissolution of precipitate occurs.  Meanwhile, the influx of chloride is 
occurring in the ALLT formulations loaded using solutions of 60 and 130 µM TPT and 
liposomes with aqueous cores containing NH4C6H6SO3 and (NH4)2SO4 respectively.  The 
initial concentration of 𝐶𝑙𝑖(𝑎𝑞) in the formulations was calculated to be 45 and 96 mM, 
respectively.  These concentrations are lower than that of the extravesicular compartment 
(ClT,o of 0.13 M) which remains relatively constant during release studies due to the small 
fraction of encapsulated volume.  As precipitate is dissolved and 𝑇𝑖(𝑎𝑞)𝐶𝑙𝑖(𝑎𝑞) > 𝐾𝑠𝑝
′  is 
satisfied, release is halted by this chloride influx.  In the case of the ALLT formulation loaded 
with a loading solution of 180 µM TPT and liposomes containing NH4C6H6SO3, 𝐶𝑙𝑖(𝑎𝑞) is 
initially 190 mM, higher than ClT,o, so TPT release continues to release due to efflux of 
chloride after 𝑇𝑖(𝑎𝑞)𝐶𝑙𝑖(𝑎𝑞) > 𝐾𝑠𝑝
′ .   
The K’sp determined for each release profile required correction for the fraction of total 
aqueous intravesicular TPT in the monomeric (f1), cationic (f+) state.  This correction can be 
calculated using the equation below. 
𝐾𝑠𝑝 = 𝑓1𝑓
+𝐾𝑠𝑝
′ =
𝐻𝑖
+(−1+√1+8𝐾2𝑇𝑖(𝑎𝑞))
4𝐾2𝑇𝑖(𝑎𝑞)(𝐻𝑖
++𝐾𝐴1)
𝐾𝑠𝑝
′       (45) 
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The importance of this correction is illustrated by Figure 6.6e.  A plot of 𝑇𝑖(𝑎𝑞) against 𝐶𝑙𝑖(𝑎𝑞)
−1  
is not linear while linearity is quite apparent when 𝑓1𝑓
+𝑇𝑖(𝑎𝑞) is plotted against 𝐶𝑙𝑖(𝑎𝑞)
−1 .  This 
linearity is expected as the slope should be 𝐾𝑠𝑝
−1.  Using these corrections, the average Ksp 
was determined to be 1.39 ± 0.08 x 10-5.  Figure 6.6e also demonstrates that the Ksp is 
independent of the ammonium salt, NH4C6H6SO3 or (NH4)2SO4, used to achieve active 
loading.  This provides further evidence supporting the hypothesis that the precipitate 
formed is the chloride salt rather than a besylate or sulfate salt of TPT.   
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D.  
E.  
Figure 6.6  The effect of high temperature loading (60 °C) on ALLT release in pH 
7.4 PBS at 37 °C.  The fractions of lactone (A) and carboxylate (B) TPT were 
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monitored from ALLT formulations loaded using different concentrations of TPT 
and liposomes containing the ammonium salts described in the legend.  The 
lines represent the profile obtained after fitting the release model which 
accounts for the formation of TPT precipitate within the liposomes.  The effect of 
ammonia influx on intravesicular pH is shown (C) to illustrate that the initial 
phase of release is a result of this increased pH while the dissolution of drug 
precipitate is shown (D) to illustrate the point at which  𝑇𝑖(𝑎𝑞)𝐶𝑙𝑖(𝑎𝑞) > 𝐾𝑠𝑝
′  is 
reached and TPT release is greatly reduced as it becomes governed by the flux of 
chloride.  Because a 𝐾𝑠𝑝
′  was fit for each release profile, corrections for 
dimerization and pH were required (E).  Without these corrections, the 
relationship between 𝑇𝑖(𝑎𝑞) and 𝐶𝑙𝑖(𝑎𝑞)
−1  (filled-in symbols) exhibits poor 
linearity.  These corrections were incorporated by plotting 𝑓1𝑓
+𝑇𝑖(𝑎𝑞) against 
𝐶𝑙𝑖(𝑎𝑞)
−1  (empty symbols).  The trend is linear even though the data represent 
liposomal formulations containing besylate (circles) and sulfate (triangles) 
anions within the aqueous core. 
6.4  Discussion 
6.4.1  Effect of TPT ion-pairing, dimerization, and intravesicular pH on active 
loading and subsequent release kinetics 
 The significance of ion-pairing and dimerization become apparent upon simulation of 
the variables these factors significantly influence.  These factors are shown in Figure 6.7.  In 
6.7a, the uptake rates corresponding to those of the zwitterion (
𝑑𝐿𝑖
𝑧
𝑑𝑡
= 𝑟𝑧,𝑖) and ion-pair 
(
𝑑𝐿𝐶𝑙𝑖
𝑑𝑡
= 𝑟𝑖𝑝,𝑖) clearly illustrate biphasic uptake as the ion-pair is rapidly taken up in the 
initial phase of release until enough chloride accumulates within the intravesicular 
compartment.  At this point, the influx of zwitterionic TPT dominates uptake and provides 
enough additional TPT to stimulate efflux of the ion pair from the intravesicular 
compartment, further slowing uptake at later times. 
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 Dimerization affects loading in drastically different ways between the intra-and extra-
vesicular compartments.  Both of these effects are illustrated by Figure 6.7b.  Focusing on 
the extravesicular compartment first, the fraction of the initial amount of lactone TPT still 
present in the loading solution (i.e. 𝑓𝑇,𝑜
0 = 𝐿𝑜 𝐿𝑜(0)⁄ ) decreases faster than the fraction of 
initial monomer (𝑓1,𝑜
0 = 𝐿1,𝑜 𝐿1,𝑜(0)⁄  still present in the loading solution.  This illustrates the 
ability of TPT dimerization to prolong the faster uptake phase.  Dimerization also affects the 
intravesicular compartment by greatly reducing the effective concentration of the 
permeable species within the intravesicular compartment.  This is represented with the 
fraction of intravesicular TPT in the monomeric form (i.e. 𝑓1,𝑖 = 𝑇1 𝑇𝑖⁄ )   
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B.  
Figure 6.7  The effects of ion pairing and dimerization on TPT active loading at 
37 °C.  (A) The uptake rates of TPT as its zwitterion, rz,i, and ion-pair, rip,I, forms 
are shown to illustrate each species’ contribution to the uptake profiles 
observed during active loading at the concentrations of TPT used in the loading 
solution (see legend). (B) Dimerization prolongs the initial phase of rapid uptake 
as the change in monomer concentration over time (represented by 𝑓1,𝑜
0 )  is 
slowed relative to the change in total TPT concentration in the loading solution 
(illustrated here with the profile of 𝑓𝑇,𝑜
0 ).  Meanwhile, the fraction of total 
intravesicular drug in the monomeric form, f1,i, is shown to be greatly reduced in 
the inset at the top right. 
 Similar effects are present for ALLT release and are shown in Figure 6.8.  In Figure 6.8a, 
the rate of ion-pair release is shown to be far greater than the rates of zwitterion release or 
chloride influx when there is no extravesicular ammonia initially present in the buffer.  
Under these conditions, zwitterion permeablity is negligible and release is greatly slowed 
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after the concentration of ion-pair is depleted over 90%.  This is illustrated by Figure 6.8b.  
At the same time, however, total intravesicular TPT is only depleted by ~ 50 %. 
 Upon the additon of ammonia to the extravesicular release media, the influx of ammonia 
and subsequently the increase in intravesicular pH (see Figure 6.4c) has a dramatic effect 
on the rate of zwitterion release.  This is illustrated by Figure 6.8c.  For the ABL 
formulations loaded in the presence of a 60 µM solution of TPT, rz,i increases over 1000-fold 
after the addition of 60 µM NH4Cl.  With the zwitterion dominating release under these 
conditions, release proceeds to completion at this higher intravesicular pH (see Figure 
6.8b).  Figure 6.8c also shows this effect is independent of the concentration range of TPT 
studied here. 
A.  
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Figure 6.8  The effects of ion-pairing, dimerization, and pH on ALLT release at 
37 °C.  (A) Simulated rates of TPT release attributed to its zwitterionic, rz,i, and 
ion-paired, rip,i, forms are shown to illistrate the ion-pair is the dominant species 
governing release when the extravesicular buffer does not contain NH4Cl.  (B)  
The slow terminal phase of release seen under the conditions in A is the result of 
ion-pair depletion well before that of total TPT.  This is illustrated for the ALLT 
loaded in the presence of 60 µM TPT by normalizing with respect to the intial 
amount of ion-pair and total TPT in the intravesicular compartment (LCli(0) and 
Ti(0), respectively).  (C) The release rates due to increases in intravesicular pH 
are shown for ALLT loaded in the presence of 60 µM TPT, illustrating rz,i 
increases dramatically and drives release to completion as ammonia 
concentrations are increased in the extravesicular buffer. The inset shows 
similar rates (i.e. much greater) of zwitterion release in PBS with 60 µM NH4Cl 
for all the loading conditions employed.  The legends in A and the insets refer to 
the concentration of TPT used during acive loading while the legends for B and C 
refer to the amount of NH4Cl added to the extravesicular buffer.  
6.4.2 Significance of loading temperature and precipitate identity  
Due to the rapid uptake of TPT at 60 °C, direct experimental observations of the loading 
kinetics of TPT could not be achieved.  Furthermore, assuming the increases in the species’ 
permeabilities would be proportional would not be appropriate since the temperature 
dependence of their water partition coefficients are unknown and the mechanism of 
transport for ion-pairs and small anions is highly debated.44, 153, 188, 189  Even so, several 
inferences can be made upon comparison of the values estimated by the loading and release 
models used during data regression.  Figure 6.9a illustrates such a comparison with the 
Cl:TPT ratios estimated from these models to be present at the end of loading at 37° and 60 
°C.  While more TPT is present than Cl after loading at 37 °C, the opposite is the case based 
on the precipitation model used to fit the release profiles of the high temperature-loaded 
ALLTs.  Furthermore, extrapolations from the 37 °C loading model would predict a decrease 
rather than an increase in the Cl:TPT ratio based on the amount of entrapped TPT observed 
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after loading at 60 °C (see Figure 6.9b).  This suggests that the relative changes in species’ 
permeability are not proportional (i.e. have different activation energies).  Based on these 
ratios being >1:1 and the observation that the initial chloride concentrations reported in 
Table 6.4 are ≤ that of the loading solution (𝐶𝑙𝑇,𝑜 = 0.25 𝑀), it is also likely that chloride 
transport is greatly dependent upon Cl- as well as the ion pair.  This conclusion is based on 
the observation that the maximum Cl:TPT ratio achievable by ion-pair transport would be 1 
while the total amount of intravesicular Cl loaded would be ≥ 𝐶𝑙𝑇,𝑜 if Cl- permeability was 
the main driving force behind Cl transport. 
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B.  
Figure 6.9.  Changes in the intravesicular Cl:TPT ratio provide insight on the 
mechanism of TPT uptake at 60 °C. (A)  Three different ratios of intravesicular 
Cl:TPT are shown for three ALLT formulations with varying combinations of 
TPT loading concentrations and ammonium salts.   The three Cl:TPT ratios for 
each formulation are estimated based on the 37 °C loading model after 72 hrs of 
uptake, the 37 °C loading model after 300 hrs of uptake to achieve the 
intravesicular concentrations observed from loading at 60 C°, and the release 
model which accounts for TPTHCl precipitate. (B) The uptake profile of 
intravesicular Cl simulated by the 37 °C loading model for the three TPT loading 
concentrations studied (see legend).  The vertical line indicates the point at 
which this model achieves the same intravesicular TPT concentration as that 
determined after loading for 30 min at 60 °C.     
In addition to these possible changes to the mechanism of uptake at higher temperature, 
these higher intravesicular chloride concentrations are biased due to the model assuming 
the Ksp governs precipitation of TPTHCl rather than anion of the ammonium salt used for 
loading.  This assumption is necessary because of the unique condition of ion-pair transport 
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across the bilayer.  The transport of both drug and the counterion of its precipitated salt, 
chloride, is necessary to account for the burst phase of release observed with ALLT 
formulations loaded at 60 °C.  This effect is better illustrated by comparing simulations of 
release profiles when another anion forms the TPT salt. 
 Under these conditions, the transport equations governing the extravesicular 
compartment (Eqns. 28, 30 and 32) and intravesicular TPT in the presence of precipitate 
(Eqn. 36a) do not change while intravesicular chloride transport reverts back to Eqn. 32a.  
In the case of a monovalent anion (benzene sulfonate for the purpose of these simulations), 
the rate of precipitate dissolution follows the following condition: 
If:  𝐾𝑠𝑝
′ ≤ 𝑇𝑖(𝑎𝑞)𝐵𝑖(𝑎𝑞)      
𝑑𝑇𝐵𝑖(𝑠)
𝑑𝑡
= −
𝑑𝑇𝑖(𝑎𝑞)
𝑑𝑡
         (46) 
where 𝐵𝑖(𝑎𝑞) and 𝑇𝐵𝑖(𝑠) are the concentrations of benzene sulfonate in the intravesicular 
solution and the TPT salt respectively.  In the instance where 𝐾𝑠𝑝
′ > 𝑇𝑖(𝑎𝑞)𝐵𝑖(𝑎𝑞), there 
should be no precipitate left, 𝑇𝐵𝑖(𝑠) = 0, and intravesicular TPT transport follows Eqn. 28.  
With a rate equation for 𝑇𝐵𝑖(𝑠), 𝐵𝑖(𝑎𝑞) can simply be expressed with the following mass 
balance. 
𝐵𝑖(𝑎𝑞) = 𝐵𝑇 − 𝑇𝐵𝑖(𝑠)        (47)    
where BT is the total concentration of benzene sulfonate.  The pH equation (Eqn. 9) may be 
satisfied by substituting 𝐵𝑖(𝑎𝑞) for 𝐵𝑖
−.  Lastly, the initial conditions to define the amount of 
precipitate and soluble drug and counterion must be solved.  This can be performed with 
Eqns. 40a and b by substituting 𝐵𝑇 (0.3 M) for 𝐶𝑙𝑇,𝑖(0).  Using these equations, release in the 
presence of TPT-besylate salt was simulated at varying fractions of total drug precipitated 
(𝑓𝑠 = 𝑇𝐵𝑖(𝑠)(0) 𝑇𝑖(0)⁄ ) and compared to the observed release profile and fit to the 
precipitate model which assumes TPTHCl is the salt.  This is illustrated in Figure 6.10.  
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These simulations show very different release profiles than those observed experimentally 
due to the presence of intravesicular Cl in both ammonium sulfate and besylate ALLTs.  This 
proposed mechanism of ion-paired TPT-Cl loading and precipitation at high temperatures 
may also explain the presence of TPT salts within liposomal TPT formulations containing 
various intravesicular solutions.  This effect was illustrated in a study by Abraham et. al 
which showed intravesicular precipitates formed after TPT loading in liposomes containing 
(NH4)2SO4, Mn SO4, citrate, and MnCl2.64. 
A.  
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B.  
Figure 6.10  The identity of TPT salt affects release. (A) The change in lactone 
was simulated for ALLTs loaded using a 180 µM solution of TPT.  The 
simulations assumed TPT was precipitaed as a besylate salt and the resulting 
changes in L(t) are shown at varying fractions of TPT initially precipitated, fs 
(see legend), while the inset shows the data and fitted model which assumes a 
TPTHCl salt.  The points at fs=0 are data from the ALLT formulation loaded at 37 
°C (using 180 µM TPT), and the dotted line indicates the profile generated from 
the code used to simulate this precipitation model.  B) The simulations in A were 
normalized to fraction retained to illustrate the release profiles more clearly.  
The solid line shown in the resulting simulation uses the TPTHCl precipitate 
model used for the inset of A.  The simulations for the TPT-besylate 
precipitation model used the initial conditions for ALLTs loaded at 37 °C and 60 
µM NH4Cl in the release media.  Varying these initial conditions resulted in 
accelerated or slowed release profiles but showed the same trends as a function 
of precipitate present. 
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6.4.3 Implications of loading conditions on optimizing release kinetics    
 The effect of chloride on loading and release of TPT is considerable based on the results 
of this study.  These effects could be exploited for controlling release kinetics by simply 
altering the amount of chloride contained in the loading solution.  This would be especially 
advantageous at high loading temperatures where intravesicular TPTHCl precipitate is 
formed.  Further studies are needed to use this chloride effect as an advantage in 
formulation development.  The current findings were only able to indicate that ion-pairing 
and 𝐶𝑙− permeabilities both contribute to TPT active loading at higher temperature since 
direct measurement of their respective permeabilities was not possible under these 
conditions.  Without these permeabilities, predicting how much chloride would need to be 
added to the loading solution is not possible.  Even so, the potential to alter the relative ratio 
of fast-to-slow release phases of TPT in these liposomal formulations is worth further 
exploration as a tunable drug release system.    
6.5 Conclusions 
The results of this study provide a mechanistic understanding of the factors governing 
the active loading process for liposomal TPT.  The loading model developed herein 
combined with experimental observations reveals TPT transport across the lipid bilayer is 
achieved in part by ion-pairing with chloride and affected by the drug’s dimerization in 
solution.  To the author’s knowledge, this is the first report demonstrating significant 
bilayer transport of a large cationic molecule due to ion-pairing.  Furthermore, subsequent 
release studies conducted with these liposomes of actively-loaded TPT were used to 
develop a mechanistic release model which incorporated the effect of drug precipitation on 
liposomal release kinetics.  Mathematical modeling also identified the TPTHCl as the 
precipitated salt rather than the other anions present in the intravesicular core of the 
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liposome.  The mechanistic underpinnings identified here for active loading of TPT and its 
subsequent release will be useful in future studies which aim to optimize the TPT loading 
process to provide tunable drug release kinetics via manipulations of the chloride-to-TPT 
ratio.  The mathematical principles and mechanistic methodology used here should also be 
applicable to developing loading and release models for other liposomal formulations of 
pharmaceutical agents.         
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Copyright © Kyle Daniel Fugit  
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CHAPTER SEVEN 
Mechanistic Modeling Provides Insights on Doxorubicin Release, 
Partitioning, and Conjugation Stability in Polymeric Micelles  
7.1  Introduction 
 Nanoparticles such as dendrimers, liposomes, and polymeric micelles have been heavily 
explored as drug carriers for the treatment of various human diseases including infection 
and cancer.2-4  These nanoparticulate systems are attractive for pharmaceutical applications 
for two main reasons: 1) their ability to entrap and release drug payloads in a manner 
capable of altering drug pharmacokinetics via increased drug solubility or modulated drug 
release from the particle3, 5 and 2) their unique size and multitudes of surface chemistry 
may potentially aid in reducing systemic toxicity through passive and active targeting 
respectively.3-5, 10-13  While many types of nanoformulations have been developed to take 
advantage of these properties, few have had clinical success.  Part of this low success rate 
may be attributable to differences in release rates observed during in vitro characterization 
studies and those which occur in vivo.  
There have been many methods used to characterize drug release kinetics from 
nanoparticles;115-117 however, stringent validation of these in vitro methods is necessary as 
many environmental effects in vitro may alter observed drug release kinetics.  Part of this 
validation requires mechanistic models which deconvolute these environmental effects 
from the intrinsic release parameters governing drug release.118, 197  With models capable of 
mechanistically describing nanoparticle drug release, incorporation of in vivo conditions 
would be possible and ultimately lead to accurate in vitro/in vivo correlations.  Such 
correlations would reduce much of the costs incurred during preclinical development due 
to extensive animal testing and unguided formulation optimization. To this end, 
considerable efforts have been made to establish mechanistic drug release models for 
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liposomal formulations;118, 130 however, similar models have yet to be developed for other 
nanoparticles.  The construction of such models for other nanoparticles will require the 
unique physicochemical properties of the drug, particle, and those of the drug-particle 
system to be considered.  
One of these systems which has received considerable attention is polymeric nano-
assemblies.5, 65  These self-assembled nanoparticles are unique structures which provide a 
plethora of characteristics that may be exploited for altering drug release (e.g. particle size, 
charge, hydrophobicity, and conjugation sites for drug).  While these may be advantageous 
to altering drug release kinetics, they may also result in a complicated drug release 
mechanism. For example, block copolymer micelles are generally composed of a hydrophilic 
shell and a hydrophobic core. Drug payloads can partition into the core of the micelle 
typically due to the drug’s affinity for the particle’s hydrophobic or highly-charged core.5, 65, 
66  Over time, drug is released from these polymeric micelles due to a combination of kinetic 
factors (i.e. drug diffusion and/or stability of drug-polymer linkage) and thermodynamic 
factors (i.e. complexation/absorption to the micelle core, CMC) intrinsic to the 
drug/polymer system and independent of the release environment.   
Further complexity is added when nanoparticles are engineered to respond to external 
stimuli such as heat, electromagnetic waves, enzymatic activity, or pH.5, 63, 65, 71-79 Chemically 
conjugating drugs to the block copolymers is another way to alter drug release kinetics and 
adds another dimension to the mechanism of drug release.  In several instances, these drug-
conjugated micelles exhibit a biphasic drug release pattern (i.e. burst drug release followed 
by an extremely slow drug release phase) that varies depending on the pH of release 
medium.80-83  
In this study, a mathematical was developed to describe hydrazone-conjugated 
doxorubicin (DOX) release from block copolymer micelles.  The block copolymers were 
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composed of 12 kDa poly(ethylene-glycol) (PEG) and 16 hydrophobic repeating units and 
conjugated with DOX using a hydrazone linkage.  Because hydrazone bonds have been 
shown to be pH-sensitive (i.e. responsive to lysosomal pH),80, 81, 198 multiple drug release 
studies were performed at pH 5.0 and pH 7.4.  Spacer insertion prior to the hydrazone 
moiety was previously shown to alter drug release. 80, 82, 83, 102, 199-201  As such, block 
copolymer micelles with glycine (GLY) or methyl 4-aminobenzoate (ABZ) spacers and 
another formulation without a spacer (HYD) were studied to assess how spacer 
modification mechanistically altered DOX release.  Dynamic dialysis was used as the 
primary method to monitor release. The dynamic dialysis setting provided an additional 
physical barrier (i.e. dialysis membrane) to the removal of released, unconjugated DOX from 
the micellar solution.  The kinetics of drug transport across the dialysis membrane were 
incorporated to isolate its effects on observed drug release profiles and generate intrinsic 
kinetic release rate constants for drug release from the block copolymer micelles.  Initial 
modeling indicated instability of the hydrazone bond during prolonged storage and was 
confirmed with subsequent experiments.  Additionally, a non-sink release method 
previously developed to determine both release kinetics and drug partitioning197 was 
adapted to determine the extent of free DOX partitioning into the HYD micelle formulations 
and validate the mechanistic model.  Using this mechanistic model, release parameters were 
generated to identify the factors governing the pH-sensitive release of DOX observed by 
these micelle formulations.  This approach and the subsequent findings from this study will 
provide useful guidance to drug release analysis for future polymeric micelle drug carriers. 
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7.2  Materials and methods 
7.2.1  Materials 
L-aspartic acid β-benzyl ester, anhydrous hydrazine, benzene, N,N’-
diisopropylcarbodiimide (DIC), 4-(dimethylamino) pyridine (DMAP), N-
Hydroxysuccinimide (NHS), N,N-dimethylformamide, anhydrous N,Ndimethylformamide 
(DMF), anhydrous dimethylsulfoxide (DMSO), ethanolamine, anhydrous ethyl ether, 
anhydrous hexane, anhydrous tetrahydrofuran (THF), triphosgene, acetate buffer solution, 
phosphate buffer solution, methyl 4-aminobenzoate, O-Benzotriazole-N,N,N’,N’-tetramethyl-
uronium-hexafluoro-phosphate (HBTU), sodium hydroxide (NaOH) were purchased from 
Sigma-Aldrich (USA). Glycine-OMe is from Novabiochem (SUI). α-Methoxy-ω-amino 
poly(ethylene glycol) (PEG-NH2, MW=12,266) was purchased from NOF Corporation 
(Japan).  Doxorubicn hydrochloride was purchased from LC Laboratories (USA).  Slide-A-
Lyzer® dialysis cassettes with 10,000 MWCO, Sephadex LH-20 gels, potassium biphthalate 
sodium hydroxide buffer solution, potassium phosphate monobasic buffer solution, and 96-
well plates were purchased from Fisher Scientific (USA).  Amicon-Ultra centrifugal 
ultrafiltration devices with MWCO 10,000 were purchased from Millipore (USA). 
7.2.2  Preparation and characterization of polymeric micelles  
 Block copolymers of PEG-polyasparte (PEG-pAsp) were synthesized by Dr. Ponta using 
a method previously reported.83  The synthesis involved the following steps:  preparation of 
β-Benzyl-L-aspartate N-carboxy anhydride monomer (BLA-NCA), block copolymer 
synthesis of PEG-poly(16 β-benzyl-L-aspartate BLA) (PEG-pBLA), formation of PEG-poly-
aspartate [PEG-p(Asp)] with hydrazide [PEG-p(Asp-Hyd)] or with a glycine (Gly) or methyl 
4-aminobenzoate (Abz) spacer between the aspartate and hydrazide (PEG-p(Asp-Gly-Hyd) 
and PEG-p(Asp-Abz-Hyd) respectively) followed by DOX conjugation via a hydrazone bond.  
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7.2.2.1  BLA-NCA monomer synthesis 
BLA-NCA was prepared by adding triphosgene (2.88 g, 9.7 mmol) to β-benzyl –L-
aspartaten (5.0 g, 22.4 mmol) in dry THF (100 mL). The reaction proceeded at 45°C under a 
N2 atmosphere.  Once the solution became clear, anhydrous hexane was slowly added until 
NCA crystals appeared, then rapidly disappeared. Crystallization of BLA-NCA was achieved 
after storage in −20°C.  
7.2.2.2  PEG-pBLA synthesis 
These BLA-NCA crystals were used for synthesis of PEG-pBLA block copolymers via 
ring-opening polymerization of BLA-NCA.  Using the terminal primary amine of PEG-NH2 as 
the initiator, block copolymers containing 16 BLAs per PEG molecule were synthesized by 
dissolving BLA-NCA (183 μmol) monomers and PEG (7.67 μmol) in separate flasks to 
achieve 50 mg material/mL anhydrous DMSO under a N2 atmosphere.  Polymerization was 
performed at 45°C for 2 days after the dissolved monomers were added to the PEG solution. 
Purification of the resulting block copolymers were was achieved by ether precipitation 
then freeze drying from benzene.  From this purified PEG-pBLA, three types of PEG-pAsp 
block copolymers were synthesized with or without an additional spacer between the 
polymer aspartate side chain and the DOX-hydrazone linkage.  
 7.2.2.3  PEG-p(Asp-Hyd) functionalization 
Freeze-dried PEG-p(BLA) (56.42 μmol) was dissolved in dry DMF, and anhydrous 
hydrazine (9034 μmol) was added to the solution.  PEG-p(Asp-Hyd) was produced after 
anhydrous hyrdrazine (9034 µmol) was added to the PEG-pBLA solution and allowed to 
react for one hour at 40°C under a N2 atmosphere and constant stirring.  The block 
copolymers were collected by ether precipitation and subsequent freeze drying.  
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7.2.2.4  Synthesis of PEG-p(Asp-Gly-Hyd) and PEG-p(Asp-Abz-Hyd) block copolymers  
Purified PEG-pBLA was subjected to 01. N NaOH to deprotect its side chains and 
subsequently yielded PEG-p(Asp) block copolymers.  Spacer modification was performed by 
dissolving freeze dried PEG-p(Asp) (12 μmol) in THF and reacting the block copolymer with 
glycine methyl ester (GlyOMe) (400 μmol) and methyl 4-aminobenzoate (AbzOMe) (450 
μmol) using HBTU at 40°C overnight. Precipitates were removed through filtration at the 
end of the reaction. Ether precipitation followed by dialysis in a deionized water: methanol 
(50:50) solution was used to remove any unreacted GlyOMe and AbzOMe from the side-
chain modified block copolymers. Hydrazide (Hyd) functionalization of PEG-p(Asp-GlyOME) 
and PEG-p(Asp-AbzOMe) was by removal of the methy esters and amide formation. This 
was performed by adding excess hydrazine with respect to number of repeating units (490 
μmol, and 515 μmol for the GlyOMe and AbzOMe modified block copolymers, respectively) 
to PEG-p(Asp-GlyOMe) (6.5 μmol) and PEG-p(Asp-AbzOMe) (6.8 μmol) in DMF and reacting 
at 40°C for 1 h to obtain PEG-p(Asp-Gly-Hyd) and PEG-p(Asp-Abz-Hyd) block copolymers, 
respectively.   The block copolymers were purified and recovered by repeated ether 
precipitation and freeze drying. 
7.2.2.5  DOX conjugation via hydrazone bond 
DOX was conjugated to each of the three block copolymers via a hydrozone linkage 
between the aspartate side change and the 13 position ketone on DOX.  The reaction 
between DOX and PEG-p(Asp-Hyd) (750 mg, 53 μmol), PEG-p(Asp-Gly-Hyd) (899 mg, 59 
μmol), or PEG-p(Asp-Abz-Hyd) (824 mg, 50 μmol) occurred in DMSO over two days under 
gentle shaking at 40°C to produce PEG-p(Asp-Hyd-DOX), PEG-p(Asp-Gly-Hyd-DOX), or PEG-
p(Asp-Abz-Hyd-DOX) respectively. Physically-entrapped DOX and DMSO were initially 
removed by ether precipitation.  The block copolymers were then dissolved in methanol 
and eluted through a Sephadex LH-20 column for further purification. After elution, the 
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block copolymers were dissolved in deionized water and filtered using a 0.22 μm filter.  The 
final product was obtained after freeze-drying and stored as solids at -20°C. 
7.2.2.6  Block copolymer micelle characterization 
Once purified, PEG-p(Asp-Hyd-DOX), PEG-p(Asp-Gly-Hyd-DOX), and PEG-p(Asp-Abz-
Hyd-DOX) block copolymers were added to DI water to form HYD, GLY, and ABZ micelles 
respectively.  Characterization of the block copolymer synthesis is reported elsewhere.83, 202  
For the purpose of these release studies, micelle particle size and ζ-potential were 
determined using Zetasizer Nano-ZS (Malvern, UK).  Block copolymers were suspended in 
DI water to a concentration of 2.0 mg copolymer/mL in triplicate for both analyses (six 
samples total).  Particle size analysis was based on the average diameter obtained from 
number distribution analysis.   
DOX loading for the three micelle formulations and subsequent DOX release was 
determined from DOX absorption spectra by Dr. Ponta.83, 202  Briefly, standards of DOX 
varying in concentration between 0.98 and 250 µM were analyzed by a SpectraMax M5 
(Molecular Devices, USA) equipped with variable spectrum filters.  Absorbance was found 
to be linear at 485 nm over this concentration range.  Spectra of DOX conjugated to micelles 
was found not to differ from free DOX in solution.202  This allowed DOX concentrations to be 
calculated in micelle suspensions during drug release studies from free DOX standards. 
7.2.3  Drug release studies  
 All drug release studies were performed by Dr. Ponta using the particles he developed 
above.  Release studies were performed at both pH 5.0 and 7.4 using Potassium biphthalate 
sodium hydroxide (pH 5.0, 0.01 M ionic strength) and potassium phosphate monobasic 
buffer solution (pH 7.4, 0.02 M ionic strength) buffers respectively for all three copolymer 
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formulations of micelles.  All release conditions were conducted in triplicate for all three 
micelle formulations.   
7.2.3.1  DOX release monitored by dynamic dialysis:  sink conditions  
 Micelle suspensions of 0.1, 0.5, and 1 mg copolymer/mL were used to fill 3 mL dialysis 
cassettes (10,000 MWCO).  These cassettes were then dialyzed against reservoirs of the 
same buffers used to suspend the micelles at a reservoir: cassette ratio of 5,000:9 (v:v).  The 
reservoirs were continuously stirred throughout the duration of release studies.  During 
dialysis, release was monitored over a 72 hour period by withdrawing 0.1 mL samples from 
within the dialysis cassettes and analyzing the concentration of DOX using the colorimetric 
method already described.   
 Additional dialysis studies were also conducted to examine DOX transport across the 
dialysis membrane along with partitioning of free DOX into the micelle particles.  For these 
determination of DOX transport across the dialysis membrane, free DOX (0.12 mg/mL) 
solutions were put into to dialysis cassettes and dialyzed under the same conditions used 
above for DOX-loaded micelle suspensions.  Lastly, 0.5 mg copolymer/mL suspensions of 
HYD, GLY, and ABZ micelles which had already undergone release for 72 hours were spiked 
with free DOX (0.1 mg/mL, 0.17 – 0.25 mg total DOX/mL) and thoroughly mixed.  These 
suspensions were dialyzed against the same reservoir conditions used in micelle release 
studies to observe if partitioning of unconjugated, free DOX into the micelle had any effect 
on observed DOX transport across the dialysis membrane. 
7.2.3.2  DOX release monitored by ultrafiltration:  non-sink conditions 
 Non-sink studies were performed based on an ultrafiltration method previously 
developed in Chapter 3 for use in liposomal release studies.  The method was modified by 
Dr. Ponta for use with HYD, GLY, and ABZ micelles.  Briefly, micelle suspensions (3 mL, 0.5 
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mg copolymer/mL) were transferred to scintillation vials and placed in a 37 °C incubator 
and gently shaken.  At various time points, aliquots (250 µL) of the micelle suspension was 
withdrawn and diluted with methanol to 500 µL.   The samples were transferred to an 
Amicon® Ultra 0.5 mL centrifugal filter cartridge with 10,000 MWCO Ultracel® membrane.  
Ultrafiltration was achieved by centrifugation of these cartridges at 14,000 rpm for 10 min.  
After centrifugation, the remaining supernatant was recovered and diluted to 500 µL with 
methanol and the process was repeated twice more.   Validation of free DOX removal was 
performed by ultrafiltration of DOX solutions and by comparison of DOX concentration in 
copolymer suspensions spiked with free DOX before and after ultrafiltration. 
7.2.4  Determination of unconjugated drug produced during storage 
 Because of the elapsed time between release studies (approx. 15 months), degradation 
of the hydrazone bond may be significant and should be accounted for during modeling.  
Two techniques were used to validate the % of unconjugated DOX generated during storage 
that was estimated by the mathematical model.  Ultrafiltration using the same procedure 
described in the non-sink release section was performed on micelle suspensions 
immediately after reconstitution.  The amount of DOX present in the sample before and 
after ultrafiltration was analyzed to calculate the % of DOX conjugated in the suspension.  
Secondly, micelle suspensions were passed through a Sephadex LH-20 column and the drug 
loading in the eluted volume pertaining to the MW of the copolymer was compared to drug 
load before Sephadex calculate the % of DOX conjugated.   
7.2.5  Model Development 
 Several models have been developed for liposomal nanoparticles in which release is 
governed mainly by drug permeability through their phospholipid membrane.50, 60, 63, 124, 127, 
128, 130  Other models describing drug release from novel pharmaceutical formulations have 
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been developed and to incorporate effects such as Fickian diffusion, particle/drug 
dissolution, and polymer degradation/swelling;203, 204 however, these models have not been 
applied to nanoparticle formulations. To our knowledge, no such model has been developed 
for a micelle formulation in which the drug has been conjugated to the copolymer scaffold of 
the micelle.  Such a mechanistic model is developed here in collaboration with Dr. Ponta.  
The model incorporates two-phase release kinetics attributable to hydrazone bond 
hydrolysis of conjugated DOX as well as partitioning of unconjugated DOX into the micelle.  
These properties are illustrated by Scheme 7.1.  For these studies, dynamic dialysis and 
ultrafiltration studies were used to probe and confirm DOX partitioning was a factor in 
release studies.  The math for both types of release studies are described in the following 
sections. 
 
Scheme 7.1.  An illustrated schematic of the mathematical model used to 
describe DOX release from the three different micelle formulations studied.  
Here, the hydrophilic PEG shell (blue) surrounds the polyaspartate core.  In the 
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core, two populations of conjugated DOX are shown.  These populations 
correspond to fast (𝐶1
𝑚 , green) and slow (𝐶2
𝑚 , yellow) hydrolysis of the 
hydrazone bond and their hydrolysis is governed by rate constants k1 and k2 
respectively.   After hydrolysis, unconjugated DOX may stay partitioned in the 
micelle nanoenvironment (𝑈𝑚) or reside in the aqueous phase (𝑈𝑤).  This 
equilibrium is governed by the partition coefficient Kp.  In dynamic dialysis 
studies, DOX transport though the dialysis membrane is governed by the rate 
constant kd and concentration of 𝑈𝑤.   
 Drug release profiles for all three types of micelles and both pH conditions studied were 
fit using Micromath Scientist non-linear regression software using a weight factor or two. 
7.2.5.1  Release studies monitored by ultrafiltration: non-sink conditions 
In release studies monitored by ultrafiltration, the various species of DOX within the 
sample vial may be expressed by the mass balance below. 
𝑀𝑇 = 𝑀1
𝑐 +𝑀2
𝑐 +𝑀𝑚
𝑢 +𝑀𝑤
𝑢         (1) 
Here, 𝑀𝑇, 𝑀1
𝑐 , 𝑀2
𝑐 , 𝑀𝑚
𝑢 , and 𝑀𝑤
𝑢 , refer to the total amount of DOX in solution, conjugated DOX 
which undergoes fast hydrazone hydrolysis, conjugated DOX which undergoes slow 
hydrazone hydrolysis, and unconjugated DOX partitioned into the micelle and aqueous 
phases respectively.  These terms may be rewritten as the concentrations of total DOX (𝐷𝑇), 
conjugated DOX undergoing fast hydrolysis kinetics (𝐶1
𝑚), conjugated DOX undergoing slow 
hydrolysis kinetics (𝐶2
𝑚), and unconjugated DOX in micelle (𝑈𝑚) and aqueous (𝑈𝑤) phases 
can be related as described by equation 2.  
  𝐷𝑇 = 𝑏𝐶1
𝑚 + 𝑏𝐶2
𝑚 + 𝑏𝑈𝑚 + 𝑎𝑈𝑤        (2) 
Here, the volume fractions of aqueous and micellar phases (a and b respectively) are used to 
relate the total volume of the solution, 𝑉𝑇, to the volume of aqueous and micelle phases (𝑉
𝑤 
and 𝑉𝑚  respectively).  This is expressed by equations 3a and b. 
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𝑎 =
𝑉𝑤
𝑉𝑇
; 𝑏 =
𝑉𝑚
𝑉𝑇
        (3a & b) 
In these studies, the density of the micelles was not known and assumed to be similar to 
that of water which allowed the weight fraction of micelle to be used for volume 
calculations.  The values used for the different concentration of micelle solutions studied are 
found below in Table 7.1. 
Table 7.1.  Volume parameters used for mathematical modeling of DOX release from block 
copolymer micelles 
Micelle Concentration a b 
1.0 mg copolymer/mL 0.9990 0.0010 
0.5 mg copolymer/mL 0.9995 0.0005 
0.1 mg copolymer/mL 0.9999 0.0001 
 
The differential equations which incorporate two-phase hydrazone hydrolysis kinetics 
and govern DOX release are shown below.   
𝑑𝐶1
𝑚
𝑑𝑡
= −𝑘1𝐶1
𝑚           (4a) 
𝑑𝐶2
𝑚
𝑑𝑡
= −𝑘2𝐶2
𝑚           (4b) 
𝑑𝑈
𝑑𝑡
= 𝑏(𝑘1𝐶1
𝑚 + 𝑘2𝐶2
𝑚)         (4c) 
This system of differential equations may only be solved by defining the initial conditions 
for each equation.  These conditions must incorporate the initial fraction of total DOX 
conjugated to the copolymer (fc), the initial fraction of conjugated DOX in the fast hydrolysis 
phase (f) in relation to the total concentration of DOX initially present in solution (𝐶𝑇,0).  
With these parameters, the initial conditions for equations 4a-c can be expressed.   
𝐶1
𝑚(0) = 𝑓𝑐
𝑓
𝑏
𝐶𝑇,0         (5a) 
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     𝐶2
𝑚(0) = 𝑓𝑐
(1−𝑓)
𝑏
𝐶𝑇,0         (5b) 
   𝑈(0) = (1 − 𝑓𝑐)𝐶𝑇,0         (5c) 
Lastly, the concentration profile of DOX obtained by ultrafiltration (𝐷𝑢) must defined.  This 
was done by assuming 𝐷𝑢 was composed of both conjugated DOX and DOX partitioned into 
the membrane.  This is expressed by equation 6.  
   𝐷𝑢 = 𝑏(𝐶1
𝑚 + 𝐶2
𝑚 +𝑈𝑚)         (6) 
Solving for Um in terms of U is required to fit 𝐷𝑢.  This may be performed by first defining a 
DOX partition coefficient as shown below.   
𝐾𝑝 =
𝑈𝑚
𝑈𝑤
          (7) 
Using this equilibrium expression and the mass balance relating 𝑈𝑚 and 𝑈𝑤 to the 
concentration of total unconjugated DOX, 𝑈𝑇 (see equation 8), 
  𝑈𝑇 = 𝑎𝑈𝑤 + 𝑏𝑈𝑚         (8) 
𝑈𝑚 can be solved in terms of U as illustrated by the following equation. 
  𝑈𝑚 =
𝐾𝑝𝑈
𝑎+𝑏𝐾𝑝
          (9) 
Upon substitution into equation 6, the final equation for 𝐷𝑢 is the result and shown below 
by equation 10.  
   𝐷𝑢 = 𝑏(𝐶1
𝑚 + 𝐶2
𝑚 +
𝐾𝑝𝑈
𝑎+𝑏𝐾𝑝
)        (10) 
7.2.5.2  Release studies monitored by dynamic dialysis: sink conditions 
Typically, dynamic dialysis is believed to maintain a “sink” for drug release if an 
adequately large reservoir volume is used to maintain the driving force for release and 
depletion of released drug from the compartment within the dialysis cassette.  However, the 
rate of drug transport across the membrane may alter observed release kinetics if initial 
 200 
 
drug release from the nanoparticle formulation is faster, similar,49, 118, 197 or if a significant 
fraction of released drug binds to the dialysis membrane or the nanoparticle itself.49, 118 
If one considers the compartment within the dialysis cassette in a context similar to that 
already defined in the ultrafiltration studies, the same differential equations governing 𝐶1
𝑚  
and 𝐶2
𝑚  and the mass balances developed there (Equations 1 – 4b) may be used.  However, 
the differential equation governing unconjugated drug (Equation 4c) must be rewritten to 
include DOX diffusion through the dialysis membrane and accumulation in the reservoir 
compartment.  These events are expressed by equations 11a and b with the parts in red 
indicating the features unique to dynamic dialysis.  
 
𝑑𝑈
𝑑𝑡
= 𝑏(𝑘1𝐶1
𝑚 + 𝑘2𝐶2
𝑚) − 𝑘𝑑(𝑎𝑈
𝑤 − 𝑅)      (11a) 
   
𝑑𝑅
𝑑𝑡
= 𝑘𝑑𝑓𝑅(𝑎𝑈
𝑤 − 𝑅)         (11b) 
Here, R accounts for DOX concentration in the reservoir compartment and fR is the volume 
ratio of dialysis tube to reservoir (9/5000).  With such a large reservoir volume relative to 
the dialysis cassette volume (𝑓𝑅 → 0), the reservoir concentration can be assumed to be 
negligible (𝑅 ≅ 0), 𝑑𝑅
𝑑𝑡
 may be ignored, and equation 11a may be simplified to the following 
equation: 
𝑑𝑈
𝑑𝑡
= 𝑏(𝑘1𝐶1
𝑚 + 𝑘2𝐶2
𝑚) − 𝑎𝑘𝑑𝑈
𝑤       (12) 
Based on this equation, removal of unconjugated DOX from the dialysis cassette is 
dependent upon a rate constant for DOX transport across the dialysis membrane, 𝑘𝑑 , and 
the concentration of unconjugated drug in the aqueous phase, 𝑈𝑤.  Using Equations 7 and 8, 
Uw may be rewritten in terms of U and substituted back into equation 12.  This is shown by 
equations 13a and b.  
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𝑈𝑤 =
𝑈
𝑎+𝑏𝐾𝑝
         (13a) 
𝑑𝑈
𝑑𝑡
= 𝑏(𝑘1𝐶1
𝑚 + 𝑘2𝐶2
𝑚) − 𝑘𝑑
𝑎𝑈
𝑎+𝑏𝐾𝑝
       (13b) 
The initial conditions for this system of differential equations are identical to those used in 
the ultrafiltration equations (5a-c).   
As a control, spike experiments were also conducted to monitor the effect DOX 
partitioning had on the disappearance of unconjugated DOX.  This was accomplished by 
dialyzing the micelle solution for 72 hours in release medium to minimize the amount of 
conjugated DOX before spiking with free DOX.  The differential equations are the same for 
these experiments as those used for release studies utilizing conjugated DOX (Equations 3a, 
3b, and 13b).  The initial conditions for spike experiments, however, required the 
concentration of conjugated DOX left after 72 hours of dialysis to be accounted for in the 
initial conditions.   These corrections are reflected in Equations 14a-c where the terms in 
blue indicate the parameters unique to the spike experiments.  
𝐶1
𝑚(0) = 𝑓𝑐
𝑓
𝑏
𝐶𝑇,0𝑒
−72𝑘1          (14a) 
𝐶2
𝑚(0) = 𝑓𝑐
(1−𝑓)
𝑏
𝐶𝑇,0𝑒
−72𝑘2        (14b) 
𝑈(0) = 𝐶𝑆𝑇,0         (14c) 
In addition to the terms present in the initial conditions already introduced by Equations 
5a-c (𝑓𝑐 , f, and CT,0), the time the micelle solutions were already dialyzed against release 
medium used a monoexponential decay for both the fast and slow compartments (with rate 
constants k1 and k2 respectively).  Because the solution was spiked with DOX solution, the 
concentration of this unconjugated DOX, 𝐶𝑆𝑇,0, was used in equation 14c. 
Lastly, dialysis of DOX solutions was also conducted to accurately estimate the rate of 
unconjugated DOX transport across the dialysis membrane.  Since no micelle material is 
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present in these studies, the release of total DOX concentration, 𝐷𝑇, may be expressed by 
equation 15a and its initial conditions are simply the initial concentration of dissolved DOX 
in solution (Equation 15b). 
𝑑𝐷𝑇
𝑑𝑡
= −𝑘𝑑𝐷𝑇         (15a) 
𝐷𝑇(0) = 𝐶𝑇,0         (15b) 
7.3  Results 
7.3.1  Micelle characterization  
Characterization of the DOX-conjugated copolymers was reported elsewhere by Dr. 
Ponta.202  Upon addition to aqueous solution, these copolymers formed micelles with drug 
loading of 26 ± 1.6, 17 ± 1.5, and 26 ± 1.1% by weight while the particle size obtained from 
dynamic light scattering resulted in hydrodynamic diameters of 117 ± 37,  54 ± 12, and 58 ± 
11 nm for the HYD, ABZ, and GLY micelles respectively.  Measurements of ζ-potential were 
also taken and found to be 13 ± 0.2, -4.0 ± 0.6, and 0.5 ± 1.5 mV for the HYD, ABZ, and GLY 
micelles respectively. Values reported here are averages of triplicate measurements along 
with the resulting standard deviation. 
7.3.2  Validation of free DOX removal for methods used to monitor release 
 Both release methods employed in this study have unique conditions which may affect 
analysis of release kinetics from observed release profiles.118, 130, 197 In the case of dynamic 
dialysis, significant drug binding or absorption may dominate the kinetics observed during 
release studies and skew the determination of rate constants and other parameters intrinsic 
to the nanoparticle/drug system.118  To assess this factor, free DOX solutions (pH 5.0 and 
7.4) were dialyzed under the same conditions used in the micelle release studies.  During 
these studies, the biphasic release anticipated if DOX binding to the dialysis membrane was 
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not evident, indicating the use of a rate constant for DOX transport across the dialysis 
membrane was sufficient for modeling purposes. 
 Analysis of ultrafiltration studies is affected by incomplete removal of unconjugated 
drug during the centrifugation and washing steps.130, 197 In the context of these release 
studies, ultrafiltration must remove unconjugated DOX in the aqueous phase from the DOX 
remaining in the micelle.  This was validated two ways.  First, free DOX was dissolved in a 
50% methanol:water mixture and underwent the ultrafiltration process described in the 
methods section. After the ultrafiltration process, spectrometric analysis determined that 
no DOX was present in the concentrate.  The second confirmation used two identical block 
copolymer solutions.  The ultrafiltration was performed on three micelle solutions and 
three more solutions that were spiked with free DOX.  Comparison of DOX present in the 
concentrate after ultrafiltration confirmed complete DOX removal as there was no statistical 
difference between the group of solutions that was or was not spiked with free DOX. 
7.3.3  Model-predicted micelle instability during storage confirmed by other 
experimental methods 
Initial modeling of the release profiles of DOX required a fraction of DOX to be 
unconjugated, fc, at the beginning of the release studies for the 0.1 and 0.5 mg micelle/mL 
solutions unlike the 1.0 mg micelle/mL solutions which indicated 100% of DOX was initially 
conjugated.  While the DOX release studies at 1.0 mg micelle/mL solutions were conducted 
shortly after synthesis (within two weeks), the other micelle solutions were constituted 
from freeze-dried block copolymer material that had been stored at -20 °C for 
approximately 15 months.   
Hydrdazone degradation during storage seemed like a plausible explanation; however, 
such degradation has not been previously reported for these micelle systems and was 
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unexpected.  Confirmation that the model-predicted degradation was indeed a factor in the 
discrepancies seen in release profiles at different micelle concentrations was confirmed 
experimentally by comparing the DOX concentrations before and after ultrafiltration.  
Analysis of drug loading before and after running the stored copolymer material through a 
Sephadex column to separate free DOX from the DOX-conjugated copolymer was also 
performed as a second validation.  Values of the percentage of conjugated DOX (𝑓𝑐 × 100%) 
calculated from the results of these methods along with those from mathematical modeling 
were similar as illustrated by Figure 7.1.  Averaging the values obtained from all four 
methods for all three micelle formulations resulted in an average percent of DOX conjugated 
of 63 ± 3% (95 % CI) after 15 months of storage.  For further regression analysis, this 
parameters was fixed for the value obtained from size exlculsion experiments (67, 68, and 
69 % for HYD, ABZ, and GLY, respectively) to increase the statistical strength of the fitted 
release parameters. 
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Figure 7.1.  The graph above displays the % of DOX conjugated (𝑓𝑐 × 100%) 
after 15 months of storage determined by mathematical modeling (under both 
pH conditions DOX release was monitored) and two other experimental 
methods (see legend at the top).  Error bars represent 95% confidence intervals. 
7.3.4  Characterization of release kinetics of HYD DOX-conjugated block 
copolymer micelles 
For the HYD micelles, both release profiles obtained from ultrafiltration and dynamic 
dialysis (including all three micelle concentrations, spike experiments, and dialysis of free 
DOX only) were simultaneously fit to the mathematical release models described in the 
model development section.  By fitting these profiles, the effects of DOX transport through 
the dialysis membrane and the % of unconjugated DOX present due to hydrazone 
degradation during storage could be separated from the intrinsic parameters to be 
estimated for the DOX/HYD system.  The experimental release profiles along with the 
resulting profiles obtained by the model-fitted release parameters (see Table 7.2) are 
shown below in Figure 7.2a and b for release in pH 5.0 and 7.4 medium respectively.  Based 
on the values reported in Table 7.2, the main parameters affected by pH are not the rate 
constants, but partitioning (Kp) and the fraction of conjugated DOX in the phase fast phase 
(f) at each pH.  
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Table 7.2.  Values of release parameters fitted to mathematical model to describe DOX 
release from micelle formulations at pH 5.0 and 7.4 
Micelle pH 𝑘1 (hr
-1) 𝑘2 × 10
2
 
(hr
-1
) 𝑘𝑑  (hr
-1
) 𝐾𝑝 × 10
−3  f 
HYD 7.4 0.24 ± 0.1 0.55 ± 0.1 0.81 ± 0.03 2.5 ± 0.6 0.38 ± 0.06 
ABZ 7.4 0.27 ± 0.2 0.36 ± 0.1 0.79 ± 0.03 1.1 ± 0.8 0.34 ± 0.06 
GLY 7.4 0.30 ± 0.1 0.46 ± 0.1 0.80 ± 0.03 2.2 ± 1 0.25 ± 0.04 
HYD 5.0 0.29 ± 0.05 0.45 ± 0.1 0.80 ± 0.03 0.62 ± 0.2 0.68 ± 0.03 
ABZ 5.0 ≥ 1.15* 0.59 ±0. 2 0.78 ± 0.03 0 0.36 ± 0.05 
GLY 5.0 0.64 ± 0.5 0.82 ± 0.1 0.77 ± 0.02 0 0.20 ± 0.05 
Values are reported along with 95% confidence intervals 
*Value used for generation of statistics as release of fast phase was rate-limited by DOX 
transport through the dialysis membrane 
 
A.  
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B.  
Figure 7.2.  DOX release profiles at pH 5.0 (A) and 7.4 (B) obtained for HYD 
micelles.  The same symbols are used to describe the micelle concentrations and 
methods at both pH conditions.  The release profile obtained by ultrafiltration of 
a 0.5 mg copolymer/mL solution is shown ( ) in addition to release profiles 
obtained by dynamic dialysis of micelle solutions composed of 1.0 ( ), 0.5 ( ), 
and 0.1 (×) mg copolymer/mL.  Additionally, the profile of free DOX (0.12 
mg/mL) allowed to dialyze from the cassette ( ) and the DOX release profile 
obtained by dynamic dialysis of a 0.5 mg copolymer/mL solution (which had 
been dialyzed for 72 hours in release media to remove conjugated DOX) spiked 
with 0.1 mg/mL of free DOX ( ) are also shown to reflect DOX transport across 
the dialysis membrane and the effect DOX partitioning to the micelle has on DOX 
transport out of the dialysis cassette respectively.  The lines of corresponding 
color to the symbols represent the simulated release profiles at those conditions 
generated by the fitted parameters reported in Table 7.2 using the mathematical 
model developed.  The inset at the top right of each plot reflects the entire time 
course release was monitored while the initial phase of release is shown in the 
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main plot.  Error bars indicate the standard deviation of triplicate release 
studies at each time point. 
 Using both ultrafiltration and dynamic dialysis methods to monitor release, DOX 
partitioning could be identified and shown to affect DOX release profiles.  Based on the 
success of this mechanistic model to describe DOX release from HYD, the same model was 
applied to the GLY and ABZ formulations to generate constants which described their 
release profiles. 
7.3.5  Characterization of release kinetics of DOX-conjugated block copolymer 
micelles with GLY and ABZ spacers 
 Release studies of GLY and ABZ micelles showed similar biphasic release profiles as 
those observed with HYD by the dynamic dialysis method.  This is illustrated by the release 
profiles in Figure 7.3.  However, release profiles could not be obtained by the ultrafiltration 
method for these micelles.  This was likely due to the smaller amount present in the fast 
phase for these solutions at pH 5.0 and then worsened by the added effect of DOX 
partitioning at pH 7.4.  Because ultrafiltration was not possible with these formulations, 
DOX partitioning was dependent upon the initial (fast) phase of release in conjunction with 
the multiple concentrations studied.  
 Based on the values reported in Table 7.2, several comparisons can be made between 
these spacer-modified micelles and the HYD micelles which lack such a spacer.  Like the 
HYD micelles, DOX partitioning, Kp, is higher at pH 7.4 than at pH 5.0; however, comparing 
the values of each formulation to each other is difficult due the large variability indicated by 
the confidence intervals.  This is not unexpected as Kp is mainly determined in the fast phase 
of release observed during dynamic dialysis.  In these micelles, this fast phase is the minor 
phase of release.  Furthermore, this section of the release profile is also complicated by the 
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effects of free DOX present in the 0.1 and 0.5 mg copolymer/mL micelle solutions.  Unlike 
the HYD micelles however, the fraction of DOX release in the fast phase, f, was similar for 
release studied at pH 5.0 and 7.4 for both the GLY and ABZ micelles.  In addition, the rate 
constants of fast hydrazine hydrolysis, k1, also appear to be pH-sensitive in contrast to the 
HYD micelles.  For GLY, the value of k1 is higher at pH 5.0 than at pH 7.4, but the variability 
of this value is high.  This is not surprising as the value estimated is similar to the rate 
constant of DOX diffusion through the dialysis membrane (kd) and again its estimation is 
complicated due to the significant amount of unconjugated DOX released in the profiles 
obtained from the 0.5 and 0.1 mg copolymer/mL solutions.  This effect essentially results in 
a triphasic release profile in which the phase governed by k1 is reduced due to the fast phase 
represented by unconjugated DOX initially present.  For the ABZ micelles at pH 5.0, the 
exact value of k1 could not be determined as the fast phase of release was rate-limited by 
DOX transport.  During modeling, it was determined that k1 needed to be at least 1.15 hr-1 to 
adequately fit the release profiles.  This value is only a lower limit for k1 for for hydrazone 
hydrolysis of ABZ under pH 5.0 conditions which indicates that release at pH 5.0 for ABZ is 
the fastest of the micelle formulations. 
 The terminal phase (i.e. slow hydrzazone hydrolysis phase) was similar for all three 
micelle formulations at both pH conditions studied.  Only DOX release from GLY micelles at 
pH 5.0 was different, resulting in a hydrazone hydrolysis rate constant of the slow phase, k2, 
to be nearly twice as fast that from the HYD micelles and was statistically different.   
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Figure 7.3.  DOX release profiles obtained for GLY micelles at pH 5.0 (A) and 7.4 
(B) along with those obtained for ABZ micelles at pH 5.0 (C) and 7.4 (D).  The 
symbols used here indicate the same conditions as those used in Figure 7.2.  The 
release profiles obtained by dynamic dialysis of GLY and ABZ micelle solutions 
composed of 1.0 (  ), 0.5 ( ), and 0.1 (×) mg copolymer/mL are shown.  The 
profiles of free DOX (0.12 mg/mL) allowed to dialyze from the cassette ( ) and 
the DOX release profile obtained by dynamic dialysis of a 0.5 mg copolymer/mL 
solution solution (which had been dialyzed for 72 hours in release media to 
remove conjugated DOX) spiked with 0.1 mg/mL of free DOX ( ) are also 
shown to reflect DOX transport across the dialysis membrane and the effect DOX 
partitioning to the micelle has on DOX transport out of the dialysis cassette 
respectively.  The lines of corresponding color to the symbols represent the 
simulated release profiles at those conditions generated by the fitted 
parameters reported in Table 7.2.  The inset at the top right of each plot reflects 
the entire time course release was monitored while the initial phase of release is 
shown in the main plot.  Error bars indicate the standard deviation of triplicate 
release studies at each time point. 
7.4  Discussion 
7.4.1  Strengths and limitations of micelle release model and methods used  
7.4.1.1  Instability of hydrazone bond under storage conditions identified with mathematical 
modeling 
 DOX degradation under the specified storage conditions was unprecedented and 
illustrates a prime example of the usefulness of mathematical modeling of drug release in 
nanoparticle systems.  Without such modeling, the instability of the hydrazone linkage 
would likely not have been identified until much later in the development process if at all.   
In addition to identifying this instability, the fact that a single value of fc could be fit to 
both fast and slow release phases indicates that the structure of the copolymer material in 
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its freeze-dried state does not possess the same domains or microenvironments as those of 
the micellar structure formed in solution. 
While modeling was able to identify hydrazone degradation, the mechanism behind 
degradation was beyond the scope of the model.  However, several possible modes of 
degradation could be hypothesized. First, DOX could have been hydrolyzed during the 
freeze-drying process prior to storage. This is unlikely since all the material was freeze-
dried (including the material used for drug release studies at a 1.0 mg/mL block copolymer 
concentration) before any analysis on DOX content was performed.  According to modeling, 
the percent of DOX conjugated was 100% for the 1.0 mg copolymer/mL release studies 
performed shortly after synthesis.  If DOX degraded during freeze-drying, the percent of 
conjugated DOX would have been similar to that observed by release studies performed 
with copolymer material that had been stored for 15 months.  
The next logical explanation would be degradation due to trace amounts of water still 
present or introduced after the freeze drying process.  In a previous study, hydrazone 
degradation of a DOX conjugate was shown to undergo degradation after lyophilization 
during storage at cooler temperatures (2 – 8 °C).198  In that study, the amount of water in 
lyophilized samples was approximately 2% and resulted in 20% degradation of the 
hydrazone bond after 12 months.  Storage of the copolymer material in this study, however, 
was stored over a longer period of time but at colder temperatures.  Because PEG is 
hydrophilic, the PEG chains here may have retained more water residue than the samples in 
this earlier study.  Increased water residue in the lyophilized cake could lead to increased 
hydrazone degradation.  This was surmised to be the most likely scenario but additional 
studies are required to elucidate the conditions attributing to degradation.  
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7.4.1.2  Probing contributions of DOX partitioning and DOX hydrolysis kinetics on release using 
sink and non-sink conditions 
The terminal phase of release in these profiles is quite slow and could be the result of 
slow hydrolysis kinetics of the DOX-hydrazone bond, DOX partitioning, or a combination of 
these effects.  Distinguishing these effects using only dynamic dialysis or ultrafiltration 
methods to monitor release is problematic.  By using both methods for the HYD release 
studies, the effects of partitioning and slow DOX release become apparent as the % of DOX 
removed is greater in all release profiles obtained from dynamic dialysis (at both pH 
conditions studied) than the extent of DOX release monitored by ultrafiltration.  This 
observation indicates partitioning of unconjugated DOX into the micelle is present for both 
micelle formulations but not the sole contributor to the terminal release phase as reflected 
by the values in Table 7.2.   
7.4.1.3  Concentration effects of conjugated and unconjugated DOX on partitioning 
While both methods provide the ability to ascertain hydrazone hydrolysis kinetics and 
partitioning effects, the simple model used here is still limited in its description of the entire 
release profile due to the complexity of the micelle system.  Because DOX is conjugated and 
initially a large percentage of the micelle (i.e. high drug loading),83 it is reasonable to expect 
that in addition to pH, Kp is also a function of the amount of DOX conjugated and the 
concentration of unconjugated, partitioned DOX.  Such an effect was previously proposed in 
liposomal studies for a different drug and was attributed to self-association effects.197  In the 
case of micelles however, these high DOX concentrations (conjugated or unconjugated) may 
alter the properties (e.g. charge, hydrophobicity) of the micelle environment itself.  This is 
evident in both Figures 7.2a and b where the fitted release profiles systematically predict 
slower release than that seen at several conditions release studies were performed.  This 
aging effect is revealed because the Kp estimated from the ultrafiltration profiles relies more 
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heavily on the terminal phase of release.  At this stage in the release study, significant 
hydrolysis (i.e. release) has occurred as opposed to dynamic dialysis in which the effects of 
Kp are more pronounced during the initial burst phase of release.  In Figure 7.2b, the release 
profiles of DOX at 0.5 and 0.1 mg micelle/mL are initially faster as the amount of DOX 
conjugated is much higher; however, the spike profile is simulated well.  This supports the 
notion of aging effects as the micelle samples used in spike experiments had already 
undergone significant DOX release and were ultimately more reflective of the micelle 
environment at the end of the ultrafiltration studies.   
In the release studies conducted with GLY at pH 7.4 (Figure 7.3b), errors in the initial 
phase of release are also present; however, it is not the systematic error of slow release 
seen in HYD release studies since ultrafiltration studies were not possible with these 
formulations and do not share in this bias.  In these release studies, Kp is ultimately 
determined by the initial phase of DOX release observed in each profile.  This is well 
illustrated by the pH 7.4 release profiles where DOX partitioning was indicated to be 
significant.  In the GLY studies, the initial phase of release observed in the spike experiment 
is predicted to be slower by the model due to the slower release seen in this initial phase at 
0.5 and 0.1 mg micelle/mL concentrations.  This would suggest that DOX partitioning may 
become diminished at later time points after significant amounts of DOX have been 
released.  Similar trends are seen to a lesser extend in the ABZ pH 7.4 release profiles as Kp 
is lower for these micelles than the Kp estimated for GLY.  Such an explanation also explains 
the high error in Kp values since it is averaging micelle formulations with different aging 
effects. 
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7.4.2  Effect of unconjugated DOX partitioning into micelle on observed drug 
release under non-sink and sink conditions  
The amount of drug released in non-sink studies will vary depending upon the 
partitioning of unconjugated DOX into the micelle (Kp).  This effect is shown by Figure 7.4 by 
comparing the release profile observed for HYD release at pH 5.0 with a simulation of the 
profile if no binding occurred. 
 
Figure 7.4.  Simulation of HYD pH 5.0 release profile under non-sink conditions.  
Using the rate constants provided in Table 7.2.  The % of DOX remaining in the 
ultrafiltered samples analyzed during release ( ) along with the fit using the 
mechanistic model developed ( ) are shown and compared to a simulation of 
that profile if there was no partitioning of unconjugated DOX (Kp=0) into the 
micelle ( ).  Based on the values in Table 7.2, the amount of unconjugated 
DOX that partitioned into the micelle was also simulated as a % of total DOX 
present in the solution ( ). 
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This partitioning effect in conjunction with the rate of DOX transport through the 
dialysis membrane has implications on the pH-sensitive nature of the initial phase of 
release observed from dynamic dialysis.  This is illustrated by Figure 7.5.  Here, the release 
profile of 1 mg/mL GLY at pH 7.4 was simulated based on the values reported in Table 7.2 
and compared to the simulated profile of drug remaining in the dialysis tube still conjugated 
to the block copolymer micelles.  It is evident that the lag seen in DOX release is due to the 
accumulation of free DOX.  This is expected based on previous reports of a similar lag in 
drug release seen with liposomal nanoparticles using dynamic dialysis.63, 118, 197  This effect 
is exaggerated at pH 7.4 where all formulations have a higher Kp.  The high partitioning of 
DOX at pH 7.4 reduces the rate DOX is able to leave the dialysis cassette and thus 
contributes to the slower release seen at pH 7.4.  This is clearly illustrated by Figure 7.5 
which compares the release profile of 1 mg/mL GLY at pH 7.4 with a simulation of this 
profile if Kp were zero (i.e. no partitioning).  If DOX partitioning was not present, observed 
release would be faster.  This is also apparent by the rate of unconjugated DOX 
accumulation in the dialysis cassette, 𝑑𝑈
𝑑𝑡
, (also shown in Figure 7.5).  Here, the accumulation 
phase (when the rate is positive) lasts much longer than it would if there was no binding of 
unconjugated DOX. 
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Figure 7.5.  The effect of unconjugated DOX partitioning is illustrated for 
dynamic dialysis release studies.  Here, the initial portion of the DOX release 
profile from a 1.0 mg GLY/mL solution at pH 7.4 (  ) is shown along with the 
profile generated by the mathematical model (  ) using the values listed in 
Table 7.2.  This is compared to a simulation of the expected release profile if 
only conjugated DOX was monitored (×).  This comparison indicates significant 
accumulation of released DOX within the dialysis cassette during the initial 
phase of release.  Furthermore, when the observed release profile is compared 
to the simulated profile which assumes Kp is zero ( ), the initial phase of 
release is shown to be further slowed by DOX partitioning.  This is also 
supported by the differences in the rate of accumulation and depletion of 
unconjugated DOX in the dialysis cassette (𝑑𝑈
𝑑𝑡
) during dynamic dialysis of the 
micelle formulation.  The accumulation phase (positive values) of unconjugated 
DOX in the dialysis cassette when binding is considered ( ) is over double 
that if there were no binding ( ).  
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These effects can be can be better understood by thinking of the effective rate 
constant for DOX transport out of the dialysis cassette as: 
𝑘′𝑑 =
𝑎𝑘𝑑
𝑎+𝑏𝐾𝑝
         (16) 
which takes into the account the fraction of unconjugated drug that is in the aqueous phase.  
The equation uses the volume coefficients of the aqueous and micelle phases (a and b 
respectively) and the DOX partitioning coefficient, 𝐾𝑝.  These effects on 𝑘′𝑑 and 
subsequently the effective half-life of DOX transport out of the dialysis cassette in the 
presence of block copolymers (𝑡1/2 =
ln (2)
𝑘′𝑑
) was simulated in Figure 7.6a and b respectively 
for several micelle concentrations.  Based on the parameters generated by the mathematical 
model, 𝑘′𝑑 and 𝑡1/2 are also plotted for the micelles studies at the two pH conditions 
employed.  As these figures show, increases in 𝐾𝑝 and micelle concentration both decrease 
𝑘′𝑑 and increase the half-life of free DOX transport from the dialysis cassette. 
Both of these effects can be considered simultaneously by calculating the free fraction in 
the aqueous phase,  𝑓𝑤 = 𝑎
𝑎+𝑏𝐾𝑝
.  Using 𝑓𝑤 , a general trend can be surmised for 𝑘′𝑑 and t1/2 
for all micelle concentrations employed.  These trends are illustrated by Figure 7.6c. 
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C.  
Figure 7.6.  The effect of micelle concentration and partioning of unconjugated 
DOX (Kp) on the effective rate constant, 𝑘′𝑑 , (A) and half-life, t1/2, (B) of 
unconjugated DOX transport from the dialysis cassette.  Lastly, micelle 
concentration and Kp can be used to determine the fraction of unconjugated DOX 
unbound to the micelle, 𝑓𝑤  (C).  The use of 𝑓𝑤  results in a more general trend 
with 𝑘′𝑑 ( ) and t1/2 ( ).  In these plots, the symbols , , and  refer to 
the values calcualted for HYD, GLY, and ABZ at pH 7.4 based on the parameters 
generated in Table 7.2.  Their color corresponds to the conditions designated by 
the trend line they are related with.  The opened symbols of the same shape 
correspond to values calculated from pH 5.0 release parameters.  
7.4.3  Intrinsic factors governing micellar DOX release 
7.4.3.1  pH-dependent DOX partitioning 
 The effects of DOX partitioning on observed drug release has already been explained; 
however the reason why partitioning is higher for all micelles at higher pH is also significant 
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and should be addressed.  The partitioning seen here may be due to change DOX speciation 
as a function of pH.  This is illustrated below in Scheme 7.2.  DOX is a weak base with a pKa 
of 8.2.107  As the pH is increased over the region studied, the fraction of DOX in its neutral 
base from increases over 200 fold.  If only the neutral form contributed to binding, the 
partitioning DOX in GLY and ABZ micelles at pH 5.0 would be 10 and 5.  These values are too 
small to affect release kinetics at the micelle concentrations employed in dynamic dialysis 
studies, making this a plausible explanation for the considerable difference in DOX 
partitioning between pH 5.0 and 7.4 studies.   
 
Scheme 7.2.  The ionization states of DOX are governed by its acid dissociation 
constant (KA) and the pH of the solution.  At higher pH, the neutral base form 
(DOXNH2) dominates while its cationic form (DOXNH3+) dominates at lower pH. 
7.4.3.2  Biphasic hydrazone hydrolysis kinetics 
Biphasic drug release has been observed for many micelle systems, but a consensus has 
not been reached on the cause of the two phases.16, 99, 104, 205, 206  The exact reason behind the 
biphasic release seen herein has not been confirmed, but the most likely hypothesis relates 
to the ability of water/hydronium ion to penetrate the micelle core.  Due to the hydrophobic 
nature of the core, the penetration of water (and subsequently hydronium ions) would not 
be a favorable interaction, but is required for acid-catalyzed hydrolysis of the hydrazone 
bond used to conjugate DOX to the micelle core.  Based on this line of thinking, most of the 
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water/hydronium likely resides at the interface of the micelle core and PEG shell.  The 
hydrophilic nature of PEG would reduce the hydrophobic effect at this interface relative to 
the core of the micelle.   Conjugated DOX near this interface is relatively free to interact with 
water/hydronium because conjugation occurs on the side chains of the polyaspartate core 
rather than the backbone of the copolymer scaffold (i.e. more rotational freedom of DOX).  
Due to the high surface-area to volume ratio associated with spherical geometries, the 
fraction of conjugated DOX susceptible to fast release, f, would only require the shell/core 
interface to extend to 7-15% of the total radial distance of the micelle’s core for values of f 
ranging from 0.2 – to 0.38.  Even the value of 0.68 obtained for HYD micelles at pH 5.0 
would only extend the interface to cover approximately 30% of the core’s total radial 
distance.  The slow phase of hydrazone hydrolysis kinetics also supports this theory as the 
core of the micelle (which is sufficiently removed from the core/shell interface) has less 
water to achieve hydrolysis.  With less water in this region, the rate constant of this phase, 
k2, should be much slower and be less sensitive to changes in pH than that expected by 
hydrolysis kinetics in bulk solution over the pH range studied here.198 This is reflects the 
trends observed in all three formulations in regards to k2. 
Such a theory also explains the fast hydrolysis kinetics observed for ABZ and GLY 
micelles as f nearly remains constant while k1 increases at lower pH. This observation is 
consistent with acid-catalyzed hydrazone hydrolysis.198  The HYD micelles however, do not 
show an increase in k1 but an increase in f.  This would suggest penetration of water 
increases but the activity of hydronium does not within the micelle environment as pH is 
lowered.  While not as straightforward as the ABZ and GLY micelles, HYD micelles may still 
conform to the above theory if acid supplied locally by unreacted hydrazide side chains of 
the polyaspartate core dominate acid catalysis.   
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7.5  Conclusions 
DOX release from HYD, ABZ, and GLY micelles was analyzed in both acidic and neutral 
conditions. Irrespective of drug release conditions and formulation, micelles exhibited 
biphasic DOX release. A drug release model accounting for biphasic release was developed 
and parameters were estimated through mathematical modeling.  Modeling results 
identified a stability issue with the hydrazone linkage used to conjugate DOX to the block 
copolymers stored after freeze drying.  This stability issue was confirmed by two other 
independent methods.  The impact of such a finding is significant as researchers considering 
the use of drug conjugation strategies employing a hydrazone linkage should be 
cognoscente of these stability issues and give careful consideration to validation of 
conjugation stability at the storage conditions selected.  Failure to do so could lead to poor 
efficacy results in preclinical testing if particles with this stability issue are administered 
after a period of time in which drug conjugation has started to degrade. 
In addition to the stability issue, mathematical modeling also revealed pH-sensitive DOX 
partitioning was present in all three micelle formulations.  Due to the complexity of the 
micelle system, this partitioning effect also appeared to be dependent upon particle aging.  
This was evident because partitioning effects in the initial phase of release observed by 
dynamic dialysis of freshly-constituted micelle solutions was different than the partitioning 
captured in micelle samples used in ultrafiltration and spike experiments.  (i.e. conditions 
where significant amounts of conjugated DOX had already been released at the point in 
which DOX partitioning was estimated).  Future studies which can capture the change in 
DOX partitioning with micelle aging may be useful in the development of in vitro/in vivo 
correlations for drug release from micelle formulations. 
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 While the variability in partition coefficient estimation was high, its effect on drug 
release kinetics was observed.  As the fast hydrazone hydrolysis rate constants for all 
micelle formulations were within the same magnitude as rate constant of free DOX 
transport across the dialysis membrane, the initial phase of release was slowed due to the 
reduction in the fraction of unconjugated DOX available to permeate the dialysis membrane.  
This reduction driving force of DOX transport from the dialysis cassette exaggerated the 
initial lag in DOX release in a manner similar to that previously reported when monitoring 
release kinetics from liposomal formulations using dynamic dialysis.49, 118, 197  
In addition to partitioning, hydrazone hydrolysis kinetics were quantified for all three 
micelle formulations and shown to be biphasic.  This was attributed to the likely scenario of 
higher water penetration at interface of the PEG shell and micelle core than at the center of 
the hydrophobic core.  The insertion of spacers appeared to keep the fraction of conjugated 
DOX that underwent fast hydrolysis similar between release studies conducted at pH 5.0 
and 7.4.  The spacers also appeared to have an effect on the hydrolysis rate constant within 
the fast phase of release.  This was most evident for DOX release from ABZ micelles at pH 
5.0.  Hydrazone hydrolysis kinetics of DOX in the fast phase was too fast to be determined 
due to rate-limiting DOX transport across the dialysis membrane. 
These results illustrate the usefulness of mechanistic mathematical models in the 
development process of micellar nanoparticles.  The approach used to here develop a 
mechanistically-based mathematical that accounts for method-specific effects on observed 
drug release profiles should prove to be a useful guide for assessing release characteristics 
intrinsic to a particular drug/nanoparticle system.      
 
Copyright © Kyle Daniel Fugit   
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CHAPTER EIGHT   
Conclusions and Future Directions 
Unlocking the full potential of nanoparticles as drug delivery vehicles requires 
developing rationally-design formulations with predictable properties in vivo.  A paradigm 
shift from the current trial-by-error approach used to design nanoparticle formulations to a 
more methodical approach will only be facilitated with fundamental knowledge of the 
critical physicochemical properties and physiological mechanisms affecting nanoparticle 
performance (i.e. drug release kinetics).  Mechanistic mathematical models supported by 
experimental studies provide a means to study these effects.  The studies conducted within 
this thesis provide several examples of identifying physicochemical properties and 
environmental (sometimes even physiological) conditions through mechanistic modeling of 
experiments rationally designed to identify such effects.  More importantly, these studies 
demonstrate a methodical approach for future nanoparticle formulation design and 
development. 
The non-sink ultrafiltration method developed in chapter three provided a way to both 
quantify drug permeability and binding constants for liposomal drug delivery systems.  This 
study also provided a quantitative example of the differences in release profiles due to the 
presence of non-sink or sink conditions.  The interplay of both kinetic and thermodynamics 
effects on liposomal release kinetics are clearly illustrated by this study and stresses the 
importance for nanoparticle formulators to consider both effects when evaluating 
characterization studies of drug release from nanoparticulate drug delivery systems.   
The results of chapter four demonstrated the applicability of the non-sink method to 
observe the pH-sensitivity of both liposomal topotecan release kinetics and interfacial 
binding at the bilayer surface.  This study is also the first attempt to develop an extensive 
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mechanistic model for topotecan release.  Developing this model required further studies to 
evaluate the ionization state (i.e. pKa) and kinetics of reversible, pH-dependent, ring-
opening/closing of topotecan.  Adaptation of the model to incorporate opening/closing of 
topotecan’s lactone ring identified the rate-limiting effect of ring-closing on release kinetics 
and the observed pH permeability profile.  The constants estimated by this mathematical 
model also laid a foundation for future studies of liposomal topotecan intended to probe 
effects on more sophisticated, and commonly studied, liposomal formulations of the drug. 
Chapter five probed the effect of ammonia on liposomal release kinetics of actively-
loaded (i.e. low intravesicular pH driven loading) topotecan.  In the course of this study, a 
spectroscopic fluorescence method was developed to monitor liposomal release kinetics 
and validated with the aid of mathematical modeling.  Consequently, modeling showed 
increases in the rate of release with increasing ammonia concentrations.  The increase in 
release correlated with increases in intravesicular pH due to ammonia influx from the 
extravesicular solution.  These simulations combined with the ammonia levels measured in 
the various release media studied (solutions or plasma) identified a correlation between 
accelerated release and increases in intravesicular pH rather than some other physiological 
effect present in the plasma samples.  The implications of this observation are significant.  
Many liposomal delivery systems are actively-loaded and take advantage of low 
intravesicular pH to increase loading efficiencies and slow release.  Any of these 
formulations will also be sensitive to ammonia influx.  This study also warns of the great 
care that should be taken when using plasma to study release as its stability can have undue 
effects (i.e. acceleration) on release kinetics.   
Chapter six built upon the physicochemical properties identified in Chapters 3- 5 to 
develop a mechanistic model capable of explaining loading and subsequent release kinetics 
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from actively-loaded formulation of liposomal topotecan.  Mathematical modeling of active 
loading kinetics at 37 °C suggested uptake of cationic topotecan across the bilayer occurred 
as an ion-pair with chloride present in the loading solution.  This prediction was confirmed 
with release studies which showed slower release in the absence of chloride.  Using the 
transport mechanism suggested by modeling these loading experiments, the effect of 
loading temperature on topotecan release was evaluated.  A mechanistic model 
incorporating the precipitation of a topotecan HCl salt within the liposome led to the 
extended release kinetics observed from topotecan loaded at 60 °C.  The mechanism of 
transport identified for actively-loaded liposomal topotecan will aid in formulation 
optimization.  These results suggest alterations in the levels of chloride during loading could 
provide a rational way to tune liposomal release kinetics of topotecan.  
Lastly, chapter seven extended the approach used to mechanistically model liposomal 
drug release to the development of mechanistic models for the characterization of drug 
release from polymeric micelle nanoparticles.  Experimental release studies of doxorubicin 
conjugated to block copolymers via a pH-sensitive hydrazone linkage were mechanistically 
modeled.  The model-predicted instability of doxorubicin conjugation during storage was 
experimentally confirmed.  This finding is considerable to the field of nanoparticle drug 
delivery systems as because many polymer-based formulations use a similar conjugation 
strategy, making them potentially susceptible to this stability issue.  Such stability issue 
could greatly alter the in vivo performance of these nanoparticle formulations if significant 
storage has been incurred between synthesis and preclinical studies.  In addition to stability 
issues, further modeling of doxorubicin release kinetics using sink and non-sink conditions 
revealed biphasic release and partitioning of unconjugated doxorubicin into the micelle 
phase.  While the stability and partitioning effects complicated the interpretation of release 
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kinetics, these studies were still able to illustrate the kinetic and thermodynamic factors 
affecting release kinetics under sink and non-sink release conditions.   
While the developed models within this thesis sometimes become quite complex, the 
same initial approach was used for the development of each model.  This approach is 
generalized by the equation below: 
∑
𝑑𝑀𝑖
𝑑𝑡
𝑖
=∑[∑𝑘𝑗(𝑡, 𝑟,∑𝑀𝑖 ,∑𝐺𝑖)
𝑗
𝑀𝑖,𝑗]
𝑖
 
essentially, any drug species, i, that may undergo transport into or out of the nanoparticle 
must be expressed by their respective rate of change, 
𝑑𝑀𝑖
𝑑𝑡
, with their sum yielding the net 
transport of drug from the nanoparticle.  These rates are governed by the sum of kinetic 
processes, j, with each process described by a rate constant for that particular driving force, 
𝑘𝑗 , which contribute to the rates affecting the release of drug species, 𝑀𝑖 .  In some cases, this 
is strictly diffusion, but other kinetic factors (e.g. drug interconversion, degradation 
kinetics, convection) may also be incorporated as was successfully demonstrated in several 
chapters of this thesis.  These rate constants may be a function of time, position (denoted by 
the variable, r), other drug species in solution (∑𝑀𝑖), as well as other excipients or solutes 
in solution (∑𝐺𝑖).  In addition to these rate constants, the driving force may also be 
dependent upon the amount of species i that is susceptible to the kinetic process 𝑘𝑗  (which 
is denoted by 𝑀𝑖,𝑗).  Two clear examples of this effect relate to the transport of only drug 
species unbound to the bilayer driving drug diffusion through the bilayer and the driving 
force governing drug transport through dialysis membranes in both liposomal and micellar 
drug release studies.   Equilibrium constants were used throughout these chapters to solve 
for 𝑀𝑖,𝑗  in terms of 𝑀𝑖 .  These mathematical manipulations also illustrate the mechanistic 
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aspect of modeling release kinetics via the incorporation of thermodynamic coefficients 
governing drug speciation.   
While the terms comprising 𝑘𝑗  appear to be complex functions in the generalized 
equation above, they can usually be simplified and assumed to be constant depending upon 
the conditions in which they are evaluated.  Much of this work assumes constant release 
rate constants for the evaluation of these release studies; however, exploration of their 
dependence on environmental factors and consequently their dependence upon some of the 
variables mentioned above may be of relevance in the future development of 
nanoformulations.  In the case of liposomal formulations, factors which alter the barrier 
properties of the lipid bilayer are of key importance to extending the predictability of 
release kinetics under in vivo conditions.  In the actively-loaded formulations studied here, 
the low intravesicular pH calculated in these formulations may alter bilayer properties as 
lipid degradation is acid-catalyzed.  The resulting lysolipids, other degradation products, or 
the loss of PEG over time may alter partitioning, drug diffusivity through the bilayer, 
interfacial drug binding, or a combination of these properties.  The first three of these 
factors would directly alter drug permeability while the last would alter the concentration 
gradient of unbound drug driving drug release.  Such changes may be particularly important 
for liposomal formulations in which release occurs over several days and remain in 
systemic circulation over a similar period of time.  Under these circumstances, liposomal 
drug release may be more dependent on bilayer degradation due to many of the factors 
illustrated to slow release (e.g. self-association, precipitation) within this thesis.   
The high concentrations of intravesicular drug observed during active-loading (in these 
studies and typically present in other formulations that employ a similar loading process) 
may also alter bilayer properties.  This was partially illustrated in chapter three which 
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illustrated the effect of charge buildup upon the bilayer surface diminishing binding as drug 
concentrations increased.  In this case, the driving force increases as higher drug loading is 
achieved.  A similar scenario may also occur for neutral, highly lipophilic compounds which 
may exhibit much higher binding constants than topotecan.  Such compounds may exhibit 
saturable binding if high enough intravesicular concentrations are achieved.  Furthermore, 
the binding of pharmaceutical agents may alter the structure of the bilayer itself.  One can 
understand this best by considering such an effect on bilayer chain ordering.  Incorporation 
of enough drug may have effects similar to the incorporation of cholesterol on bilayer chain 
ordering and surface density calculations.  The diffusivity of drug as well as the volume 
contributions of the membrane and aqueous volume may be significantly altered if enough 
drug is incorporated into the bilayer.  Such effects may become important and require 
further study for liposomal formulations that incorporate more lipophilic agents.  Lastly, 
these high intravesicular drug concentrations may also increase osmotic stress on the 
bilayer.  Considerable effort was made to maintain isotonic conditions during release 
studies, but the effect of high intravesicular concentrations of drug were problematic to 
address as release or uptake during studies could conceivably alter intravesicular 
osmolality throughout the experiment.  While these stresses did not seem to change particle 
size significantly (which would have suggested ruptured or shriveled vesicles), significant 
counter-transport of water across the bilayer may have occurred to compensate for the 
changes in intravesicular osmolality due to solute transport.  The transport of water across 
the bilayer (and consequently its presence within the bilayer) may also alter bilayer 
properties and may enhance the partitioning of a TPT-Cl ion-pair within the bilayer.  
Enhancing ion-pair partitioning of topotecan and Cl would consequently promote its  
transport across the bilayer.             
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Developing more mechanistic approaches to modeling drug release for other 
nanoparticle formulations should also be explored.  For polymeric micelles, identifying the 
factors which affect the hydrolysis kinetics of drug conjugated to the copolymers 
comprising the micelle may be advantageous.  It may also be helpful to perform additional 
studies that probe the mechanism governing partitioning of unconjugated drug to the 
micelle core and/or its surface.  Developing rational ways to test the mechanisms of drug 
release in other nanoformulations should also be possible if one is cognizant of the general 
transport equation above and correctly identifies the factors likely to govern drug transport 
from the nanoparticle under consideration.     
As more variables affecting release kinetics are incorporated, evaluating the validity of 
these mechanistic mathematical models will also be of greater importance.  During the 
course of these studies, most of the effort given to regression analysis of these mechanistic 
models concerned the achievement of the global minimum for the objective function and 
reducing correlation coefficients.  Confidence in achieving the global minimum can be quite 
difficult when multiple data sets and parameters are fit simultaneously (as was the case in 
nearly every chapter of this thesis) due to a high probability of multiple local minima 
existing under these scenarios.  Such a challenge is best addressed by careful consideration 
of the initial values provided for parameters to be evaluated by regression.  Sensical initial 
values can sometimes be determined by preliminary simulations of the model using a range 
of parameter values.  Sometimes, logical reasoning based on previous studies in the lab or 
from values reported in the literature (e.g. properties of similar particles or drugs) can be 
used to provide reasonable estimates for these initial values.  At other times, especially in 
the case of more complex models, regression may fail when multiple parameters have 
similar mathematical (but mechanistically distinct) effects on fitting the data.  Chapter four 
contains a good example of this situation as changes in both ring-opening kinetics and the 
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pKa of topotecan’s phenol could provide similar effects on the drug’s liposomal release 
profile.  This is one of the main reasons why separate experiments were required to validate 
the constants for both topotecan’s phenol ionization and ring-opening/closing 
interconversion kinetics.  Further evidence of the relationship of these parameters was also 
observed by the correlation coefficients obtained during model fitting of these parameters. 
Correlation coefficients aid in understanding the limitations of using a particular data 
set to provide high statistical confidence for parameters evaluated by regression.  High 
positive or negative correlation (values approaching 1 or -1, respectively) between multiple 
fitted parameters will also result in poor confidence limits for those parameters in most 
cases.  This issue may require additional experiments to isolate one or more of these 
parameters (as already mentioned for chapter four).  Another way of circumventing this 
issue may be mathematical transformation of the equation or parameters of interest.  
Rewriting the rate constants for ring opening and closing in chapter four in terms of the ring 
closing rate constant and an equilibrium constant between the ring-opened and closed 
forms is an example of such a transformation.   
Sometimes mathematical transformations may also allow the removal of bias when 
parameters from previous studies are used.  Such was the case in chapter six.  Here, an 
expression for topotecan’s true pKa was rewritten in terms of the previously determined 
pKa and its ion pairing association constant with Cl.  This effort was made to remove any 
bias ion-pairing with Cl may have contributed during the previous study which determined 
TPT’s pKa.  While such considerations remove some bias, one can argue that any of these 
previously determined values (whether from other studies performed by the experimenter 
or reported in the literature) are still only a sample mean of a population and therefore 
must have a measure of the variance of the sample data too.  Fixing certain parameters in 
 234 
 
this manner may lead to underestimates in the uncertainty of those parameters that are 
fitted.  Perhaps simultaneous regression of those data sets along with the new data sets (e.g. 
release profiles) would provide a better assessment of the values of interest for the 
population.  Currently, however, many of the data fitting software packages available are 
not capable of handling multiple data sets during regression analysis.  Hopefully, further 
advancements in software and processing will allow such a global fit of data to be 
achievable.   
Perhaps advancements in regression software will also provide a better statistic to 
determine the validity of these complex models.  Most regression software packages do 
have some indicator of the model’s ability to fit the data set.  This indicator is illustrated in 
chapter six by the Model Selection Criterion (MSC) as it is the calculation made by the 
regression program used for these studies to assess goodness-of-fit.  MSC, like similar 
values reported by other software programs, is only useful as a relative scale in the 
determination of whether one model or another is a better fit of a certain data set.  It 
cannot, however, provide an absolute statistic indicating the probability that the fitted 
model accurately explains the data.  In this thesis, the validity of a model has been handled 
to an extent by using parameters generated by one data set to predict the outcomes of 
separate experiments performed under different conditions.  Another future test for model 
validity might be the analysis of residuals between experimental and predicted values from 
the fitted model.  Such an analysis would speak to the scatter of data and identify systematic 
deviations in the data.  Both of these approaches, however, only provide a qualitative 
demonstration of the model’s validity.  One possible solution may be a lack-of-fit test 
performed as part of the analysis of the multiple conditions fitted to the developed models 
during regression.  This test, however, requires the ability to determine the sum of square 
errors attributable to the lack-of-fit (SL) and noise of the experimental method (SE).  
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Calculation of these variables, however, requires repeated experiments at the same 
conditions to isolate SE., which was not done in many of these studies.  It would appear 
reasonable for future studies which aim to utilize such a statistical test to have at least one 
condition repeated to assess this error and calculate the lack-of-fit F-statistic.  Assessing the 
sensitivity of this statistic, however, is a more complicated issue.  The F-statistic calculated 
by the lack-of-fit test (as well as the critical F-value used to judge the probability of a lack-
of-fit) is highly dependent upon the degrees of freedom associated with the model-
evaluated data set.  More specifically, the number of parameters, study conditions (e.g. 
release studies at different conditions), and total number of observations will alter the 
magnitude of both the experimental and critical F-values of the study.  High critical F-values 
are an indication that the number of fitted parameters is too high for the number of 
conditions evaluated in the study (i.e. a statistical false negative would result).  Under this 
scenario, the lack-of-fit test would be too insensitive for a meaningful evaluation of the 
model’s ability to explain the data set in question.  Use of this test for the evaluation of 
future models will thus require careful consideration of the statistical power necessary for a 
meaningful lack-of-fit test. 
While this work provides insights that will aid in the optimization of the nanoparticle 
formulations studied herein, future work is still necessary to probe the issues mentioned 
above.  Such studies will aid in the eventual prediction of in vivo nanoparticle drug delivery 
systems from in vitro characterization studies.  Even so, these studies illustrate the 
advantages of a combined experimental and mechanistic modeling approach to characterize 
the physicochemical properties governing release in nanoparticle drug delivery systems.  
The studies discussed in this dissertation will provide examples for future approaches to 
analyzing drug release kinetics and developing models capable of predicting drug release.  
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